DMID/NIAID/NIH  CONFIDENTIAL  Page 1 of 146 
  
A Multicenter, Adaptive, Randomized Blinded Controlled Trial o f the Safety and 
Efficacy of Investigational Therapeutics for the Treatment of COVID -19  
in Hospi[INVESTIGATOR_769094]: Adaptive COVID-19 Treatment Trial (ACTT)  
 
  
DMID Protocol Number:  20-0006 
 
Sponsor :  
Division of Microbiology and Infectious Diseases (DMID), 
National Institute of Allergy and Infectious Diseases,  
National Institutes of Health  
  
Version Number: 
6.0 
 
25 May 2020 
 
   
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 2 of 146 STATEMENT  OF COMPLIANCE  
Each institution engaged in this research will hold a current Federalwide Assurance (FWA) 
issued by [CONTACT_28820] (OHRP) for federally funded research.  The 
Institutional Review Board ( IRB)/Independent or Institutional Ethics Committee (IEC) must be 
registered with OHRP as applicable to the research.   
 
The study will be carried out in accordance with the following as applicable:  
• All National and Local Regulations and Guidance applicable at each site  
• The International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E6(R2) Good Clinical Practice, and the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research  
• [LOCATION_002]  (US) Code of Federal Regulations (CFR) 45 CFR Part 46: Protection of 
Human Subjects 
• US Food and Drug Administration (FDA) Regulations: 21 CFR Part 50 (Protection of 
Human Subjects), 21 CFR Part 54 (Financial Disclosure by [CONTACT_6230]), 21 CFR Part 56 ( IRBs ), 21 CFR Part 11, and 21 CFR Part 312 (Investigational New Drug 
Application), and/or 21 CFR 812 (Investigational Device Exemptions) 
• The policies and procedures of National Institutes of Health (NIH) Office of Extramural Research and Division of Microbiology and Infectious Diseases (DMID)  
 The signature [CONTACT_42749], and according to local legal and regulat ory requirements , US federal regulations , and ICH E6(R2) 
GCP guidelines.  
Site Investigator  Signature : 
 
 
[INVESTIGATOR_14586]:   Date:   
 Name  [CONTACT_119984] 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055149] OF FIGURES  ...................................................................................................................... 10  
1. OVERALL PROTOCOL SUMMARY ................................................................................ 11  
1.1 Synopsis ........................................................................................................................ 11  
1.2 Stages in the adaptive trial  ............................................................................................ 16  
1.3 Schedule of Assessments  .............................................................................................. 16  
1.4 Study Schema ................................................................................................................ 17  
2. INTRODUCTION  ................................................................................................................ 18  
2.1 Study Rationale ............................................................................................................. 18  
2.2 Background ................................................................................................................... 18  
 Purpose of Study ................................................................................................... 18  
2.3 Risk/Benefit Assessment  .............................................................................................. [ADDRESS_1055150] 
DISCONTINUATION/WITHDRAWAL ..................................................................................... [ADDRESS_1055151] to Follow- Up ......................................................................................................... 25  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055152] Values or 
Abnormal Clinical Findings  .................................................................................................. 31  
 Unscheduled Visits ............................................................................................... 31  
8.3 Adverse Events and Serious Adverse Events ............................................................... 32  
 Definition of Adverse Event (AE) ........................................................................ 32  
 Definition of Serious Adverse Event (SAE) ......................................................... 32  
 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]R) .............................. [ADDRESS_1055153] Policy  ..................................................................................... 43  
10.2  Additional Considerations ............................................................................................ 43  
 Research Related Injuries  ..................................................................................... 43  
10.3  Abbreviations ................................................................................................................ 44  
10.4  Protocol Amendment History ....................................................................................... 45  
11. REFERENCES  ..................................................................................................................... 50  
Appendix A - ACTT -1: Remdesivir vs P lacebo  ........................................................................... 54  
1. PROTOCOL SUMMARY .................................................................................................... 54  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 5 of 146 1.1 Synopsis ........................................................................................................................ 54  
1.2 Schedule of Assessments  .............................................................................................. 61  
1.3 Study Schema ................................................................................................................ 62  
2. INTRODUCTION  ................................................................................................................ 62  
2.1 Study Rationale ............................................................................................................. 62  
2.2 Background ................................................................................................................... 62  
 Purpose of Study ................................................................................................... 62  
 Potential Therapeutics  ........................................................................................... 63  
2.3 Risk/Benefit Assessment  .............................................................................................. [ADDRESS_1055154] .............................................................................................................. 73  
6.1 Study Produc t(s) and Administration – GS -5734 (Remdesivir) and placebo ............... [ADDRESS_1055155] Description .................................................................................... 74  
 Dosing and Administration ................................................................................... 74  
 Dose Escalation  ..................................................................................................... 74  
 Dose Modifications ............................................................................................... 74  
 Overdosage ........................................................................................................... 74  
6.2 Preparation/Handling/Storage/Accountability  .............................................................. [ADDRESS_1055156] Storage and Stability................................................................................ 76  
 Preparation  ............................................................................................................ 76  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 6 of 146 6.3 Measures to Minimize Bias: Randomization and Blinding  .......................................... [ADDRESS_1055157] 
DISCONTINUATION/WITHDRAWAL ..................................................................................... [ADDRESS_1055158] Values or 
Abnormal Clinical Findings  .................................................................................................. 85  
 Unscheduled Visits ............................................................................................... 85  
8.3 Adverse Events and Serious Adverse Events ............................................................... 86  
 Definition of Adverse Event (AE) ........................................................................ 86  
 Definition of Serious Adverse Event (SAE) ......................................................... 86  
 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]R) .............................. 87  
 Classification of an Adverse Event ....................................................................... 87  
 Time Period and Frequency for Event Assessment and Follow- Up ..................... 88  
 Serious Adverse Event Reporting ......................................................................... 88  
 Reporting of Pregnancy ........................................................................................ 89  
8.4 Unanticipated Problems ................................................................................................ 89  
 Definition of Unanticipated Problems .................................................................. 89  
 Unanticipated Problem Reporting......................................................................... 90  
9. STATISTICAL CONSIDERATIONS .................................................................................. 90  
9.1 Statistical Hypotheses  ................................................................................................... 90  
9.2 Sample Size Determination ........................................................................................... 91  
9.3 Populations for Analyses .............................................................................................. 95  
9.4 Statistical Analyses  ....................................................................................................... 95  
 General Approach  ................................................................................................. 95  
 Anal ysis of the Primary Efficacy Endpoint .......................................................... 95  
 Analysis of the Secondary Endpoint(s)................................................................. 95  
 Safety Analyses  ..................................................................................................... 96  
 Baseline Descriptive Statistics  .............................................................................. 96  
 Planned Interim and Early Analyses  ..................................................................... 96  
 Sub-Group Analyses ............................................................................................. 97  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 7 of 146 
 Exploratory Analyses ............................................................................................ 97  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ....... 98  
Appendix B - ACTT -2: Baricitinib/Remdesivir Vs. Remdesivir Trial......................................... 99  
1. PROTOCOL SUMMARY .................................................................................................... 99  
1.1 ACTT -2 – Synopsis ...................................................................................................... 99  
1.2 Schedule of Assessments  ............................................................................................ 102  
1.3 Study Schema .............................................................................................................. 103  
2. INTRODUCTION  .............................................................................................................. 103  
2.1 Background ................................................................................................................. 103  
 ACTT -2 – Baricitinib/Remdesivir vs. Remdesivir Trial .................................... 103  
2.2 Risk/Benefit Assessment  ............................................................................................ [ADDRESS_1055159](s) and Administration .......................................................................... [ADDRESS_1055160] Description .................................................................................. 118  
 Dosing and Administration ................................................................................. 118  
 Dose Escalation  ................................................................................................... 119  
 Dose Modifications ............................................................................................. 119  
 Overdosage ......................................................................................................... 120  
6.2 Preparation/Handling/Storage/Accountability  ............................................................ 120  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055161] Storage and Stability.............................................................................. 121  
 Preparation  .......................................................................................................... 122  
6.3 Measures to Minimize Bias: Randomization and Blinding  ........................................ [ADDRESS_1055162] 
DISCONTINUATION/WITHDRAWAL ................................................................................... [ADDRESS_1055163] Values or 
Abnormal Clinical Findings  ................................................................................................ 133  
 Unscheduled Visits ............................................................................................. 134  
8.3 Adverse Events and Serious Adverse Events ............................................................. 134  
 Definition of Adverse Event (AE) ...................................................................... 134  
 Definition of Serious Adverse Event (SAE) ....................................................... 135  
 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]R) ............................ 135  
 Classification of an Adverse Event ..................................................................... 136  
 Time Period and Frequency for Event Assessment and Follow- Up ................... 137  
 Serious Adverse Event Reporting ....................................................................... 137  
 Reporting of Pregnancy ...................................................................................... 138  
8.4 Unanticipated Problems .............................................................................................. 138  
 Definition of Unanticipated Problems ................................................................ 138  
 Unanticipated Problem Reporting....................................................................... 138  
9. STATISTICAL CONSIDERATIONS ................................................................................ 139  
9.1 Statistical Hypotheses  ................................................................................................. 139  
9.2 Sample Size Determination ......................................................................................... 139  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 9 of 146 9.3 Populations for Analyses ............................................................................................ 143  
9.4 Statistical Analyses  ..................................................................................................... 143  
 General Approach  ............................................................................................... 143  
 Analysis of the Primary Efficacy Endpoint ........................................................ 143  
 Analysis of the Secondary Endpoint(s)............................................................... 143  
 Safety Analyses ................................................................................................... 144  
 Baseline Descriptive Statistics  ............................................................................ 144  
 Planned Interim and Early Analyses  ................................................................... 144  
 Sub-Group Analyses ........................................................................................... 145  
 Exploratory Analyses .......................................................................................... 145  
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS – ALL 
STAGES  ..................................................................................................................................... [ADDRESS_1055164]  OF TABLES  
Table 1. Schedule of Assessments (SOA)  .................................................................................. 16  
Table 2. National Early Warning Score (NEWS)  .................................................................... 28  
Table 3. Venipuncture Volumes1 ............................................................................................... 31  
Table 1. Schedule of Assessments (SOA)  .................................................................................... 61  
Table 2. National Early Warning Score (NEWS)  .................................................................... 82  
Table 3. Venipuncture Volumes1 ............................................................................................... 85  
Table 4 Number of recoveries needed for 85% power assuming a type I error rate of 5% for 
various recovery ratios.  ................................................................................................................. 91  
Table 5. Possible scenarios for the distribution of ordinal outcomes for the control arm at Day 15.
....................................................................................................................................................... 92  
Table 6. Sample size calculations for scenarios in Table 5 for a two-arm study assuming 85% 
power, a two-sided type I error rate of 5%, and various true odds ratios. .................................... 93  
Table 7. Treatment ordinal outcome proportions under an odds ratio of 1.75 for five scenarios in Table 6 at Day 15. ......................................................................................................................... 93
 
Table 1. Schedule of Assessments (SOA)  ................................................................................ 102  
Table 2. National Early Warning Score (NEWS)  .................................................................. [ADDRESS_1055165] for ACTT-1 and ACTT-2 ................................................. 139  
Table 5. Number of recoveries needed f or 85% power assuming a type I error rate of 5% 
for various recovery ratios. ...................................................................................................... 140  
Table 6: Possible scenarios for the distribution of ordinal outcomes for the control arm at Day 15................................................................................................................................................. 141
 
Table 7: Sample size calculations for scenarios in Table 6 for a two -arm study a ssuming 85% 
power, a two-sided type I error rate of 5%, and various true odds ratios. .................................. 142  
Table 8. Treatment ordinal outcome proportions under an odds ratio of 1.75 for five scenarios in Table 5 at Day 15. ................................................................................................ 142
 
  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055166]  OF FIGURES  
No table of figures entries found.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 11 of 146 1. OVERALL  PROTOCOL  SUMMARY 
 
1.1 Synopsis  
Rationale for Proposed Clinical Study  
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated severe acute respi[INVESTIGATOR_6507] 2 ( SARS -CoV -2), and the disease caused by [CONTACT_435650] 2019  (COVID -19). There were 59 cases o n January 5, 2020, 278 cases on 
January 20, 2020, 318,000 cases on March 22, 2020, and more than 1,800,000 cases and 113,000 
deaths as of April 12, 2020 according to various international health reporting agencies (1). 
Currently there are no approved therapeutic agents available for coronaviruses.  
 
Study Design  
This study is an adaptive randomized double-blind placebo- controlled trial to evaluate the safety 
and efficacy  of novel therapeutic agents in hospi[INVESTIGATOR_249106]-19. The 
study is a multicenter trial that will be conducted in up to  approximately  100 sites  globally. The 
study will compare different investigational therapeutic agents to a control arm. New arms can 
be introduced according to scientific and public health needs. There will be interim monitoring to allow early stoppi[INVESTIGATOR_16589], efficacy, or safety. If one therapy proves to be efficacious, then this treatment may  become the control arm for comparison(s) with new experimental 
treatment(s) . Any such change would be accompanied by [CONTACT_435651].  This  adaptive 
platform is used  to rapi[INVESTIGATOR_769095] a population of those hospi[INVESTIGATOR_769096] -19. The platform will provide a common framework sharing a 
similar population, design, endpoints, and safety oversight.  New stages with new therapeutics 
can be introduced and will be described in a stage- specific appendix.  One independent D ata and 
Safety Monitoring B oard (DSMB) will actively monitor interim data in all stages to make 
recommendations about early study closure or changes to study arms.   Subjects will be assessed daily while hospi[INVESTIGATOR_057]. See section study specific Schedule of 
Assessment for details.  All subjects will undergo a series of efficacy, safety, and laboratory 
assessments. See stage specific s chedule of assessm ent for details.   
 The primary outcome is time to recovery by [CONTACT_2006] 29 (see table below for definition based on the ordinal scale).  A key secondary outcome evaluates treatment -related improvements in the 8 -point 
ordinal scale at Day 15. Each stage may prioritize different secondary endpoints for the purpose of multiple comparison analyses. 
 
Study Objectives  
OBJECTIVES  ENDPOINTS  
(OUTC OME MEASURES)  
Primary   
To evaluate the clinical efficacy, as assessed 
by [CONTACT_435652], of different Day of recovery is defined as the first day on 
which the subject satisfies one of the 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 12 of 146 OBJECTIVES  ENDPOINTS  
(OUTC OME MEASURES)  
investigational therapeutics as compared to 
the control arm. following three categories from the ordinal 
scale:  
• Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen - no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation  on activities 
and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on activities.  
Recovery is evaluated up until Day 29.  
Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics relative to the control arm in adults hospi[INVESTIGATOR_21391] -19 according to clinical status (8 -
point ordinal scale) at Day 15 
 
  • Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical 
ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation 
or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing medical care (COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on 
activities.  
1. To evaluate the clinical efficacy of 
differen t investigational therapeutics as 
compared to the control arm as assessed by:  
• Clinical Severity  
o Ordinal scale:  
 Time to an improvement of one category and two categories from Day 1 (baseline)  using an ordinal 
scale.  
 Subject clinical status using ordinal scale at Days 3, 5, 8, 11, 15, 22, and 29.  
 Mean change in the ordinal scale from Day  1 to Days 3, 5, 8, 11, 15, 
22, and 29.  
  
• Clinical outcome assessed using ordinal scale daily while hospi[INVESTIGATOR_119818] 15, 22, and 29. 
   
    
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 13 of 146 OBJECTIVES  ENDPOINTS  
(OUTC OME MEASURES)  
 
o National Early Warning Score 
(NEWS):  
 Time to discharge or to a NEWS of 
≤ [ADDRESS_1055167].  
 Change from Day 1  to Days 3, 5, 8, 
11, 15, and 29 in NEWS.  
  
 
• NEWS assessed daily while hospi[INVESTIGATOR_435619] 15 and  29 (if the subject 
attends an in -person visit or still 
hospi[INVESTIGATOR_057]) 
o Oxygenation:  
 Oxygenation use up to Da y 29. 
 Incidence and duration of new oxygen use during the study. 
  
• Days of supplemental oxygen (if applicable) up to Day 29  
 
o Non-invasive ventilation/high flow 
oxygen: 
 Non-invasive ventilation/high flow 
oxygen use up to Day 29. 
 Incidence and duration of new non-invasive ventilation or high flow oxygen use during the study. 
 • Days of non -invasive ventilation /high 
flow oxygen (if applicable)  up to Day 29 
o Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation (ECMO):  
 Ventilator / ECMO use up to Day 
29. 
 Incidence and duration of new mechanical ventilation or ECMO use during the study.  
  
• Days of invasive mechanical ventilation /ECMO  (if applicable)  up to 
Day 29 . 
 
• Hospi[INVESTIGATOR_059]  
o Duration of hospi[INVESTIGATOR_059] (days).  
  
• Days of hospi[INVESTIGATOR_135583] 29 
• Mortality  
o 14-day mortality  
o 28-day mortality  
  
• Date and cause of death (if applicable)  
 
2. To evaluate the safety of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Cumulative incidence of SAEs through 
Day 29.   
  
• SAEs  
• Grade 3 and 4 AEs  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 14 of 146 OBJECTIVES  ENDPOINTS  
(OUTC OME MEASURES)  
• Cumulative incidence of Grade 3 and 4 
clinical and/or laboratory AEs through 
Day 29 . 
• Discontinuation or temporary suspension of study product administration s (for any reason)  
• Changes in white blood cell (WBC) 
count with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and  prothrombin time (PT 
reported as INR ) over time (analysis of 
lab values in addition to AEs noted 
above).  • WBC  with differential , hemoglobin, 
platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT /INR  on 
Day 1; Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and Days 15 and 29 (if attends in -person visit or still 
hospi[INVESTIGATOR_057]). 
 
Exploratory   
To evaluate the virologic efficacy of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Percent of subjects with SARS-CoV-2 detectable in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in OP 
sample at Days 3, 5, 8, 11, 15, and 29. 
• Development of resistance of SARS-CoV-2 in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in 
blood at Days 3, 5, 8, and 11. 
  
 
 
• Qualitative and quantitative polymerase 
chain reaction (PCR)  for SARS -CoV-2 in 
OP swab on Day 1; Days 3, 5, 8, and 11 
(while hospi[INVESTIGATOR_057]); and Days 15 and 29 
(if attends in -person visit or still 
hospi[INVESTIGATOR_057]). 
• Qualitative and quantitative PCR for 
SARS -CoV-2 in blood on D ay 1; Days 3, 
5, 8, and 11 (while hospi[INVESTIGATOR_057]). 
 
Study Population  
This trial will study putative therapeutics in a hospi[INVESTIGATOR_769097] -19. The platform trial will have common inclusion criteria  but may be modified for each 
stage for the unique risk of the study product in that stage. Exclusion criteria are described in each stage specific appendix.  
 Inclusion Criteria  
1. Admitted to a hospi[INVESTIGATOR_435629] -19. 
2. Subject (or legal ly authorized representative) provides informed consent prior to 
initiation of any study procedures. 
3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 
4. Male or non-pregnant female adult ≥18 years of age at time of enrollment.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 15 of 146 5. Has laboratory -confirmed SARS -CoV-2 infection as determined by [CONTACT_435653], as documented by [CONTACT_435654]:  
• PCR positive in sample collected < 72 hours prior to randomization; OR  
• PCR positive in sample collected ≥ 72 hours prior to randomization, documented 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-[ADDRESS_1055168] one of the following: 
• Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, etc.), OR  
• SpO2 ≤ 94% on room air, OR 
• Requiring supplemental oxygen, OR  
• Requiring mechanical venti lation.  
7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.  
8. Agrees to not participate in another clinical trial for the treatment of COVID -19 through 
Day 29. 
 
Exclusion Criteria  
Exclusion criteria are described in each stage specific appendix.  
  
Study Phase  
• Phase 3  
 
Study Population  
Hospi[INVESTIGATOR_119800] ( ≥18 years old) with COVID -19. 
 
Study Sites  
There will be up to approximately  [ADDRESS_1055169] will complete the study in about 29 days, from screening at Day -1 or 1 to follow-up on Day 29 ± 3 days.  
 
Safety  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 16 of 146 • Given the potential severity of COVID-19 and limited information about the expected 
clinical course , there are no pre- specified  study stoppi[INVESTIGATOR_004] (except as noted under 
DSMB) . A subset of the protocol team will review blinded /pool ed data of  Grade 3 and 4 
AE / SAE every 2 weeks.  If there is a pattern of unexpected AEs  that is out of proportion 
to the current understanding of the natural history of the disease, the DSMB will be asked 
to review unblinded safety data in an ad hoc meeting. 
• The DSMB will have access to safety data electronically in real time, will have form al 
safety/efficacy reviews after approximately every [ADDRESS_1055170] met recovered status  
for each pairwise comparison . Additionally, the DSMB will be  available for ad hoc  
reviews for safety concerns  as described above. The study will not stop enrollment 
awaiting these DSMB reviews , though the DSMB may recommend temporary or 
permanent cessation of enrollment based on their safety reviews. 
  
1.2 Stages in the adaptive trial  
Each new intervention represents a new stage in the a daptive design clinical trial.  In order to 
clearly convey the protocol elements, interventions, objectives and endpoints for each stage, common elements are described in the main protocol document while each stage is noted in a stage specific appendix.  
 The stages in the clinical trial include: ACTT -1: Remdesivir vs Placebo  Trial  
ACTT -2: Baricitinib /Remdesivir  vs. Remdesivir Trial  
  
1.3 Schedule of Assessments  
Table 1. Schedule of Assessments (SOA)  
  Screen  Baseline  Study Intervention Period  Follow -up Visits  
Day +/ - Window  −1 or 1 1 Daily until hospi[INVESTIGATOR_7954]  157  
± 2 227 
± 3 297 
± 3 
ELIGIBILITY        
Informed consent  X      
Demographics & Medical History  X      
Targeted physical exam  X      
Review SARS -CoV -2 results  X      
       
STUDY INTERVENTION        
Randomization   X     
Administration of investigational 
agent   Detailed in the stage specific 
appendix .    
      
STUDY PROCEDURES        
Vital signs including SpO 2  X4 Daily until discharge  X7  X7 
Clinical data collection1   X4 Daily until discharge  X7 X7 X7 
Adverse event evaluation   X4 Daily until discharge  X7 X7 X7 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 17 of 146 Concomitant medication review  X4 Detailed in the stage 
specific appendix     
       
SAFETY LABORATORY        
Safety hematology, chemistry and 
liver tests X2,3 X4,5,6 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_057]5,[ADDRESS_1055171] for PCR 
SARS -CoV -2  X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_435621] 8  X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_057]  X7  X7 
Blood for serum (secondary 
research)   X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_057]  X7  X7 
Notes:  
1 Refer to Section 8.1 of the protocol for details of clinical data to be collected including ordinal score, NEWS, oxygen 
requirement, mechanical ventilator requirement, etc.  
2 Screening laboratory tests include: ALT, AST, creatinine (and calculate an estimated glomerular filtration rate (eGFR) 
the formula used is determined by [CONTACT_30107], but should be consistent throughout the study), and pregnancy test. See stage -
specific appendix as additional screening laboratory tests may be added based on study product risk profile.  
[ADDRESS_1055172] risk profile.  
6 Any laboratory tests performed as part of routine clinical care within the specified visit window can be used for safety 
laboratory testing. Window during the 10 days of dosing is ±[ADDRESS_1055173]’s ability to return to the 
site for the visit. In this case, the visit may be performed by [CONTACT_648].  
• If still hospi[INVESTIGATOR_53481] 15 and 29 or returns to the site for an in- person visit: collect clinical data  (ordinal and 
NEWS) , vital signs, safety laboratory tests, and research laboratory samples (OP swab and serum only) as able.  
• If phone call only on Days 15 and 29 and all Day 22 visits: assess adverse events, clinical status (ordinal scale), 
readmission to a hospi[INVESTIGATOR_307], and mortality only.  
8 Oropharyngeal swabs are preferred, but if these are not obtainable, nasopharyngeal or nasal swabs may be substituted.  
 
1.4 Study Schema  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 18 of 146  
 
 
2. INTRODUCTION 
2.1 Study Rationale  
COVID -19 is a respi[INVESTIGATOR_19538] a novel coronavirus (SARS-CoV-2) and causes 
substantial morbidity and mortality. There is currently no vaccine to prevent infection with SARS -CoV-2 or therapeutic agent to treat COVID- 19. This clinical trial is designed to evaluate 
investigational therapeutics for the treatment of adults hospi[INVESTIGATOR_21391] -19. 
2.2 Background  
 Purpose of Study  
Coronavirus (CoVs) are positive- sense, single st randed, enveloped RNA viruses, many of which 
are commonly found in humans and cause mild symptoms. Over the past two decades, emerging pathogenic CoVs capable of causing life-threatening disease in humans and animals have been identified, namely, severe acute respi[INVESTIGATOR_6507] (SARS-CoV) in 2002-[ADDRESS_1055174] respi[INVESTIGATOR_6507] (MERS-CoV) in 2012.   In December 2019, the Wuhan Municipal Health Committee (Wuhan, China) detected an outbreak 
of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly ide ntified in some 
patients . This novel coronavirus has been designated as SARS -COV- 2 and has 89% nucleotide 
identity with bat SARS -like-CoVZXC21 and 82% with that of human SARS -CoV-1. The human 
disease caused by [CONTACT_7544] -CoV- [ADDRESS_1055175] (~80%) cases, COVID -
19 presents as a mild -to-moderately severe, self -limited acute respi[INVESTIGATOR_769098], cough, 
and shortness of breath. Symptoms are thought to appear 2 to 14 days after exposure. COVID -19 
can be severe, resulting in pneumonia, severe acute respi[INVESTIGATOR_7686]  (ARDS) , kidney failure, 
and death. The first US COVID-19 death occurred on February 29, 2020.  During this COVID -19 outbreak, the incidence of cases has rapi[INVESTIGATOR_769099] 
5, 2020 there were 59 confirmed cases, 278 cases on January 20, 2020, and more than 318,000 
cases and 13,000 deaths as of March 22, 2020 according to various international health reporting 
Drug X  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 19 of 146 agencies. As a result, on January 30, 2020, the Intern ational Health Regulations Emergency 
Committee of the World Health Organization (WHO) declared the COVID -[ADDRESS_1055176] that these numbers will continue to rise ( 2).  
 Global efforts to evaluate novel antivirals and therapeutic interventions to treat COVID -[ADDRESS_1055177] 
intensified. There is currently no vaccine to prevent SARS-CoV-2 infection or therapeutic agent to treat COVID -19. Therefore, there is an urgent public health need for rapid development of 
novel interventions.   
2.3 Risk/Benefit Assessment  
Each stage will detail the stage and study specific risk/benefit assessment.   
3. OBJECTIVES  AND  ENDPOINTS 
The overall objective of the study is to evaluate the clinical efficacy and safety of different 
investigational therapeutics relative to the control arm among hospi[INVESTIGATOR_119816] -19. 
 
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
To evaluate the clinical efficacy, as assessed 
by [CONTACT_435652], of different investigational therapeutics as compared to the control arm. Day of recovery is defined as the first day on 
which the subject satisfies one of the following three categories from the ordinal scale:  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on activities.  
Recovery is evaluated up until Day 29.  
Key Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics relative to the control arm in adults hospi[INVESTIGATOR_21391] -19 according to clinical status (8 -
point ordinal scale) at Day 15 
 
 
 • Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 20 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen - requiring ongoing medical care 
(COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplem ental 
oxygen - no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on 
activities.  
Additional Secondary   
1. To evaluate the clinical efficacy of 
different investigational therapeutics as compared to the control arm as assessed by:  
• Clinical Severity  
o Ordinal scale:  
 Time to an improvement of one category and two categories from Day 1 (baseline) using an ordinal scale.  
 Subject clinical status using ordinal scale at Days 3, 5, 8, 11, 15, 22, and 29.  
 Mean change in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and 29. 
  
  
• Clinical outcome assessed using ordinal 
scale daily while hospi[INVESTIGATOR_119818] 
15, 22, and 29. 
   
    
o National Early Warning Score 
(NEWS):  
 Time to discharge or to a NEWS of ≤ [ADDRESS_1055178].  
 Change from Day 1 to Days 3, 5, 8, 11, 15, and 29 in NEWS.  
  
 
• NEWS assessed daily while hospi[INVESTIGATOR_435619] 15 and 29. 
o Oxygenation:  
 Oxygenation use up to Day 29. 
 Incidence and duration of new oxygen use during the study. 
  
• Days of supplemental oxygen (if 
applicable) up to Day 29 
 
o Non-invasive ventilation/high flow 
oxygen: 
 Non-invasive ventilation/high flow 
oxygen use up to Day 29.  • Days of non -invasive ventilation/high 
flow oxygen (if applicable) up to Day 29 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 21 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
 Incidence and duration of new non -
invasive ventilation or high flow 
oxygen use during the study. 
 
o Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation (ECMO):  
 Ventilator / ECMO use up to Day 29. 
 Incidence and duration of new mechanical ventilation or ECMO use during the study.  
  
• Days of invasive mechanical ventilation/ECMO(if applicable) up to Day 29. 
 
• Hospi[INVESTIGATOR_059]  
o Duration of hospi[INVESTIGATOR_059] (days).  
  
• Days of hospi[INVESTIGATOR_119819] 29 
• Mortality  
o 14-day mortality  
o 28-day mortality  
  
• Date and cause of death (if applicable)  
 
2. To evaluate the safety of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Cumulative incidence of SAEs through Day 29. 
• Cumulative incidence of Grade 3 and 4 
clinical and/or laboratory AEs through 
Day 29 . 
• Discontinuation or temporary suspension of study product administration s (for any reason)  
• Changes in white blood cell (WBC) count with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and prothrombin time (PT) over time (analysis of lab values in addition 
to AEs noted above).   
  
• SAEs  
• Grade 3 and 4 AEs  
• WBC  with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and Days 15 and 29 (if attends in-person visit or still hospi[INVESTIGATOR_057]) . 
 
Exploratory   
To evaluate the virologic efficacy of different 
investigational therapeutics as compared to 
the control arm as assessed by:   
 
 
[CONTACT_1738] 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 22 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• Percent of subjects with SARS -CoV -2 
detectable in OP sample at Days 3, 5, 
8, 11, 15, and 29.  
• Quantitative SARS -CoV-[ADDRESS_1055179] e at Days 3, 5, 8, 11, 15, and 29. 
• Development of resistance of SARS-CoV-2 in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in 
blood at Days 3, 5, 8, and 11. 
 • Qualitative and quantitative polymerase 
chain reaction (PCR) for SARS -CoV-2 in 
OP swab on Day 1; Days 3, 5, 8, and 11 
(while hospi[INVESTIGATOR_057]); and Days 15 and 29 
(if attends in -person visit or still 
hospi[INVESTIGATOR_057]). 
• Qualitative and quantitative PCR for 
SARS -CoV-2 in blood on Day 1; Days 3, 
5, 8, and 11 (while hospi[INVESTIGATOR_057]). 
  
4. STUDY  DESIGN 
4.1 Overall Design  
This study is an adaptive randomized double-blind placebo- controlled trial to evaluate the safety 
and efficacy of novel therapeutic agents in hospi[INVESTIGATOR_249106]-19. The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. New arms can be introduced according to scientific and public health needs. There will be interim monitoring to allow early stoppi[INVESTIGATOR_16589], efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by [CONTACT_435651]. This adaptive platform is used to rapi[INVESTIGATOR_769095] a population of those hospi[INVESTIGATOR_605514] -19. The platform will provide a common f ramework sharing a 
similar population, design, endpoints, and safety oversight. New stages with new therapeutics can be introduced and will be described in a stage- specific appendix.  One independent Data and 
Safety Monitoring Board (DSMB) will actively monitor interim data in all stages to make recommendations about early study closure or changes to study arms.   Subjects will be assessed daily while hospi[INVESTIGATOR_057]. See section study specific Schedule of Assessment for details. All subjects will undergo a ser ies of efficacy, safety, and laboratory 
assessments. See  stage specific schedule of assessment for details.  
 The primary outcome is time to recovery by [CONTACT_2006] 29 (see table below for definition based on the ordinal scale). A key secondary outcome evaluates treatment -related improvements in the 8 -point 
ordinal scale at Day 15. Each stage may prioritize different secondary endpoints for the purpose of multiple comparison analyses.  The sample size will be described in each stage specific appendix.   
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055180] meet all of the following criteria:  
1. Admitted to a hospi[INVESTIGATOR_435629] -19. 
2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study pr ocedures.  
3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 
4. Male or non-pregnant female adult ≥18 years of age at time of enrollment. 
5. Has laboratory -confirmed SARS -CoV-2 infection as determined by [CONTACT_435653], as documented by [CONTACT_147664]:  
• PCR positive in sample collected < 72 hours prior to randomization; OR 
• PCR positive in sample collected ≥ 72 hours prior to randomization, document ed 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-[ADDRESS_1055181] one of the following:  
• Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, etc.), OR  
• SpO2 ≤ 94% on room air, OR 
• Requiring supplemental oxygen, OR  
• Requiring mechanical ventilation.  
7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 24 of 146 8. Agrees to not participate in another clinical trial for the t reatment of COVID -19 or 
SARS -CoV-2 through Day 29. 
5.2 Exclusion Criteria 
Exclusion criteria are described in each stage specific appendix.  
5.3 Specific Populations  
The inclusion of vulnerable subjects and exclusion of specific populations need to be customized 
according to each intervention, with the current understanding of epi[INVESTIGATOR_769100]. Inclusion and exclusion of specific populations will be described for each stage in the 
stage -specific appendices . 
5.4 Strategies for Recruitment and Retention  
 Recruitment  
It is anticipated that patients with COVID -19 will present to participating hospi[INVESTIGATOR_600], and that no 
external recruitment efforts towards potential subjects are needed. Recruitment efforts may also 
include dissemination of information a bout this trial to other medical professionals / hospi[INVESTIGATOR_600].  
 The IRB will approve the recruitment process and all materials provided prior to any recruitment to prospective subjects directly.  Screening will begin with a brief discussion with study staff.  Some will be excluded based on 
demographic data and medical history (i.e., pregnant, < 18 years of age, renal failure, etc.). Information about the study will be presented to potential subjects (or legally authorized representative) and questions will be asked to determine potential eligibility. Screening 
procedures can begin only after informed consent is obtained. 
 
 Retention  
Retention of subjects in this trial is very important for determining the primary endpoint. As such, after hospi[INVESTIGATOR_2345], participating subjects will be reminded of subsequent study visits and every effort will be made to accommodate the subject’s schedule to facilitate follow -up 
within the specified visit window. Additionally, there are many circumstances that influence the ability to obtain outcome information after discharge. Follow-up visits may be conducted by 
[CONTACT_119916]-person visits are not feasible.   
 Compensation Plan for Subjects  
Compensation, if any, will be determined locally and in accordance with local IRB requirements, and subject to local IRB approval.   
 Costs  
There is no cost to subjects for the research tests, procedures/evaluations and study product while taking part in this trial. Procedures and treatment for clinical care including costs associated with hospi[INVESTIGATOR_435630], subject’s insurance or third party. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055182] (s) for a given stage can be found in the st age specific appendix.  
7. STUDY  INTERVENTION  DISCONTINUATION  AND  
SUBJECT  DISCONTINUATION/WITHDRAWAL 
7.[ADDRESS_1055183] to follow-up after signing the informed consent form (ICF) and administration of the study product, will not be replaced. The reason for subject withdrawal from the study will be recorded on the appropriate CRF. 
7.[ADDRESS_1055184]’s records.  
8. STUDY  ASSESSMENTS  AND  PROCEDURES 
8.1 Screening and Efficacy Assessments  
 Screening Procedures  
Screening procedures may be done over one to two calendar days (from Day -1 to Day 1). However, in many cases all the screening assessments can be done in less than [ADDRESS_1055185] administration baseline assessments, specimen collection and 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055186] administration  can occur on the same calendar day as the screening 
procedures.  
 After the informed consent, the following assessments are performed to determine eligibility and obtain baseline data:  
• Confirm the positive SARS-CoV- [ADDRESS_1055187] result (per inclusion criteria).  
• Take a focused medical history, including the following information . Additional information 
may be needed based on risk profile of the study product and the exclusion criteria (e.g., 
recent live vaccine history). Please consult stage- specific appendix.  The minimum histor y 
includes :  
• Day of onset of COVID-19 signs and symptoms. 
• History of chronic medical conditions including chronic oxygen requirement prior to onset of COVID-19. 
• History of medication allergies.  
• Medications and therapi[INVESTIGATOR_119836] 7 days prior to Day 1. 
• Ask if they are participating in another clinical trial or plan to enroll in another clinical trial in the next 30 days.  
• Women of childbearing potential should be counseled to either practice abstinence or use at 
least one primar y form of contraception not including hormonal contraception from the time 
of screening through Day 29. Women should be confirmed to not be breastfeeding. 
• Note: If a woman is either postmenopausal (i.e., has had ≥12 months of spontaneous 
amenorrhea) or surgically sterile (i.e., has had a hysterectomy, bilateral ovariectomy (oophorectomy), or bilateral tubal ligation), she is not considered to be of childbearing potential.  
• Height and weight (height can be self -reported).  
• Results of recent radiographic imagi ng (x -ray or CT scan).  
• SpO2. 
• Blood for screening laboratory evaluations if not done as part of routine clinical care in the 
preceding [ADDRESS_1055188] for a gi ven stage of the study.  Please see stage specific 
appendix. The minimum screening laboratory evaluations include: 
 ALT.  
 AST.  
 Creatinine (and calculate eGFR).  
• Any automated calculation by [CONTACT_226300]. The site should select a formula to be used for all 
subjects enrolled at the site for the duration of the study. 
• Urine or serum pregnancy test (in women of childbearing potential). 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055189] administration including the collection of OP s wab 
and blood, assessment of the ordinal scale and NEWS and completing or recording a baseline physical examination that was done.  
 Efficacy Assessments  
For all baseline assessments and follow-up visits, refer to the Schedule of Assessments (SOA) for proced ure to be done, and details below for each assessment. 
 
 Measures of clinical support, limitations and infection control  
The subject’s clinical status will be captured on each study day while hospi[INVESTIGATOR_769101] 29. If a subject is disch arged prior to Day 15, clinical status is captured on Day [ADDRESS_1055190] 
administration, as time permits. The following measures are recorded for the ordinal scale: 
• Hospi[INVESTIGATOR_059].  
• Oxygen requirement. 
• Non-invasive mechanical ventilation (via mask) requirement. 
• High flow oxygen requirement. 
• Invasive mechanical ventilation (via endotracheal tube or tracheostomy tube) requirement.  
• ECMO requirement.  
• Ongoing medical care preventing hospi[INVESTIGATOR_2345] (COVID- 19 related or other medical 
conditions). 
• Limitations of physical activity (self -assessed).  
• Isolated for infection control purposes.  
 Ordinal Scale  
The ordinal scale is the primary measure of clinical outcome.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 28 of 146  
The scale used in this study is as follows (from worst to best): 
• Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing medical care (COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical care;  
o This would include those kept in hospi[INVESTIGATOR_41348]/infection control, awaiting bed in reha bilitation facility or homecare, etc.  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on activities  
 
 National Early Warning Score (NEWS) 
NEWS has demonstrated an ability to discriminate subjects at risk of poor outcomes. (Smith, 
2016). This score is based on 7 clinical parameters (see Table 2). The NEWS is being used as an 
efficacy measure. The NEW Score should be evaluated daily w hile hospi[INVESTIGATOR_119818] [ADDRESS_1055191] (EMR) using the last measurement prior to the time of assessmen t and a numeric score is given for each parameter 
(e.g., a RR of 9 is one point, oxygen saturation of 92 is two points). This is recorded for the day obtained (i.e., on Day 3, the vital signs and other parameters from Day 3 are used to obtain NEW Score for  Day 3).  ECMO and mechanically ventilated subjects should be assigned a score of 3 
for RR (RR <8) regardless of the ventilator setting. Subjects on ECMO should get a score of 3 
for heart rate since they are on cardiopulmonary by[CONTACT_6476].  Table 2. National Early Warning Score (NEWS) 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 29 of 146  
  Level of consciousness = alert (A), and non-alert and arousable only to voice (V) or pain (P), and 
unresponsive (U).  
 
  Exploratory assessments 
 Viral Load and/or Shedding  
As outlined on the SOA, OP swabs and plasma and serum will be collected on Day 1; and Days 
3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and OP swabs and serum on Day 15 and 29 (if attends an in- person visit or still hospi[INVESTIGATOR_057]). Samples are  stored as outlined in the MOP. These assays are 
not developed yet, and the ability to test samples at one central lab is not clear. Therefore, while viral load/shedding is thought to be an important endpoint, considering the limitations above, it is listed as an exploratory endpoint.  
 OP swabs are preferred, but if these are not obtainable, nasopharyngeal (NP) or nasal swabs may 
be substituted. Due to limited lack of swabs and other supplies at some sites and limitations on 
personal protective equipment (PPE), the inability to obtain these samples are not considered 
protocol deviations and should be documented in the subject’s record.   If virology assays can be set up with enough numbers of specimens tested, these data will be submitted as part of the Clinical Study Report ( CSR). This may be submitted separately, as a 
supplemental CSR.   Samples collected for viral assessment may be probed for the emergence of antiviral resistance at a future date. These data, if available, may be submitted as a supplement report.  
 
The schedule of assessments (SOA, Section  1.3) lists several research laboratory samples. It is 
preferred that these samples are collected and sent to the NIAID repositor y to be tested in one 
central laboratory. Current US Centers for Disease Control and Prevention (CDC) guidance is these samples can be processed in a Biosafety Laboratory (BSL) 2 environment. However, 

Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 30 of 146 institutions may impose restrictions on processing the samples (i.e., they may require BSL -3) or 
there may be restrictions on sending samples. In these circumstances, the following apply: 
 Blood for PCR SARS -CoV-2 
• If the samples can be processed but cannot be sent to the repository, the samples may be stored l ocally.  
• The sponsor may elect to have some or all of these samples run locally, pending 
confirmation of the assays to be used and the qualifications of the local laboratory. The 
sponsor will work with the site to determine when this could occur and how these data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.  
 Oropharyngeal swab 
• If the samples can be processed but cannot be sent to the repository, the samples may be stored locally.  
• The sponsor may elect to have some or all of these samples run locally, pending confirmation of the assays to be used and the qualifications of the local laboratory. The sponsor will work with the site to determine when this could occur and how these data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.  
 Blood for serum (for secondary research)  
• If the samples can be processed and but not sent to the repository, the samples may be stored locally.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.  
 
8.2 Safety and Other Assessments  
Study procedures are specifi ed in the SOA. A study physician licensed to make medical 
diagnoses and listed on the 1572 will be responsible for all trial- related medical decisions.  
 
Physical examination :  
A targeted physical examination will be performed at baseline prior to initial study product 
administration  on Day 1. The baseline physical examination can be one that is conducted from 
screening to Day 1. Post- baseline physical examinations will be done o nly when needed to 
evaluate possible adverse event(s) (i.e. any new signs or symptoms). No routine physical exam is needed for study visits after Day 1.   Study staff at some sites are not allowed into the subject’s rooms due to a limited supply of PPE and the need for strict respi[INVESTIGATOR_119837]-[ADDRESS_1055192] information from the hospi[INVESTIGATOR_119838].  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 31 of 146  
Clinical laboratory evaluations : 
• Fasting is not required before collection of laboratory samples. 
• Blood will be collected at the time points indicated in the SOA.  
• Minimal c linical safety laborato ry tests include WBC, differential, Hgb, PLT, 
creatinine, glucose, total bilirubin, AST, ALT, and PT. Sites that do not have 
access to a test for  PT/INR will be allowed to report an international normalized 
ratio (INR).  Additional safety laboratory tests may be required for a given stage 
due to the study product risk profile. See safety laboratory in the stage- specific 
appendix. 
• Day [ADDRESS_1055193] administration should be given. 
• Clinical laboratory testing will be performed at each clinical trial site in real time.  
  Table 3. Venipuncture Volumes
1 
 Screen  Baseline        
Day +/ - Window  −1 to 1  1 ± 1  3 ± 1  5 ±1 8 ± 1  11 ± 1  15 ± 2  29 ± 3  
Safety hematology, 
chemistry and liver 
tests  X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2  X3 
10mL2 X3 
10mL2 
Blood for Serum   X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  
Plasma  
(includes PCR)   X 
8mL  X 
8mL  X 
8mL  X 
8mL  X 
8mL    
Total volume  10mL  42ml 42mL  42ml 42ml 42ml 34mL  34mL  
Total all study days         268~[ADDRESS_1055194] Values or 
Abnormal Clinical Findings  
If a physiologic parameter (e.g., vital signs, or laboratory value) is outside of the protocol-specified range, then the measurement may be repeated once if, in the judgment of the investigator, the abnormality is the result of an acute, short-term, rapi[INVESTIGATOR_119846]. A physiologic parameter ma y also be repeated if there is a technical problem with 
the measurement caused by [CONTACT_566276] (i.e., inappropriate- sized BP cuff).  
 
 Unscheduled Visits  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055195]’s well -being, it is permissible in this protocol.  However, no 
research data is collected at this visit.   
8.3 Adverse Events and Serious Adverse Events  
 Definition of Adverse Event (AE)  
AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention- related. An AE can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.  If mu ltiple abnormalities are part 
of the same clinical syndrome, they can be reported together as one AE under a unifying clinical diagnosis. For example, the diagnosis of bacterial sepsis may include hypotension, positive blood culture, and increased white blood cell count.  Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severi ty of any pre -existing (baseline) 
medical condition increases above baseline to severity grade [ADDRESS_1055196] many symptoms and abnormalities in vital sign s and laboratory values. Only Grade 3 and 4 AEs will be captured in 
this trial. In addition, the following AEs will be reported: 
• Any Grade [ADDRESS_1055197] administration will be re ported as an AE.  
 Intermittent abnormal laboratory values or vital sign measurements common in the severely ill populations (such as electrolyte abnormalities, low blood pressure, hyperglycemia, etc.) that are part of the same clinical diagnosis (e.g., uncontrolled diabetic) can be recorded once with the worst grade for each adverse event (grade 3 and 4 only for this trial), with the start and stops dates of the intermittent syndrome.  If there is clear resolution of the event, and then recurrence, it 
should be treated as a separate adverse event. Resolution is defined as return to baseline (either normal if was normal at Day 1, or baseline (Day 1) grade if already an abnormality on the toxicity table at Day 1) for > 48 hours.    
 Definition of Serious Adverse Event (SAE)  
An AE or suspected adverse reaction is considered serious (i.e., is an SAE) if, in the view of either the investigator or the Sponsor, it results in any of the following outcomes: 
• Death;  
• A life -threatening AE;  
• Inpatient hospi[INVESTIGATOR_1081]; 
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 33 of 146 • A congenital anomaly/birth defect.  
 
Important medical events that may not meet the above criteria may be considered serious when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical  events include allergic bronchospasm requiring intensive treatment in 
an emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  “Life -threatening” ref ers to an AE that at occurrence represents an immediate risk of death to a 
subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening. Similarly, a hospi[INVESTIGATOR_178105] a SAE.  
 All SAEs, as with any AE, will be assessed for severity and relationship to study intervention.  All SAEs will be recorded on the SAE CRF.  All SAEs will be followed through resolution or stabilization by a licensed study physician (for IND st udies, a physician listed on the Form FDA 1572 as the site PI [INVESTIGATOR_54720]-Investigator). 
 All SAEs will be reviewed and evaluated by [CONTACT_435661] (for periodic review), and the IRB/IEC. 
 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]R)  
A S[LOCATION_003]R is any SAE where a causal relationship with the study product is at least reasonably possible but is not listed in the IIB, Package Insert, and/or Summary of Product Characteristics. 
 Classification of an Adverse Event  
The determination of seriousness, severity, and causality will be made by [CONTACT_63689]- site investigator 
who is qualified (licensed) to diagnose AE information, provide a medical evaluation of AEs, and classify AEs based upon medical judgment. This includes but is not limited to physicians, physician assistants, and nurse practitioners. 
 Severity of Adverse Events  
All AEs and SAEs will be assessed for severity using the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1 (July 2017).   
For AEs not included in the Table, the following guidelines will be used to describe severity. In addition, all deaths related to an AE are to be classified as grade 5 according to the DAIDS Table.   
  
• Moderate (Grade 2) : Events that are usually alleviated with additio nal specific 
therapeutic intervention. The event interferes with usual activities of daily living and causes discomfort but poses no significant or permanent risk of harm to the research subject.  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 34 of 146 • Severe (Grade 3) : Events that interrupt usual activities of  daily living, or significantly 
affect clinical status, or may require intensive therapeutic intervention. Severe events are 
usually incapacitating.  
 
• Severe (Grade 4) : Events that are potentially life threatening.  
 
• Deaths (Grade 5):  All deaths related to an AE are to be classified as grade 5. (per DAIDS 
Table).  
 
 Relationship to Study Intervention 
For each reported adverse reaction, the PI [INVESTIGATOR_435632]:  
• Related  – There is a temporal relationship between the study intervention and event, and 
the AE is known to occur with the study intervention or there is a reasonable possibility that the study intervention caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.  
 
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established. 
 Time Period and Frequency for Event Assessment and Follow -Up 
For this study, all Grade [ADDRESS_1055198] 
administration  will be reported as an AE.  
 
 Investigators Reporti ng of AEs  
Information on all AEs will be recorded on the appropriate CRF. All clearly related signs, symptoms, and results of diagnostic procedures performed because of an AE should be grouped together and recorded as a single diagnosis. If the AE is a laboratory abnormality that is part of a clinical condition or syndrome, it should be recorded as the syndrome or diagnosis rather than the individual laboratory abnormality. Each AE will also be described in terms of duration (start and stop date), severity, association with the study product, action(s) taken, and outcome. 
 Serious Adverse Event Reporting  
 Investigators Reporting of SAEs 
Any AE that meets a protocol -defined criterion as a SAE must be submitted within 24 hours of 
site awareness on an SAE form to the DMID Pharmacovigilance Group, at the following address:  
 
DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS) [ADDRESS_1055199]. Suite 650 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 35 of 146 Bethesda, MD [ZIP_CODE], [LOCATION_003] 
SAE Hot Line: 1 -[PHONE_889] (US) or [PHONE_2619] (outside US) 
SAE FAX Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Address: [EMAIL_1393] 
 Other supporting documentation of the event may be requested by [CONTACT_295051]. The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct.  At any time after completion of the study, if the site PI [INVESTIGATOR_29353]- investigator becomes 
aware of an SAE that occurred during the subject’s participation in the study, the site PI [INVESTIGATOR_29353]- investigator will report the event to the DMID Pharmacovigilance Group. 
 Regulatory Reporting of SAEs 
Following notification from the site PI [INVESTIGATOR_29353]-investigator, DMID, as the IND Sponsor, will report any S[LOCATION_003]R in an IND safety report to the FDA and will notify all participating site PIs as soon as possible. DMID will report to the FDA any unexpected fatal or 
life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 
calendar days after the Sponsor’s initial receipt of the information. If the event is not fatal or life -
threatening, the IND safety report will be submitted within [ADDRESS_1055200] additional local reporting requirements (to the IRB and/or national regulatory authority).  
 Reporting of Pregnancy 
Pregnancy is not an AE. However, any pregnancy that occurs during study participation should be reported to the Sponsor on the appropriate CRF. Pregnancy should be followed to outcome.  
8.4 Unanticipated Problems  
 Definition of Un anticipated Problems  
An Unanticipated Problem (UP) is any event, incident, experience, or outcome that meets the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research 
protocol and informed consent document; and (b) the characteristics of the subject population being studied; 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 36 of 146  Related to participation in the research (meaning there is a reasonable possibility that the 
incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
 Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 Unanticipated Problem Reporting  
To satisfy the requirement for prompt reporting, all UPs will be reported using the following timeline:  
 UPs that are SAEs will be reported to the IRB and to the Statistical and Data Coordinating Center (SDCC)/study Sponsor within 24 hours of the investigator becoming aware of the event per the above describe SAE reporting process.  
 Any other UP will be reported to the IRB and to the SDCC/study Sponsor within 3 days of the investigator becom ing aware of the problem.  
9. STATISTICAL  CONSIDERATIONS 
This is an adaptive platform study is intended to allow for several  adaptations: 1) sample size re -
estimation and 2) addition of new experimental arm(s) into one stage, or 3) addition of separate study s tages . A brief summary is provided the study specific appendix for each stage. Details 
will be described in the statistical analysis plan (SAP)  for each stage.   
 
10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS 
10.1 Regulatory, Ethical, and Study Oversight Considerations  
This study will be conducted in conformity with the principles set forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research (US National Commission for the Protection of Human Subject s of Biomedical and Behavioral 
Research; April 18, 1979), and the federal policy for the Protection of Human Subjects codified in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Subjects), and the ICH E6 (R2).  Each institution engaged in this research will hold an OHRP -approved FWA. OHRP- registered 
IRBs will review and approve this protocol, associated informed consent documents, recruitment material, and handouts or surveys intended for the subjects, prior to the recruitment, screening, and en rollment of subjects. The IRB review shall be in accordance with 45 CFR 46 and 21 CFR 
50, 21 CFR 56 (IRBs), and other federal, state, and local regulations and policies, as applicable.  Site IRBs may have additional national and local regulations.  Any amendments to the protocol or consent materials will be approved by [CONTACT_106526]. IRB review and approval will occur at least annually throughout the duration 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055201] receive the documentation that verifies IRB -approval for this protocol, informed 
consent documents, and associated documents prior to the recruitment, screening, and enrollment of subjects, and any IRB -approvals for continuing review or amendments as required by [CONTACT_394452].  
 Informed Consent Process  
Informed consent is a process that is initiated prior to an individual agreeing to participate in a trial and continuing throughout the individual’s trial participation. Investigators or designated research staff will obtain a subject’s informed consent in accordance with the requirements of 45 CFR 46, 21 CFR 50 and 21 CFR 56 for FDA-regulated studies, state and local regulations and policy, and ICH E6 GCP before any study procedures or data collection are performed. 
Typi[INVESTIGATOR_897], subjects or their legally authorized representatives (LAR) receive a concise and 
focused presentation of key information about the clinical trial, verbally and with a written consent form. Subjects will be asked to read and review the consent form. Subjects (or LAR) must sign the ICF prior to starting any study procedures being done specifically for this trial. Once signed, a copy of the ICF will be given to the subject or the L AR for their records.  
 However, due to strict respi[INVESTIGATOR_435635], limited access to COVID -19 patient rooms 
and SARS-CoV- 2 transmissibility via droplet-contaminated paper, verbal consent and alternative 
methods of obtaining consent (e.g., by [CONTACT_648]) will be allowed if approved by [CONTACT_1201]. In addition, if a signed paper copy of the ICF is allowed by [CONTACT_2360][INVESTIGATOR_41361], how it will be obtained and stored will need to be determined. Any variation from the standard consent process due to isolation and infection control should be sent to the IRB for approval prior to enrollment. The site should document the process in their regulatory files and demonstrate that the process has IRB concurrence or approval.  Regardless of the method for obtaining consent, the key information about the study will be organized and presented in lay terminology and language that facilitates understanding why one might or might not want to participate. The site should translate the consent into non-English languages consistent wit h the local population. Translations should be sent to the sponsor for any 
necessary back translations. New information will be communicated by [CONTACT_7880] [INVESTIGATOR_422703]. The inform ed 
consent document will be updated, and subjects will be re-consented per IRB requirements, if necessary.  
 
 Requirements for Permission by [CONTACT_122781]/Guardians and Assent by [CONTACT_63779] (in case of a minor) 
Not Applicable  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055202] additional blood, the use of residual specimens, and 
samples for secondary research. Extra blood will be drawn for secondary research during each visit when a study blood samples are obtained.   The stored samples w ill be labeled with barcodes to maintain confidentiality. Research with 
identifiable samples and data may occur as needed; however, subject confidentiality will be maintained as described for this protocol and with IRB approval.  Samples designated for secondary research use may be used for understanding the SARS-CoV-[ADDRESS_1055203]’s medical record. 
Incidental findings will not be shared with the subject, including medically actionable incidental findings, unles s required by [CONTACT_2371].  
Subjects may withdraw permission to use samples for secondary use at any time. They will need to contact [CONTACT_769127] s the reason for withdrawal 
of permission for secondary use of samples.   
 Study Termination and Closure  
Section 7, Study Intervention Discontinuation and Subject Discontinuation/Withdrawal, 
describes the temporary halting of the study.  This study may be prematurely terminated if there is sufficient reasonable cause, including but not limited to:  
• Determination of unexpected, significant, or unacceptable risk to subjects 
• Results of interim analysis  
• Insufficient compliance with protocol requirements  
• Data that are not sufficiently complete and/or not evaluable 
• Regulatory authorities decide that study should be terminated 
If the study is prematurely terminated, then the site PI [INVESTIGATOR_435637]. The site PI [INVESTIGATOR_154338] -up for the subjects, as 
necessary.  
 The Sponsor will notify regulatory authorities as applicable. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055204] by [CONTACT_3486], their staff, and 
the Sponsor(s) and their agents. This confidentiality is extended to cover clinical information 
relating to subjects, test results of biological samples, and all other info rmation generated by 
[CONTACT_9286]. No identifiable information concerning subjects in the study will be released to any unauthorized third party. Subject confidentiality will be maintained when study results are published or discussed in conf erences.  
 The study monitor, other authorized representatives of the Sponsor, representatives of the IRB, and/or regulatory agencies may inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to medical r ecords (office, clinic, or hospi[INVESTIGATOR_307]) and 
pharmacy records for the subjects in this study. The clinical study site will permit access to such records.  
 All source records including electronic data will be stored in secured systems in accordance with institu tional policies and federal regulations. 
 All study data and research specimens that leave the site (including any electronic transmission of data) will be identified only by a coded number that is linked to a subject through a code key maintained at the clinical site. Names or readily identifying information will not be released unless DMID approves and it aligns with the consent form, or according to laws for required reporting.  
 Secondary Use of Stored Specimens and Data  
This section applies to those subjects who consented to storage of samples for secondary research. Secondary Human Subject Research is the re- use of identifiable data or identifiable 
biospecimens that were collected from some other ‘‘primary’’ or ‘‘initial’’ activity, such as the data and samples collected in this protocol. Any use of the sample or data for secondary research 
purposes, however, will be presented in a separate protocol and require separate IRB approval. 
 
Each sample will be labeled only with a barcode and a unique tracking number to protect subject confidentiality. Secondary research with coded samples and data may occur; however, subject confidentiality will be maintained as described for this protocol. An IRB review of the secondary research using coded specimens is required. 
 The subject’s decision can be changed at any time by [CONTACT_154387]. If the subject subsequently changes his/her decision, the samples will be destroyed if the samples have not been used for research or relea sed for a specific research project.  
 Data Sharing for Secondary Research 
Data from this study may be used for secondary research. All of the individual subject data collected during the trial will be made available after de -identification. The SAP and Anal ytic 
Code will also be made available. This data will be available immediately following publication, with no end date.   
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055205] been distributed for approved research use cannot be retrieved. 
 Key Roles and Study Governance 
The study is sponsored by [CONTACT_122830]. Decisions related to the study will be made by a protoc ol team 
that includes representatives from all countries, and separate networks within a country. 
 Safety Oversight 
 Protocol team oversight 
A subset of the protocol team will review blinded pools of AE data every 2 weeks to ensure no significant number of unexpected AEs (AEs that do not fit with the known course of COVID-19). If there are a significant number of unexpected AEs, the DSMB will be asked to review unblinded safety data in an ad hoc meeting.  
 Data Safety Monitoring Board 
Safety oversight will be conducted by a DSMB that is an independent group of experts that 
monitors subject safety and advises DMID. The DSMB members will be separate and independent of study personnel participating in this trial and should not have scientific, financial or other c onflicts of interest related to this trial. The DSMB will consist of members with 
appropriate expertise to contribute to the interpretation of the data from this trial. The DSMB should be as broadly informed as possible regarding emerging evidence from related studies. The DSMB will operate under the guidelines of a DMID- approved charter that will be written at the 
organizational meeting of the DSMB. The DSMB will review SAEs on a regular basis and ad hoc during this trial. The DMID Medical Monitor will be responsible for reviewing SAEs in real 
time. The DSMB will review SAEs on a regular basis and ad hoc during this trial.  The DSMB will conduct the following reviews: 
• Intermittent safety reviews at a frequency as determined by [CONTACT_4318].  The DSMB will 
have access to safety data electronically in real time.  
• Formal safety/efficacy reviews after approximately every [ADDRESS_1055206] met recovered status for each pairwise comparison  
• Ad hoc meeting if the protocol team raises any concerns  
• A final review meeting a fter final clinical database lock, to review the cumulative 
unblinded safety data for this trial.  
 The study will not stop enrollment awaiting these DSMB reviews, although the DSMB may recommend temporary or permanent cessation of enrollment based on thei r safety reviews.  
  Additional data may be requested by [CONTACT_4318], and interim statistical reports may be generated as deemed necessary and appropriate by [CONTACT_122830]. The DSMB may receive data in aggregate and presented by [CONTACT_2939]. The DSMB may also be provided with expected and observed rates 
of the expected AEs in an unblinded fashion and may request the treatment assignment be unblinded for an individual subject if required for safety assessment. The DSMB will review grouped and unblinded data in the closed session only. At each meeting, the DSMB will make a recommendation as to the advisability of proceeding with study interventions (as applicable), and to continue, modify, or terminate this trial.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055207] of the trial is in compliance with the currently approved protocol/ amendment(s), ICH, GCP, and with applicable regulatory requirement(s) and Sponsor requirements. Clinical monitoring will also verify that any critical study procedures are completed following specific instructions in the protocol- specific MOP . 
 Monitoring for this study will be performed by [CONTACT_435665]. Details of clinical site monitoring are documented in a clinical monitoring plan (CMP). The CMP describes in detail who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. Monitoring visits will include, but are not limited to, review of regulatory files, accountability records, CRFs, ICFs, medical and laboratory reports, site study intervention storage records, training records, 
and protocol and GCP compliance. Site monitors will have access to each participating site, study personnel, and all study documentation according to the DMID- approv ed site monitoring 
plan. Study monitors will meet with site PIs to discuss any problems and outstanding issues and will document site visit findings and discussions. 
 Data Handling and Record Keepi[INVESTIGATOR_769102]. The site PI [INVESTIGATOR_257903].  Clinical research data from source documentation (incl uding, but not limited to, AE/SAEs, 
concomitant medications, medical history, physical assessments, clinical laboratory data) will be entered by [CONTACT_769128] a [ADDRESS_1055208] current v ersions of MedDRA and WHODrug, respectively. 
 The SDCC for this study will be responsible for data management, quality review, analysis, and reporting of the study data.  The IND Sponsor is responsible for review of data collection tools and processes, and review of 
data and reports.  A separate study specific Study Data Standardization Plan (SDSP) appendix will be developed which describes the technical recommendations for the submission of human study data and related information in a standardized electro nic format throughout product development.  
 At the end of the study, a copy of all datasets including annotated CRFs and data dictionary will be provided to DMID. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055209] for the indication for which it is being investigated; or, if no application is to be filed or if the application is not approved for such indication, until [ADDRESS_1055210] research.  
 Source Records  
Source data are all information in original records (and certified copi[INVESTIGATOR_63062]) of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data should be attributable, legible, contemporaneous, original, accurate, and complete. Each participating site will maintain appropriate medical an d research records for this trial, in compliance with ICH GCP, regulatory, 
and institutional requirements. Data recorded in the CRF derived from source documents should be consistent with the data recorded on the source documents.   It is understood that biocontainment may necessitate alternative processes for storing consents and other source documents. Each site will determine and document this process.  Interview of subjects is sufficient for obtaining medical history. Solicitation of medical records from the subject’s primary care provider is not required. 
  Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, any process that is noted in the protocol and refers to details in the protocol- specific MOP, or GCP req uirements or 
any critical study procedures with specific instructions in ancillary documents referenced in the protocol such as a protocol- specific MOP.  
 The noncompliance may be either on the part of the subject, the investigator, or the study site staff. Following a deviation(s), corrective actions should be developed by [CONTACT_3483]. All individual protocol deviations will be addressed in subject study records.  
 It is the responsibility of the site PI [INVESTIGATOR_154339], or within five working days of the scheduled protocol-required activity. All deviations must be promptly reported to DMID per the protocol deviation reporting procedures. Protocol deviations must be sent to the local IRB/IEC per their guidelines. The site PI [INVESTIGATOR_154366]. A completed copy of the DMID Protocol Deviation For m must be maintained in the Regulatory File, as well as in the subject’s chart if the 
deviation is subject specific.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 43 of 146 
 Publication and Data Sharing Policy 
Following completion of the study, results of this research will be published in a scientific 
journal. As this is an adaptive study and given the public health urgency to disseminate results, data from individual comparisons (i.e. the initial 2 study arms) can be published when those arms are fully enrolled and all subjects in those arms are followed through to completion of the study.   Data will be available immediately following publication, with no end date, with data sharing at the discretion of the Sponsor. Sites may also obtain individual or country level data from the database for separate publicatio ns is desired. Publication may occur prior to completion of a final 
clinical study report for the entire trial.  
  Human Data Sharing Plan 
This study will be conducted in accordance with the following publication and data sharing policies and regulations: 
• NIH Public Access Policy, which ensures that the public has access to the published 
results of NIH funded research. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication.  
 Publication  
Following completion of the study, the protocol team is expected to publish the results of this research in a scientific journal. This study will adhere to the following publication and data sharing policies and regu lations:  
• This study will comply with the NIH Public Access Policy, which ensures that the public has access to the published results of NIH funded research. As such, the final peer-reviewed journal manuscripts will accessible to the public on PubMed Centra l no later 
than [ADDRESS_1055211]. The site PI 
[CONTACT_1738] 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055212]  
FDA  Food and Drug Administration  
FWA  Federal Wide Assurance  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practices  
Hgb Hemoglobin  
HR Heart Rate  
IB Investigator’s Brochure  
ICD International Classification of Diseases  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IND Investigational New Drug Application  
INR International Normalized Ratio 
IRB Institutional Review Board  
IV Intravenous  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055213] Respi[INVESTIGATOR_435639]  
N Number (typi[INVESTIGATOR_19737])  
NDA  New Drug Application  
NEWS  National Early Warning Score  
NIAID  National Institute of Allergy and Infectious Diseases  
NIH National Institutes of Health  
NP Nasopharyngeal  
OHRP  Office for Human Research Protections  
OP Oropharyngeal  
PHI Protected Health Information  
PI [INVESTIGATOR_769103] -beta-cyclodextrin  
SDCC  Statistical and Data Coordinating Center  
SDSP  Study Data Standardization Plan  
SNP Single Nucleotide Polymorphisms  
SOA  Schedule of Assessments  
SOC  System Organ Class  
SOP Standard Operating Procedure  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
T. Bili  Total Bilirubin  
TNF  Tumor Necrosis Factor  
UP Unanticipated Problem  
US [LOCATION_002]  
WBC  White Blood Cell  
10.4 Protocol Amendment History 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 46 of 146 Version/Date    
Section  Description of 
Change  Brief Rationale 
2.0 
2MAR2020    
 Overall  This version addresses the comments received from the US 
FDA, Japanese PDMA, DSMB, IRBs, and NIAID scientific 
review.  
 Improved 
clarity and 
brevity  Multiple areas throughout the document were reworded to 
improve clarity (recognized after implementation) and edited 
to minimize redundant statements.  
1.[ADDRESS_1055214] (OR 1.75) and the 8- category scale and give the 
sample size of 440.  
 Addition of 
phone call on 
Day [ADDRESS_1055215] some 
COVID -19 patients worsen between 2 and 4 weeks of 
illness. We added Day 22 because of concerns that the peak 
illness may be missed. There are also concerns if the more 
severe population will be discharged by [CONTACT_2006] 29.  
 Ordinal scale 
was increased 
to 8 categories.  This addresses the concern raised by [CONTACT_769129] 
“Hospi[INVESTIGATOR_179423]” is two separate populations – 
those still needing medical care and those kep t in hospi[INVESTIGATOR_769104].  
 Objectives and 
endpoints were 
put into table 
format  Multiple comments that the tabular form of objectives and 
endpoints (that was previously in Section 4) was much easier 
to read and understand. 
 Added 
inclusion 
criteria for 
admission to 
hospi[INVESTIGATOR_435642], but never stated 
in the inclusion criteria.  
 Inclusion 
criteria #8  Contraceptive requirement aligned to new IB from February 
21, 2020  
 Phase of study Changed to phase 3. After discussion with company, and 
new IB that outlines safety data of > 500 subjects, the 
company thought this was more accurately called a phase 3 
trial. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055216] 
enrollment.  
8.1.2 Efficacy 
assessments 
more detailed  More detail is provided to facilitate these assessments. Also, 
each compone nt that contribute to the categories will not be 
captured separately. This will allow the ordinal scale as 
structured, but also will allow analysis of alternative ordinal 
scales.  
[IP_ADDRESS] Viral load in 
plasma and 
resistance  The assessment of viral load in plasma and detection of 
resistance was previously noted on the SOA, but never 
discussed in the text. This has now been added in this 
section.  
9.[ADDRESS_1055217] change leading to new tables.  
3.0 
27MAR2020    
 Improved 
clarity  Multiple areas throughout the document were reworded to 
improve clarity (issues that arose with implementation)  
 Flexibility  The pandemic has limited ability for people to be seen in 
follow-up due to infection control and restrictions on travel. 
Additionally, staff at some sites have limited ability to go 
into rooms due to limited personal protective equipment. So 
flexibility has been added where possible while still ensuring 
safety and good scientific data.  
1.[ADDRESS_1055218] which 400 subjects with 
a “recovered” status (per the primary objective). 
Additionally, enrollment is permitted after the 400 
recoveries up to April 20 to provide additional data about 
important subgroups.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 48 of 146  Primary 
Endpoint Given evolving data, the precise day of assessment of the 
primary endpoint is not clear. Modeling of the prior endpoint 
suggested if the day is chosen incorrectly, the power is 
significantly decreased. So the primary endpoint has been 
changed from a ordinal scale on a given day to days to 
recovery (the best three categories of the ordinal scale).  
 Key secondary 
endpoint  The prior primary endpoint has been labeled as the key 
secondary endpoint.  
 Inclusion 
Criteria #5  Given delays of PCR results in some sites (given number of 
tests and throughput within the lab), the PCR positive 
requirement has been written to allow flexibility if the PCR 
results are delayed.  
 Inclusion 
Criteria #6  Removed auscultation req uirement given challenges of 
accurate auscultation while in full PPE.  
 Exclusion 
Criteria #[ADDRESS_1055219], the newly 
manufactured lot of remdesivir is in 100mg vials. Second, 
there is limited supply of placebo and the options for using 
saline with an opaque bag for the control infusion was 
added.  
6.5 Concomitant 
Therapy  There has been significant increase in use of off label 
therapi[INVESTIGATOR_135297] -19, including many repurposed agents 
and therapi[INVESTIGATOR_769105]. So additional 
wording was added to cover these scenarios to minimize 
additional confounding medicatio ns.  
8.1.3 Sample 
Processing  Some sites are reporting needing to process samples in BSL -
3 and/or have limitations on processing, shippi[INVESTIGATOR_007], storage, 
etc. of samples. So wording was added to allow exclusion of 
these samples (which may be cost prohibitive)  
8.2 Venipuncture 
volume  This table was corrected for total volumes, but not new 
samples were added.  
9 Statistical 
Considerations  This section was rewritten to given the change in sample 
size. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 49 of 146 10.1.1 Informed 
consent Given isolation and infection control issues with COVID -19, 
traditional consenting documentation is not always possible. 
This section was rewritten to allow alternative consent 
processes and documentation as long as these are acceptable 
to the site’s IRB.  
4.0 
13APR2020  Note – version 4 was submitted to the US FDA and some IRBs, but  given  
the interim DSMB findings this version was  never implemented.  
 General , 
Appendix A, 
Appendix B As this is an adaptive study, an additional treatment stage 
“ACTT -2” was added.  To allow better organization, the 
general protocol was separated from the study specific 
Appendix A (remdesivir vs placebo) and Appendix B (2x2 
study factorial design of +/ - remdesivir and +/ - baricitinib).  
 Appendix B Appendix B is a  new stage in the platform study that 
describes all study specifics of the 2x2 study factorial design 
of +/ - remdesivir and +/ - baricitinib  
Appendix  B- 
[ADDRESS_1055220] a 2 
arms study -  Baricitinib/Remdesivir Vs. Remdesivir  
App B – [ADDRESS_1055221] of a 
second agent (i.e. the incremental value of no treatment to 1 treatment is likely larger than from 1 treatment to a 
combination.  
App B – [ADDRESS_1055222] that all subjects (both 
arms) will receive remdesivir.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055223] by [CONTACT_769130] (CSSE) at Johns Hopkins University (JHU) 2020 [Available from: https://coronavirus.jhu.edu/map.html. App B – 
[IP_ADDRESS]  Potential 
benefits  Updated with the preliminary findings from ACTT-1. 
App B – 
[IP_ADDRESS]  Potential Risks 
of Baricitinib  Updated with additional language about drug -drug 
interactions as requested by [CONTACT_1622].  
App B – 
6.1.[ADDRESS_1055224] 
Description  Additional wording was added to better describe the 
baricitinib placebo.  
App B – 
6.3.1  Randomization Stratification was revised to match the ordinal scale 
categories rath er than separate criteria.  
App B – 
6.3.[ADDRESS_1055225]  (baricitinib only), and the unblinding process 
(both routine and unplanned for given subjects).  
App B – 
[IP_ADDRESS]  Expl oratory 
endpoints  Exploratory endpoints were added for cytokine assessments 
to support the mechanism of action of the baricitinib arm.  
App B – 
[IP_ADDRESS]  Reporting of 
AEs Added wording for better reporting of new infections, and 
requested by [CONTACT_1622].  
App B – 
[IP_ADDRESS] Investigator 
reporting of 
SAEs  Revised wording for SAE reporting.  All SAEs are saptured 
in the regular database.  Only those SAEs that are judged to be relat ed to either study product are submitted on a larger 
SAE form.  
6.0 
21MAY2020    
Appendix  B – 
1.1 Exclusion 
Criteria  Added exclusion for remdesivir use prior to study entry 
(exclusing 3 or more doses).  
Appendix B – 
1.1 Exclusion 
Criteria  Separated prior exclusion based on immunosuppressants into 
different categories with different time periods (based on FDA’s comments).  Small molecule exclusion shortened to 1 
week and some biologics increased to 3 months.   
Appendix B – 
1.1 Exclusion 
Criteria Revised exclusion for corticosteroid use to permit larger 
amounts prior to enrollment (this is often used for syndromes related to COVID such as asthma exacerbation, 
and the prior wording was too restrictive).  
Appendix B – 
4.2 Scientific 
Rationale for 
Study Design  This section was blank before, so scientific rationale for 
ACTT -2 was added (scientific rational was previously 
conveyed in the background, but not this section).  
Appendix B – 
5.4 Lifestyle 
Considerations Revised to be more prec ise regarding what types of studies 
subjects can be co -enrolled in (reflecting questions that have 
arisen during the study).  
Appendix B – 
6.[ADDRESS_1055226] 
care for non -COVID -19 syndromes.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 51 of 146 2. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia 
associated with the 2019 novel coronavirus indicating person- to-person transmission: a study of 
a family cluster. Lancet. 2020;395([ZIP_CODE]):514-23. 3. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential dome stic and 
international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020;395([ZIP_CODE]):689-97. 4. Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, et al. GS-5734 and its parent nucleoside analo g inhibit Filo -, Pneumo-, and Paramyxoviruses. Sci Rep. 
2017;7:[ZIP_CODE]. 5. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS -[ADDRESS_1055227] Ebola virus in rhesus monkeys. Nature. 
2016;531(7594):381-5. 6. Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, et al. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. Sci Transl Med. 2019;11(494). 7. Mulangu S, Dodd LE, Davey RT, Jr., Tshiani Mbaya O, Proschan M, Mukadi D, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019;381(24):2293-303. 8. Brown AJ, Won JJ, Graham RL, Dinnon KH, 3rd, Sims AC, Feng JY, et al. Broad spectrum antiviral remdesivir inhibits human endemic an d zoonotic deltacoronaviruses with a 
highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541. 9. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopi[INVESTIGATOR_054], ritonavir, and interferon beta against MERS -CoV. Nat Commun. 2020;11(1):222. 
10. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS -5734) Is Mediated by [CONTACT_769131] d 
the Proofreading Exoribonuclease. mBio. 2018;9(2). 11. de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, et al. Middle East respi[INVESTIGATOR_6507] (MERS- CoV) causes transient lower respi[INVESTIGATOR_769106]. Proc Natl Acad Sci U S A. 2013;110(41):[ZIP_CODE]-603. 12. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al. Prophylactic and therapeutic remdesivir (GS -5734) treatment in the rhesus macaque model of MERS- CoV 
infection. Proc Natl Acad Sci U S A. 2020;117(12):6771-6. 13. Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, Wong MM, et al. Treatment of severe acute respi[INVESTIGATOR_435647]/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399-406. 14. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon -1 plus corticosteroids in severe acute respi[INVESTIGATOR_7686]: a preliminary study. JAMA. 
2003;290(24):3222-8. 15. Wong VW, Dai D, Wu AK, Sung JJ. Treatment of severe a cute respi[INVESTIGATOR_769107]. Hong Kong Med J. 2003;9(3):199-201. 16. Barnard DL, Hubbard VD, Burton J, Smee DF, Morrey JD, Otto MJ, et al. Inhibition of severe acute respi[INVESTIGATOR_7686] -associated coronavirus (SARSCoV) by [CONTACT_769132]-D- N4-hydroxycytidine. Antivir Chem Chemother. 2004;15(1):15-22. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 52 of 146 17. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of 
lopi[INVESTIGATOR_054]/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-6. 18. Cinatl J, Jr., Michaelis M, Scholz M, Doerr HW. Role of interferons in the treatment of severe acute respi[INVESTIGATOR_7686]. Expert Opin Biol Ther. 2004;4(6):827-36. 19. Haagmans BL, Kuiken T, Martina BE, Fouchier RA, Rimmelzwaan GF, van Am erongen 
G, et al. Pegylated interferon -alpha protects type [ADDRESS_1055228] SARS coronavirus 
infection in macaques. Nat Med. 2004;10(3):290-3. 20. Hensley LE, Fritz LE, Jahrling PB, Karp CL, Huggins JW, Geisbert TW. Interferon- beta 
1a and SARS coronavirus replication. Emerg Infect Dis. 2004;10(2):317-9. 21. Tan EL, Ooi EE, Lin CY, Tan HC, Ling AE, Lim B, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis. 2004;10(4):581-6. 22. Yamamoto N,  Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV protease 
inhibitor nelfinavir inhibits replication of SARS -associated coronavirus. Biochem Biophys Res 
Commun. 2004;318(3):719-25. 23. Zheng B, He ML, Wong KL, Lum CT, Poon LL, Peng Y, et al. Potent inhibition of SARS -associated coronavirus (SCOV) infection and replication by [CONTACT_24975] I interferons (IFN-
alpha/beta) but not by [CONTACT_435670] (IFN-gamma). J Interferon Cytokine Res. 2004;24(7):388-90. 24. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS- associated coronavirus. Lancet. 
2003;361(9374):2045-6. 25. Mair -Jenkins J, Saavedra -Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. 
The effectivenes s of convalescent plasma and hyperimmune immunoglobulin for the treatment 
of severe acute respi[INVESTIGATOR_228208]: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90. 26. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broad- spectrum antivirals 
for the emerging Middle East respi[INVESTIGATOR_6507]. J Infect. 2013;67(6):606-16. 27. Cheng KW, Cheng SC, Chen WY, Lin MH, Chuang SJ, Cheng IH, et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain -like protease of Middle East 
respi[INVESTIGATOR_6507]. Antiviral Res. 2015;115:9-16. 28. Wang Y, Sun Y, Wu A, Xu S, Pan R, Zeng C, et al. Coronavirus nsp10/nsp16 Methyltransferase Can Be Targeted by [CONTACT_435671]10 -Derived Peptide In Vitro and In Vivo To Reduce 
Replication and Pathogenesis. J Virol. 2015;89(16):8416-27. 29. Mulangu S, Dodd LE, Davey RT, Jr., Tshiani Mbaya O, Proschan M, Mukadi D, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019;381(24):2293-303. 30. McInnes IB, By[CONTACT_41449], Higgs RE, Lee J, Macias WL, Na S, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183. 31. Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, et al. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12 -week, Double -blind, Randomized Plac ebo-controlled Study. J 
Rheumatol. 2016;43(3):504-11. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Main protocol document 
DMID/NIAID/NIH  CONFIDENTIAL  Page 53 of 146 32. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as 
potential treatment for 2019 -nCoV acute respi[INVESTIGATOR_3765]. Lancet. 2020;395([ZIP_CODE]):e30- e1. 
33. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395([ZIP_CODE]):497-506. 34. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID -19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 
2020. 35. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID -19 in Wuhan, China: a retrospective cohort study. 
Lancet. 2020;395([ZIP_CODE]):1054-62. 36. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, et al. JAK1/[ADDRESS_1055229]. 2018;128(7):3041-52. 37. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: 
combining antiviral and anti- inflammatory treatments. Lancet Infect Dis. 2020.  
38. Genovese MC, Smolen JS, Takeuchi T. THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: 
AN UPDATED INTEGRATED SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 2019;78:308-309. 39. Favalli EG, Biggioggero M, Maioli G, Caporali R. Baricitinib for COVID- 19: a suitable 
treatment? Lancet Infect Dis. 2020.  
40. Shi JG, Chen X, Lee F, Emm T, Scherle PA, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354-61. 41. Winthrop KL, Bingham CO, 3rd, Komocsar WJ, Bradley J, Issa M, Klar R, et al. Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long -term extension trial substudy. Arthritis Res Ther. 
2019;21(1):102. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treat ment Trial (ACTT)   21 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 54 of 146 
 APPENDIX A - ACTT- 1: REMDESIVIR VS PLACEBO  
 
1. PROTOCOL  SUMMARY 
1.1 Synopsis  
Rationale for Proposed Clinical Study 
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated severe acute respi[INVESTIGATOR_6507] 2 (SARS- CoV -2), and the disease caused by [CONTACT_435650] 2019  (COVID -19). There were 59 confirmed cases on January 5, 2020, 278 
cases on January 20, 2020, rising to more than 318,000 confirmed cases and 13,000 deaths as of March 22, 2020 according to various international health reporting agencies. Currently there are no approved therapeutic agent s available for coronaviruses.  
 
Study Design  
This study is an adaptive, randomized, double-blind, placebo- controlled trial to evaluate the 
safety and efficacy of novel therapeutic agents in hospi[INVESTIGATOR_249106]-19. The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stoppi[INVESTIGATOR_68037] y, efficacy, or 
safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by [CONTACT_435651]. Because background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board ( DSMB) will actively monitor interim data to 
make recommendations about early study closure or changes to study arms.   The initial sample size is projected to be 572 subjects to achieve 400 subjects with a “recovered” status (per the primary objective). Th e primary analysis will be based on those subjects enrolled 
in order to 400 recoveries. An additional analysis of the moderate severity subgroup (those with baseline status of “Hospi[INVESTIGATOR_057], requiring supplemental oxygen” or “Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing medical care”)  is also of public health importance. 
Hence, enrollment will be permitted until the date of April 20, [ADDRESS_1055230] a study visit at Days 15, 22, and 29 as an outpatient. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and OP swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may li mit the ability of the subject 
to return to the clinic. In this case, Day 15 and 29 visits may be conducted by [CONTACT_648], and only 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055231] laboratory tests or collection of 
samples and may also be conducted by [CONTACT_648].   All subjects will undergo a series of efficacy, safety, and laboratory assessments. Safety laboratory tests and blood (serum and plasma) research samples and oropharyngeal (OP) swabs will be obtained on Days 1 (prior to infusion) and Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]). OP swabs and blood (serum only) plus safety laboratory tests will be collected on Day 15 and 29 (if the subject attends an in -person visit or are still hospi[INVESTIGATOR_057]).  
 The primary outcome is time to recovery by [CONTACT_2006] 29 (see table below for definition based on the ordinal scale). A key secondary outcome evaluates treatment -related improvements in the 8 -point 
ordinal scale at Day 15. As little is known about the clinical course of COVID-19, a pi[INVESTIGATOR_769108] a blinded sample size reassessment (see section 9 for more details).  
 
Study Objectives  
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
To evaluate the clinical efficacy, as assessed 
by [CONTACT_435652], of different investigational therapeutics as compared to the control arm. Day of recovery is defined as the first day on 
which the subject satisfies one of the following three categories from the ordinal scale:  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on 
activities.  
Recovery is evaluated up until Day 29. 
Key Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics relative to the 
control arm in adults hospi[INVESTIGATOR_21391] -19 according to clinical status (8 -
point ordinal scale) at Day 15 
 
  • Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental 
oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen - requiring ongoing medical care (COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing 
medical care;  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 56 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• Not hospi[INVESTIGATOR_057], limitation on activities 
and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on 
activities.  
Additional Secondary   
1. To evaluate the clinical efficacy of 
different investigational therapeutics as 
compared to the control arm as assessed by:  
• Clinical Severity  
o Ordinal scale:  
 Time to an improvement of one category and two categories from Day 1 (baseline) using an ordinal 
scale.  
 Subject clinical status using ordinal scale at Days 3, 5, 8, 11, 15, 22, and 29.  
 Mean change in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and 29. 
  
  
• Clinical outcome assessed using ordinal scale daily wh ile hospi[INVESTIGATOR_119818] 
15, 22, and 29. 
   
    
o National Early Warning Score 
(NEWS):  
 Time to discharge or to a NEWS of ≤ [ADDRESS_1055232].  
 Change from Day 1 to Days 3, 5, 8, 11, 15, and 29 in NEWS.  
  
 
• NEWS assessed daily while hospi[INVESTIGATOR_435619] 15 and 29. 
o Oxygenation:  
 Oxygenation use up to Day 29. 
 Incidence and duration of new oxygen use during the study. 
  
• Days of supplemental oxygen (if 
applicable) up to Day 29 
 
o Non-invasive ventilation/high flow 
oxygen: 
 Non-invasive ventilation/high flow 
oxygen use up to Day 29. 
 Incidence and duration of new non-invasive ventilation or high flow oxygen use during the study. 
 • Days of non -invasive ventilation/high 
flow oxygen (if applicable) up to Day 29 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 57 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
o Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation 
(ECMO):  
 Ventilator / ECMO use up to Day 29. 
 Incidence and duration of new mechanical ventilation or ECMO use during the study.  
  
• Days of invasive mechanical ventilation/ECMO (if applicable) up to Day 29. 
 
• Hospi[INVESTIGATOR_059]  
o Duration of hospi[INVESTIGATOR_059] (days).  
  
• Days of hospi[INVESTIGATOR_119819] 29 
• Mortality  
o 14-day mortality  
o 28-day mortality  
  
• Date and cause of death (if applicable)  
 
2. To evaluate the safety of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Cumulative incidence of SAEs through Day 29. 
• Cumulative incidence of Grade 3 and 4 clinical and/or laboratory AEs through Day 29 . 
• Discontinuation or temporary suspension of study product administration s (for any reason)  
• Changes in white blood cell (WBC) count with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and prothrombin time (PT) over time (analysis of lab values in addition 
to AEs noted above).   
  
• SAEs  
• Grade 3 and 4 AEs  
• WBC  with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and Days 15 and 29 (if attends in-person visit or still hospi[INVESTIGATOR_057]) . 
 
Exploratory   
To evaluate the virologic efficacy of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Percent of subjects with SARS-CoV-2 detectable in OP sample at Days 3, 5, 8, 11, 15, and 29.   
 
 
• Qualitative and quantitative polymerase 
chain reaction (PCR) for SARS -CoV-2 in 
OP swab on Day 1; Days 3, 5, 8, and 11 
(while hospi[INVESTIGATOR_057]); and Days 15 and 29 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 58 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• Quantitative SARS -CoV -[ADDRESS_1055233] e at Days 3, 5, 8, 11, 15, and 29. 
• Development of resistance of SARS-
CoV-2 in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in 
blood at Days 3, 5, 8, and 11. 
 (if attends in -person visit or still 
hospi[INVESTIGATOR_057]). 
• Qualitative and quantitative PCR for 
SARS -CoV-2 in blood on Day 1; Days 3, 
5, 8, and 11 (while hospi[INVESTIGATOR_057]). 
  
Inclusion Criteria  
1. Admitted to a hospi[INVESTIGATOR_435629] -19. 
2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 
3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 
4. Male or non-pregnant female adult ≥18 years of age at time of enrollment. 
5. Has laboratory -confirmed SARS -CoV-2 infection as determined by [CONTACT_435653], as documented by [CONTACT_147664]:  
• PCR positive in sample collected < 72 hours prior to randomization; OR 
• PCR positive in sample collected ≥ 72 hours prior to randomization, documented 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc.). AND progressive disease suggestive of ongoing SARS-CoV-[ADDRESS_1055234] one of the following: 
• Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, etc.), OR  
• SpO2 ≤ 94% on room air, OR 
• Requiring supplemental oxygen, OR  
• Requiring mechanical ventilation.  
7. Women of childbearing potential must agr ee to either abstinence or use at least one 
primary form of contraception not including hormonal contraception from the time of screening through Day 29.  
8. Agrees to not participate in another clinical trial for the treatment of COVID -[ADDRESS_1055235] > 5 times the upper limit of normal.  
2. Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving 
hemodialysis or hemofiltration).  
3. Pregnancy or breast feeding.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 59 of 146 4. Anticipated discharge from th e hospi[INVESTIGATOR_119804] a 
study site within 72 hours. 
5. Allergy to any study medication.  
 
Study Phase  
• Phase 3  
 
Study Population  
Hospi[INVESTIGATOR_119800] ( ≥18 years old) with COVID -19. 
 
Study Sites  
There will be up to approximately [ADDRESS_1055236] or placebo as follows:  
• Remdesivir will be administered as a 200 mg intravenous (IV) loading dose on Day 1, followed by a 100 mg once-daily IV maintenance dose for the duration of the hospi[INVESTIGATOR_83263] a 10-day total course.  
• A placebo will be given at an equal volume at the same schedule.  
 The study will randomize subjects 1:[ADDRESS_1055237]. If additional arms are added to or dropped from the trial, randomization will proceed with an equal probability of assignment to each of the remaining arms. As new interventions are added, the protocol will be amended and reviewed by [CONTACT_1744]/IEC and applicable regulatory agencies before implementation. The current protocol, however, does lay out the general principles of how the multi-intervention trial would be implemented.  
 
Study Duration  
The study will last for up to [ADDRESS_1055238] will complete the study in about 29 days, fr om screening at Day -1 or 1 to 
follow-up on Day 29 ± 3 days.   
Safety  
• Given the potential severity of COVID-19 and limited information about the expected clinical course, there are no pre-specified study stoppi[INVESTIGATOR_004] (except as noted under DSMB). A subset of the protocol team will review blinded pools of Grade 3 and 4 AE / 
SAE data every 2 weeks. If there is a pattern of unexpected AEs that is out of proportion 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 60 of 146 to the current understanding of the natural history of the disease, the DSMB will be asked 
to review unblinded safety data in an ad hoc meeting. 
• The DSMB will have access to safety data electronically in real time, will have formal safety/efficacy reviews after approximately every [ADDRESS_1055239] met recovered status for each pairwise comparison. Additionally, the DSMB will be available for ad hoc  
reviews for safety concerns as described above. The study will not stop enrollment awaiting these DSMB reviews, though the DSMB may recommend temporary or permanent cessation of enrollment based on their safety reviews.   
  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 61 of 146  
1.2 Schedule of Assessments  
Table 1. Schedule of Assessments (SOA)  
  Screen  Baseline  Study Intervention Period  Follow -up Visits  
Day +/ - Window  −1 or 1 1 Daily until hospi[INVESTIGATOR_7954]  157  
± 2 227 
± 3 297 
± 3 
ELIGIBILITY        
Informed consent  X      
Demographics & Medical History  X      
Targeted physical exam  X      
Review SARS -CoV -[ADDRESS_1055240] given after Day 10.     
      
STUDY PROCEDURES        
Vital signs including SpO 2  X4 Daily until discharge  X7  X7 
Clinical data collection1   X4 Daily until discharge  X7 X7 X7 
Adverse event evaluation   X4 Daily until discharge  X7 X7 X7 
Concomitant medication review   X4 From Day -7 to Day 11     
       
SAFETY LABORATORY        
Safety hematology, chemistry and 
liver tests X2,3 X4,5,6 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_057]5,[ADDRESS_1055241] for PCR 
SARS -CoV -2  X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_435621] 8  X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_057]  X7  X7 
Blood for serum (secondary 
research)   X5 Day 3, 5, 8, 11 (all ± 1 
day) if hospi[INVESTIGATOR_057]  X7  X7 
Notes:  
1 Refer to Section 8.1 of the protocol for details of clinical data to be collected including ordinal score, NEWS, oxygen 
requirement, mechanical ventilator requirement, etc.  
2 Screening laboratory tests include: ALT, AST, creatinine (and calculate an estimated glomerular filtration rate (eGFR) 
the formula used is determined by [CONTACT_30107], but should be consistent throughout the study), and pregnancy test.  
[ADDRESS_1055242], 
and PT.  
6 Any laboratory tests performed as part of routine clinical care within the specified visit window can be used for safety 
laboratory testing. Window during the 10 days of dosing is ±[ADDRESS_1055243]’s ability to return to the 
site for the visit. In this case, the visit may be performed by [CONTACT_648].  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 62 of 146 • If still hospi[INVESTIGATOR_53481] 15 and 29 or returns to the site for an in -person visit:  collect c linical data, vital signs, 
safety laboratory tests, and research laboratory samples (OP swab and serum only) as able.  
• If phone call only on Days 15 and 29 and all Day 22 visits: assess adverse events, clinical status (ordinal scale), 
readmission to a hospi[INVESTIGATOR_307], and mortality only.  
8 Oropharyngeal swabs are preferred, but if these are not obtainable, nasopharyngeal swabs may be substituted.  
 
1.3 Study Schema  
 
 
2. INTRODUCTION 
2.1 Study Rationale  
COVID -19 is a respi[INVESTIGATOR_19538] a novel coronavirus (SARS-CoV-2) and causes 
substantial morbidity and mortality. There is currently no vaccine to prevent infection with 
SARS -CoV-2 or therapeutic agent to treat COVID- 19. This clinical trial is designed to evaluate 
investigational therapeutics for the treatment of adults hospi[INVESTIGATOR_18552] d with COVID-19. 
2.2 Background  
 Purpose of Study  
Coronavirus (CoVs) are positive-sense, single stranded, enveloped RNA viruses, many of which are commonly found in humans and cause mild symptoms. Over the past two decades, emerging pathogenic CoVs capable of causing life-threatening disease in humans and animals have been 
identified, namely, severe acute respi[INVESTIGATOR_6507] (SARS-CoV) in 2002-[ADDRESS_1055244] respi[INVESTIGATOR_6507] (MERS-CoV) in 2012.   In December 2019, the Wuhan Municipal Health Committee (Wuhan, China) identi fied an 
outbreak of viral pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these patients. This novel coronavirus has been designated as SARS -COV- 2 and has 89% 
nucleotide identity with bat SARS -like-CoVZXC21 and 82% with that of human SARS-CoV (2). 
The human disease caused by [CONTACT_7544] -CoV- [ADDRESS_1055245] (~80%) 

Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055246] US COVID-19 death occurred on February 29, 2020.  During this COVID -19 outbreak, the incidence of cases has rapi[INVESTIGATOR_769109] 
5, 2020 there were 59 confirmed cases, 278 cases on January 20, 2020, and more than 318,000 
cases and 13,000 deaths as of March 22, 2020 according to various international health reporting agencies. As a result, on January 30, 2020, the International  Health Regulations Emergency 
Committee of the World Health Organization (WHO) declared the COVID -[ADDRESS_1055247] that these numbers will continue to rise  (3).  
 Global efforts to evaluate novel antivirals and therapeutic interventions to treat COVID -[ADDRESS_1055248] 
intensified. There is currently no vaccine to prevent SARS-CoV-2 infection or therapeutic agent to treat COVID -19. Therefore, there is an urgent public health need for rapid development of 
novel interventions.   
 Potential Therapeutics  
Remdesivir (GS -5734) is a broad-spectrum nucleotide prodrug that inhibits RNA-dependent 
RNA polymeras e activity among a diverse group of RNA viruses including filoviruses (e.g. 
Ebola, Sudan, Marburg), paramyxoviruses (e.g., RSV, Nipah, Hendra) and pathogenic coronaviruses (4-6). Multiple nonhuman primate studies demonstrated the therapeutic efficacy of 
remdesivir against Ebola virus (4, 5). Remdesivir was used in a randomized clinical trial for Ebola (the PALM study) (7). While remdesivir was demonstrated to be inferior to investigational 
treatment with monoclonal antibodies MAb114 and REGN-EB3 in the PALM study, the lack of a control arm limits interpretation of the clinical efficacy of remdesivir. Studies in human airway epi[INVESTIGATOR_769110], 
including MERS-CoV (8). In mouse infection models, rem desivir had therapeutic efficacy 
against SARS -CoV and MERS- CoV (8, 9). In vitro studies with mouse hepatitis virus (a murine 
coronavirus) found that remdesivir inhibits coronavirus replication through interference with the viral polymerase, despi[INVESTIGATOR_435624] a viral proofreading exoribonuclease (10). In that study, 
coronaviruses that were partially resistant to inhibition by [CONTACT_769133], and fitness was impaired in the resistant viruses as compared to wild- type MERS -CoV. In a recent non-human primate study, therapeutic remdesivir 
treatment initiated [ADDRESS_1055249] inoculation with MERS-CoV provided clinical benefit w ith a 
reduction in clinical signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions (11, 12). These nonclinical data suggest that remdesivir might be useful for the treatment of COVID -19 for which no medical countermeasures are currently approved, 
and support testing the efficacy of remdesivir treatment in hospi[INVESTIGATOR_103138] -19. 
2.3 Risk/Benefit Assessment  
 Known Potential Risks  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 64 of 146 Potential risks of participating in this trial are those associated with having blood d rawn, the IV 
catheterization, possible reactions to remdesivir (as noted in Section 2.3.2), and breach of 
confidentiality.  
 Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and managed by [CONTACT_226295]/her legs. Bruising at the blood collection sites may occur but can be prevented or lessened by [CONTACT_119911] a few minutes after the blood is taken. IV catheterization may cause insertion site pain, phlebitis, 
hematoma formation, and infusate extravasation; less frequent but significant complications include bloodstream and local infections. The use of aseptic (ste rile) technique will make 
infection at the site where blood will be drawn or at catheter site less likely.  
 Risks to Privacy Subjects will be asked to provide personal health information (PHI). All attempts will be made to keep this PHI confidential within  the limits of the law. However, there is a chance that 
unauthorized persons will see the subject’s PHI. All study records will be kept in a locked file cabinet or maintained in a locked room at the participating clinical site. Electronic files will be password protected. Only people who are involved in the conduct, oversight, monitoring, or 
auditing of this trial will be allowed access to the PHI that is collected. Any publication from this trial will not use information that will identify subjects. Organizations that may inspect and/or copy research records maintained at the participating site for quality assurance and data analysis include groups such as the IRB, NIAID and applicable regulatory agencies (e.g., FDA). For more information about confidential ity and privacy see Section 10.1.3. 
 For each new therapeutic agent under investigation, findings from the preclinical and clinical studies will be briefly described  in this section and a summary of the findings described in the 
Investigator Brochure (IB) will be in an appendix.   
 Potential Risks of Remdesivir  
Remdesivir is an investigational therapeutic agent. As of February 14, 2020, [ADDRESS_1055250] been observed with single doses of remdesivir up to 225 mg and multiple once daily doses of remdesivir 150 mg for up to 14 days. Mild (Grade 1) reversible PT prolongation was also noted in some subjects but without any clinically significant change in INR or other evidence of hepatic effects. The mechanism of these elevations is currently unknown. Based on these clinical observations, patients with ALT or AST >5 times the upper limit of normal will not be eligible for study enrollment. Regular laboratory assessments will be performed in order to monitor hepatic function and PT. Any observed liver function- related 
laboratory abnormalities or possibly related AEs will be treated appropriately and followed to 
resolution.   In nonclinical animal studies, toxicity studies found dose-dependent and reversible kidney injury and dysfunction. In clinical studies, no evidence of nephrotoxicity has been observed with single 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 65 of 146 doses of remdesivir up to 225 mg or multiple once daily doses of remdesivir 150 mg for up to 14 
days. A 150-mg dose of the solution and lyophilized formulations of remdesivir contains 9 g and 
4.5 g, respectively, of sulfobutylether- beta- cyclodextrin  (SBECD), for which the maximum daily 
recommended daily dose (based  on a European Medicines Agency (EMA) safety review) is 
approximately 250 mg/kg. Because SBECD is renally cleared, subjects with moderate or severe renal impairment may have SBECD exposures greater than those with less severe renal impairment or normal ren al function. Based on this information, patients with an estimated 
glomerular filtration rate (eGFR) of less than 30 ml/min (including subjects requiring hemodialysis or hemofiltration) will not be eligible for study enrollment.  
 Remdesivir is a substrate for CYP2C8, CYP2D6, and CYP3A4. However, coadministration with 
inhibitors of these CYP isoforms is unlikely to markedly increase remdesivir levels, as its metabolism is likely to be predominantly mediated by [CONTACT_435656].  See IB for full 
discussion of clinical experience and risks.  
 There is the potential of the SARS-CoV-[ADDRESS_1055251] been self -limited and resolve d after cessation of the 
medication. There is the potential for renal toxicities as observed in pre -clinical data. By [CONTACT_435657] (eGFR < 30 ml/min or 
requires hemodialysis or hemofiltration), and appropriate monitoring during the study, we can minimize the risk to subjects. While there may not be benefits for an individual subject, there may be benefits to society if a safe, efficacious therapeutic agent can be identified during this globa l 
COVID -19 outbreak. The potential risks therefore are thought to be acceptable given the potential 
benefits.  
3. OBJECTIVES  AND  ENDPOINTS 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055252] 
COVID -19. 
 
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
To evaluate the clinical efficacy, as assessed 
by [CONTACT_435652], of different investigational therapeutics as compared to 
the control arm. Day of recovery is defined as the first day on 
which the subject satisfies one of the following three categories from the ordinal scale:  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities 
and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on 
activities.  
Recovery is evaluated up until Day 29.  
Key Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics relative to the control arm in adults hospi[INVESTIGATOR_21391] -19 according to clinical status (8 -
point ordinal scale) at Day 15 
 
  • Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental 
oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen - requiring ongoing medical care (COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on 
activities.  
Additional Secondary   
1. To evaluate the clinical efficacy of 
different investigational therapeutics as 
compared to the control arm as assessed by:  
• Clinical Severity  
o Ordinal scale:  
 Time to an improvement of one 
category and two categories from  
  
• Clinical outcome assessed using ordinal scale daily while hospi[INVESTIGATOR_119818] 15, 22, and 29. 
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 67 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Day 1 (baseline) using an ordinal 
scale.  
 Subject clinical status using ordinal 
scale at Days 3, 5, 8, 11, 15, 22, and 29.  
 Mean change in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and 29. 
  
 
    
o National Early Warning Score 
(NEWS):  
 Time to discharge or to a NEWS of ≤ [ADDRESS_1055253].  
 Change from Day 1 to Days 3, 5, 8, 11, 15, and 29 in NEWS.  
  
 
• NEWS assessed daily while hospi[INVESTIGATOR_435619] 15 and 29. 
o Oxygenation:  
 Oxygenation use up to Day 29. 
 Incidence and duration of new oxygen use during the study. 
  
• Days of supplemental oxygen (if 
applicable) up to Day 29 
 
o Non-invasive ventilation/high flow 
oxygen: 
 Non-invasive ventilation/high flow 
oxygen use up to Day 29. 
 Incidence and duration of new non-invasive ventilation or high flow oxygen use during the study. 
 • Days of non -invasive ventilation/high 
flow oxygen (if applicable) up to Day 29 
o Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation (ECMO):  
 Ventilator / ECMO use up to Day 29. 
 Incidence and duration of new mechanical ventilation or ECMO use during the study.  
  
• Days of invasive mechanical 
ventilation/ECMO(if applicable) up to 
Day 29. 
 
• Hospi[INVESTIGATOR_059]  
o Duration of hospi[INVESTIGATOR_059] (days).  
  
• Days of hospi[INVESTIGATOR_119819] 29 
• Mortality  
o 14-day mortality   
• Date and cause of death (if applicable)  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 68 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
o 28-day mortality  
  
2. To evaluate the safety of different 
investigational therapeutics as compared to 
the control arm as assessed by:  
• Cumulative incidence of SAEs through Day 29. 
• Cumulative incidence of Grade 3 and 4 
clinical and/or laboratory AEs through 
Day 29 . 
• Discontinuation or temporary suspension of study product administration s (for any reason)  
• Changes in white blood cell (WBC) count with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and prothrombin time (PT) over time (analysis of lab values in addition 
to AEs noted above).   
  
• SAEs  
• Grade 3 and 4 AEs  
• WBC  with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and Days 15 and 29 (if attends in-person visit or still hospi[INVESTIGATOR_057]) . 
 
Exploratory   
To evaluate the virologic efficacy of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Percent of subjects with SARS-CoV-2 detectable in OP sample at Days 3, 5, 8, 11, 15, and 29.  
• Quantitative SARS -CoV-[ADDRESS_1055254] e at Days 3, 5, 8, 11, 15, and 29. 
• Development of resistance of SARS-
CoV-2 in OP sample at Days 3, 5, 8, 
11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in 
blood at Days 3, 5, 8, and 11. 
  
 
 
• Qualitative and quantitative polymerase 
chain reaction (PCR) for SARS -CoV-2 in 
OP swab on Day 1; Days 3, 5, 8, and 11 
(while hospi[INVESTIGATOR_057]); and Days 15 and 29 
(if attends in -person visit or still 
hospi[INVESTIGATOR_057]). 
• Qualitative and quantitative PCR for 
SARS -CoV-2 in blood on Day 1; Days 3, 
5, 8, and 11 (while hospi[INVESTIGATOR_057]). 
  
4. STUDY  DESIGN 
4.1 Overall Design  
This study is an adaptive, randomized, double-blind, placebo- controlled trial to evaluate the 
safety and efficacy of novel therapeutic agents in hospi[INVESTIGATOR_435625]-19. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 69 of 146 The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. 
The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to allow  early stoppi[INVESTIGATOR_16589], efficacy, or safety. If one therapy 
proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by [CONTACT_435651]. Because background standards of supportive care may evolve/improve over time as more is 
learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms.  
 The initial sample size is projected to be 572 subjects to achieve 400 subjects with a “recovered” status (per  the primary objective). The primary analysis will be based on those subjects enrolled 
in order to 400 recoveries. An additional analysis of the moderate severity subgroup (those with baseline status of “Hospi[INVESTIGATOR_057], requiring supplemental oxygen” or “Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing medical care”)  is also of public health importance. 
Hence, enrollment will be permitted until the date of April 20, [ADDRESS_1055255] a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and OP swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic. In this case, these visits may be conducted by [CONTACT_648], and only clinical data will be 
obtained. The Day [ADDRESS_1055256] laboratory tests or collection of samples and may also be conducted by [CONTACT_648].   
The primary outcome is time to recovery by [CONTACT_2006] 29 (see table below for defini tion based on the 
ordinal scale). A key secondary outcome evaluates treatment -related improvements in the 8 -point 
ordinal scale at Day 15. As little is known about the clinical course of COVID-19, an evaluation 
of the pooled (i.e., blinded to treatment assignment) proportion recovered will be used to gauge whether the targeted total number of subjects in the recovered categories of the ordinal scale will be achieved with a planned sample size of 572. The primary analysis will include data from both severity  groups using a stratified log-rank test. The analysis of the pi[INVESTIGATOR_435626], 
allowing for the pi[INVESTIGATOR_435627].   The study will randomize subjects 1:[ADDRESS_1055257]. In the absence of an  
established treatment, the use of placebo is justified. If additional arms are added to or dropped from the trial, randomization will proceed with an equal probability of assignment to each of the remaining arms. Randomization will be stratified by [CONTACT_3725] a nd severity (severe versus mild -
moderate). See Section 6.3 for more information on randomization and stratification. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055258] in vitro pre-clinical data that support their efficacy (13-25). Since the SARS -CoV outbreak in 2002-
2003, new therapeutic agents targeting viral entry proteins, proteases, polymerases, and methyltran sferases have been tested; however, none of them has been shown to be efficacious in 
clinical trials  (26-28).  
 This study utilizes an adaptive design that increases efficiency to identify safe and efficacious therapeutic agents for patients with COVID -[ADDRESS_1055259], collecting clinical and virologic data on enrolled subjects using a standardized timeline and collection instruments should provide valuable information about the clinical course of and morbidities associated with COVID -19 in a diverse group of hospi[INVESTIGATOR_435628].  
4.3 Justification for Dose  
The dose of remdesivir used in this study will be the same dose that was used in the Ebola clinical trials.  
 
5. STUDY  POPULATION  
Approximately 572 male and non-pregnant female adults ≥[ADDRESS_1055260] the community at large. The estimated time from screening (Day -1 or Day 1) to end of study for an individual subject is approximately [ADDRESS_1055261] is eligible for study enrollment. There is no exclusion for receipt of SARS -CoV-2 
vaccine (experimental or licensed).  
 
5.1 Inclusion Criteria  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055262] meet all of the following criteria:  
1. Admitted to a hospi[INVESTIGATOR_435629] -[ADDRESS_1055263] (or legally authorized representative) provides informed consent prior to 
initiation of any study procedures. 
3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 
4. Male or non-pregnant female adult ≥18 years of age at time of enrollment. 
5. Has laboratory -confirmed SARS -CoV-2 infection as determined by [CONTACT_435653], as documented by [CONTACT_147664]:  
• PCR positive in sample collected < 72 hours prior to randomization; OR 
• PCR positive in sample collected ≥ 72 hours prior to randomization, documented 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc.). AND progressive disease suggestive of ongoing SARS-CoV-[ADDRESS_1055264] one of the following: 
• Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, etc.), OR  
• SpO2 ≤ 94% on room air, OR 
• Requiring supplemental oxygen, OR  
• Requiring mechanical ventilation.  
7. Women of childbearing potential must agree to either abstinence or use at least one 
primary form of contraception not including hormonal contraception from the time of screening through Day 29.  
8. Agrees to not participate in another clinical trial for the treatment of COVID -19 or 
SARS -CoV-2 through Day 29. 
 
5.2 Exclusion Criteria 
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. ALT or AST > 5 times the upper limit of normal.  
2. Estimated glomerular filtration rate (eGFR) < 30 ml/min (including patients receiving hemodialysis or hemofiltration).  
3. Pregnancy or breast feeding.  
4. Anticipated discharge from the hospi[INVESTIGATOR_119804] a study site within 72 hours. 
5. Allergy to any study medication.  
 
 Exclusion of Specific Populations  
Children and adolescents will not be included in this trial. Remdesivir has only been used in a small number of pediatric patients. Initial information about the epi[INVESTIGATOR_40270]-19 indicates that the overwhelming burden of severe disease occurs among older adults, especially those with comorbidities. Given significant gaps in knowledge in this population, and a low 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 72 of 146 incidence of severe morbidity/mortality in children, the risk/benefits do not warrant inclusion of 
this population into this trial at this  time.  
 In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo -fetal development when administered to pregnant animals. Embryonic toxicity was seen 
when remdesivir was initiated in female animals prior to mating and conce ption, but only at a 
systemically toxic dose. Remdesivir has not been studied in pregnant women. Because the effects on the fetus and the pregnant woman are not fully known, pregnant women will not be eligible for the trial.  
 In animal studies, remdesivir  metabolites have been detected in the nursing pups of mothers 
given remdesivir. It is not known whether remdesivir is secreted in human milk. Because the effects of remdesivir on the breastfeeding infant is not known, women who are breast feeding will not be eligible for the trial.  
 
5.[ADDRESS_1055265] is cognitively impaired, federal and institutional regulations permit researchers to obtain consent from a legally authorized representative (LAR). The study team will obtain consent from these vulnerable subjects using an IRB-approved protocol- specific process for consent using a LAR.  For subjects for whom a LAR gave consent, during the course of the study, if the subject regains the capacity to consent, informed consent must be obtained from the subject and the subject offered the ability to leave the study if desired.  
 
5.4 Lifestyle Considerations  
During this study, subjects are asked to: 
• Refrain from drinking alcohol through Day 15.  
• Avoid getting pregnant during the study from Day 1 through Day 29. 
• Avoid participation in another clinical trial for the treatment of COVID -19 or SARS-
CoV-2. Co- enrollment for natural history studies of COVID -19 or SARS-CoV-2 is 
permitted; however, participation in both ACTT and natural history studies can only 
occur if the recommended blood collection volumes are not exceeded.  
5.[ADDRESS_1055266] been completed, the investigator or design ee is to review the inclusion/exclusion criteria and determine the subject’s eligibility for 
the study. If there is any uncertainty, the PI [INVESTIGATOR_119820] a potential subject is eligible for study enrollment.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 73 of 146  
Only basic demographic i nformation and the reason(s) for ineligibility will be collected on 
screen failures. Subjects who are found to be ineligible will be told the reason(s) for ineligibility.  Individuals who do not meet the criteria for participation in this study (screen fai lure) because of 
an abnormal laboratory finding may be rescreened once. 
5.6 Strategies for Recruitment and Retention  
 Recruitment  
It is anticipated that patients with COVID -19 will present to participating hospi[INVESTIGATOR_600], and that no 
external recruitment efforts towards potential subjects are needed. Recruitment efforts may also include dissemination of information about this trial to other medical professionals / hospi[INVESTIGATOR_600].  
 The IRB will approve the recruitment process and all materials provided prior to any recruitment to prospective subjects directly.  Screening will begin with a brief discussion with study staff. Some will be excluded  based on 
demographic data and medical history (i.e., pregnant, < 18 years of age, renal failure, etc.). Information about the study will be presented to potential subjects (or legally authorized representative) and questions will be asked to determine pot ential eligibility. Screening 
procedures can begin only after informed consent is obtained.  
 Retention  
Retention of subjects in this trial is very important for determining the primary endpoint. As such, after hospi[INVESTIGATOR_2345], participating subjects will be reminded of subsequent study visits and every effort will be made to accommodate the subject’s schedule to facilitate follow -up 
within the specified visit window. Additionally, there are many circumstances that influence the ability to obtain outcome information after discharge. Follow-up visits may be conducted by [CONTACT_119916]-person visits are not feasible.  
 Compensation Plan for Subjects  
Compensation, if any, will be determined locally and in accordance with local IRB requirements, and subject to local IRB approval.  
 
 Costs  
There is no cost to subjects for the research tests, procedures/evaluations and study product while taking part in this trial. Procedures and treatment for clinical care including costs associated with hospi[INVESTIGATOR_435630], subject’s insurance or third party. 
 
6. STUDY  PRODUCT 
6.[ADDRESS_1055267](s) and Administration – GS-5734 (Remdesivir) and 
placebo  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055268] Description  
Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular 
delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, SBECD, and hydrochloric acid and/or sodium hydroxide.  The supplied matching placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, due to limitations on placebo supplies, normal saline may be given at an equal volume as a placebo in 
place of the lyophilized formulation.  
 Dosing and Administration 
Subjects will be randomized 1:[ADDRESS_1055269] 2 arms:  
• Remdesivir will be administered as a [ADDRESS_1055270] is no longer hospi[INVESTIGATOR_057], then infusions will no longer be given.  
o The total course should not exceed 10 calendar days even if an infusion was missed.  
• A matching placebo will be given at an equal volume at the same schedule.  
 The dose should be given the same time each day (+/- 2 hours for medication scheduling).  Any d ose that is delayed may be given later that calendar day. Any dose that is missed (not given 
that calendar day) is not made up. The treatment course continues as described above even if the subject becomes PCR negative.  
 
 Dose Escalation 
Not Applicable  
 Dose Modifications  
There are no clinical safety or pharmacokinetic data available for remdesivir in patients with renal and/or hepatic impairment. Given the benefit- to-risk ratio in patients with COVID -19, these 
subjects are excluded from the study.  
 If the  eGFR decreases to an eGFR < 25 ml/min, the study infusion should not be given on that 
day. The infusion may be resumed on the next day if the eGFR returns to ≥ 30 ml/min. If the subject’s renal function worsens to the point that they require hemodialysis or hemofiltration, study product will be discontinued.  If the ALT and/or AST increases to > [ADDRESS_1055271] ≤ 5 times upper limits of normal.  
 Overdosage 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055272]´s signs and symptoms. 
 
6.2 Preparation/Handling/Storage/Accountability  
 Acquisition and Accountability  
Investigational products (I P) will be shipped to the site either directly from participating 
companies, from the Sponsor, or from other regional or local drug repositories. All other supplies 
should be provided by [CONTACT_779]. Multiple lots of each IP may be supplied.  Study products received at the sites will be open label and not kit specific, unless specified in the protocol- specific Manual of Procedures (MOP). Drug preparation will be performed by [CONTACT_122844]’s research pharmacist on the same day of administration to the subject. See the MOP Appendices for detailed information on the preparation, labeling, storage, and administration of remdesivir and placebo.   
Accountability: 
The site PI [INVESTIGATOR_769111] s ultimate 
responsibility for study product accountability. The site PI [INVESTIGATOR_119829]’s research pharmacist responsibility for study product accountability. The participating site’s research pharmacist will be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, storage conditions, and final disposition of the study product(s). Time of study drug administration to the subject will be recorded on the appropriate data collection form (CRF). All study product(s), whether administered or not, must be documented on the appropriate study product accountability record or dispensing log. The Sponsor’s monitoring staff will verify the participating site’s study product accounta bility 
records and dispensing logs per the site monitoring plan. Refer to the protocol- specific MOP for 
details on storing study medications.  
Destruction:  
After the study treatment period has ended or as appropriate over the course of the study after 
study product accountability has been performed, used active and placebo vials can be destroyed on-site following applicable site procedures with a second staff member observing and verifying the destruction.  
Unused vials at the end of the study should be saved until instructed by [CONTACT_1034]. 
 
 Formulation, Appearance, Packaging, and Labeling 
Product: Remdesivir  
The lyophilized formulation of remdesivir  is a preservative- free, white to off-white or yellow, 
lyophilized solid containing 150 mg or 100 mg of remdesivir to be reconstituted with 29 mL or 
19 mL (respectively) of sterile water for injection respectively and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL remdesivir concentrated solution with sufficient volume to allow withdrawal of 30 mL (150 mg of remdesivir) or 20 mL (100 mg of remdesivir).  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055273] in a single-use, Type 1 clear glass vial. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, SBECD, hydrochloric acid, and/or sodium hydroxide. For more information, refer to the MOP.  
 
Placebo:  
The supplied matching placebo lyophilized formulation, 150 mg or 100 mg equivalent, is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. The lyophilized formulation of matching placebo is filled in a Type 1 clear glass vial closed with a rubber stopper and aluminum seal w ith a plastic flip -off cap. Each single-
use vial contains sufficient volume to allow withdrawal of 30 mL or 20 mL of placebo following reconstitution.  Alternatively, due to limitations on placebo supplies, a matching placebo of normal saline may be given at an equal volume at the same schedule. In this case, IV bags of study treatment (both 
the Active and the Placebo) will be covered to mask the slight color difference between the remdesivir solution and placebo to maintain the study blind.   Each of the study products will be labeled according to manufacturer specifications and include 
the statement “Caution: New Drug Limited by [CONTACT_12201]. ” 
 
 Product Storage and Stability  
Product: Remdesivir  
Ambient vials of the lyophilized formulation of remdesivir should be stored below 30°C. The lyophilized formulation needs to be reconstituted and then diluted into IV infusion fluids before use. After reconstitution, the total storage time before completion of administration (including any time before or after dilution) should not exceed 4 hours at room temperature (20°C to 25°C) or 24 hours at refrigerated temperature (2°C to 8°C). See MOP for additional information.   
Placebo:  
Vials of the lyophilized formulation of matching placebo should be stored below 30°C. The lyophilized formulation needs to be reconstituted and then diluted into IV infusion fluids before use. After reconstitution, the total storage time before completion of administration (including any time  before or after dilution) should not exceed 4 hours at room temperature (20°C to 25°C) 
or 24 hours at refrigerated temperature (2°C to 8°C).  If used, the saline placebo should be kept under the same conditions as the matching lyophilized placebo, in orde r to maintain the blind.  
 
 Preparation 
Refer to the protocol-specific MOP for details about preparation.   
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055274] with the body should always be considered during handling, preparation, and disposal procedures as indicated in the IB.  
6.3 Measures to Minimize Bias: Randomization and Blinding  
The study will randomize subjects 1:[ADDRESS_1055275]. If additional arms are added to or dropped from the trial, randomization will proceed with an equal probability of assignment to each of the remaining arms. Randomization will be stratified by:  
• Site 
• Severity of illness at enrollment:  
o Severe disease: requiring mechanical ventilation, requiring oxygen, a SpO2 ≤ 94% on room air, or tachypnea (respi[INVESTIGATOR_697] ≥ 24 breaths/min). 
o Mild -moderate disease: SpO2 > 94% and respi[INVESTIGATOR_697] < 24 breaths/min without 
supplemental oxygen.  
 The randomization procedure will be described in the MOP.   
6.[ADDRESS_1055276]. Administration and date, and time, will be entered into the case report form (CRF).  
 
6.5 Concomitant Therapy  
Therapy prior to enrollment with any other experimental treat ment or off- label use of marketed 
medications that are intended as specific treatment for COVID -19 or the SARS-CoV-2 infection 
(i.e., post-exposure prophylaxis [PEP]) are permitted but must be discontinued on enrollment. There is no waiting period between discontinuation of these treatments and infusion of study product. However, these prior treatments and their end date should be documented on the Concomitant Medication (CCM) form.  
 
Subjects who are taking another antiviral for a concurrent infection (e.g . oseltamivir for an 
influenza virus, lopi[INVESTIGATOR_054]/ritonavir for HIV, etc.) or immunosuppressive drugs for other medical conditions (tocilizumab for rheumatoid arthritis, hydroxychloroquine for lupus, etc.) may continue with the treatment.  
 
A subject cannot participate in another clinical trial for the treatment of COVID -19 until after Day 
29 (see exclusion criteria).  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055277] of care per written policies or guidelines for treatment for COVID -19 or 
SARS -CoV-2 infection (i.e., not just an individual clinician decision) includes lopi[INVESTIGATOR_054]/ritonavir 
(Kaletra), hydroxychloroquine or other agents (e.g. those targeting the host immune response), 
then continuing these during the study is permitted, but may require additional safety monitoring as determ ined by [CONTACT_68071]. Additionally, there should be plans on how the 
concomitant drugs are stopped for additive toxicities (Section 6.1.4). If there are NO written policies or guidelines for local standard of care, concomitant use of any other experimental treatment or off -label use of marketed medications intended as specific t reatment for COVID -[ADDRESS_1055278] immune 
response.
 
 
No clinical drug -drug interaction (DDI) studies have been conducted with remdesivir. Final 
guidance about the drug and possible DDI should come from the IB and the protocol. Site PIs 
should review the prescription drugs that the subject is getting for pre- existing comorbidities  and 
determine if these agents may lead to antagonism or synergy with remdesivir and modify safety monitoring accordingly. 
 There is no available data on potential interactions between remdesivir and other anti -SARS -
CoV investigational agents. Administering remdesivir concurrently with other agents may lead to antagonism or synergy or may have no effect.   Concomitant medications will be assessed only from [ADDRESS_1055279]  DISCONTINUATION/WITHDRAWAL 
7.1 Halting Criteria and Discontinuation of Study Intervention  
 Individual Infusion Halting  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055280] a suspected drug -
related event of hypersensitivity (Grade 2 or higher) during the infusion. While there are no criteria 
for grading “hypersensitivity” in the Division of AIDS (DAIDS) Table for Grading the Severity of Adverse Events, sites should use acute allergic reaction from that toxicity table. Subjects who have an IV infusion stopped for a safety related issues will not continue with dosing.  
The treatment of any given subject may be stopped for SAEs, clinically significant adverse events, 
severe laboratory abnormalities, or any other medical conditions that indicate to the Investigator 
that continued dosing is not in the best interest of the patient. 
In addition, a subject in this clinical study may discontinue study drug at their request for any 
reason. Every effort should be made to encourage subjects to remain in the study for the duration of their planned outcome assessments. Subjects should be educated on the continued scientific importance of their data, even if they discontinue study drug.  
Unless the subject withdraws consent, those who discontinue study drug early wi ll remain in the 
study. The reason for subject discontinuation of study drug should be documented in the case 
report form.  
 Study Halting  
Given the potential severity of COVID-19, there are no pre-specified study stoppi[INVESTIGATOR_004]. Instead there will be close oversight by [CONTACT_769134].  
 
7.[ADDRESS_1055281] to follow-up after signing the informed consent form (ICF) and administration of the study product, will not be replaced. The reason for subject withdrawal from the study will be recorded on the appropriate CRF. 
7.[ADDRESS_1055282]’s records.  
8. STUDY  ASSESSMENTS  AND  PROCEDURES 
8.1 Screening and Efficacy Assessments 
 Screening Procedures  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 80 of 146 Screening procedures may be done over one to two calendar days (from Day -1 to Day 1). 
However, in many cases all the screening assessments can be done in less than [ADDRESS_1055283] administration  can occur on the same calendar day as the screening 
procedures.   After the informed consent, the following assessments are performed to determine eligibility and obtain baseline data:  
• Confirm the positive SARS-CoV- [ADDRESS_1055284] result (per inclusion criteria).  
• Take a focused medical history, including the following information:  
• Day of onset of COVID-19 signs and symptoms. 
• History of chronic medical conditions including chronic oxygen requirement prior to 
onset of COVID-19. 
• History of medication allergies.  
• Medications and therapi[INVESTIGATOR_119836] 7 days prior to Day 1. 
• Ask if they are participating in another clinical trial or plan to enroll in another 
clinical trial in the next 30 days.  
• Women of childbearing potential should be counseled to either practice abstinence or use at 
least one primary form of contraception not including hormonal contraception from the time 
of screening through Day 29. Women should be confirmed to not be breastfeeding. 
• Note: If a woman is either postmenopausal (i.e., has had ≥12 months of spontaneous 
amenorrhea) or surgically sterile (i.e., has had a hysterectomy, bilateral ovariectomy (oophorectomy), or bilateral tubal ligation), she is not considered to be of childbearing potential.  
• Height and weight (height can be self -reported).  
• Results of recent radiographic imaging (x -ray or CT scan).  
• SpO2. 
• Blood for screening laboratory evaluations if not done as part of routine clinical care in the 
preceding 48 hours: 
 ALT.  
 AST.  
 Creatinine (and calculate eGFR).  
• Any automated calculation by [CONTACT_226300]. The site should select a formula to be used for all 
subjects enrolled at the site for the duration of the study. 
• Urine or serum pregnancy test (in women of childbearing potential). 
 
Clinical screening laboratory evaluations will be performed locally by [CONTACT_50821]. The 
volume of venous blood to be collected is presented in Table 3. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055285] infusion including the collection of OP swab and blood, assessment of the ordinal scale and NEWS and completing or recording a baseline physical examination that was done. 
 Efficacy Assessments  
For all baseline assessments and follow-up visits, refer to the Schedule of Assessments (SOA) 
for procedure to be done, and details below for each assessment.  
 Measures of clinical support, limitations and infection control  
The subject’s clinical status will be captured on  each study day while hospi[INVESTIGATOR_243729] 29. If a subject is discharged prior to Day 15, clinical status is captured on Day [ADDRESS_1055286] administration, as time permits. The following measures are recorded for the ordinal scale: 
• Hospi[INVESTIGATOR_059].  
• Oxygen requirement. 
• Non-invasive mechanical ventilation (via mask) requirement. 
• High flow oxygen requirement. 
• Invasive mechanical ventilation (via endotracheal tube or tracheostomy tube) requirement.  
• ECMO requirement.  
• Ongoing medical care preventing hospi[INVESTIGATOR_2345] (COVID -19 related or other medical 
conditions). 
• Limitations of physical activity (self -assessed).  
• Isolated for infection control purposes.  
 Ordinal Scale  
 The ordinal scale is the primary measure of clinical outcome.  
 The scale used in this study is as follows (from worst to best): 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 82 of 146 • Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing medical care 
(COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical 
care;  
o This would include those kept in hospi[INVESTIGATOR_41348]/infection control, awaiting 
bed in rehabilitation facility or homecare, etc.  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on activities  
 To determine a subject’s clinical status using the ordinal scale: On Day 1, report their clinical status at randomization. On Day 2, report the period from randomization to midnight on Day 1. On Day [ADDRESS_1055287] clinical assessment for the previous day (i.e., midnight to midnight; 00:00 – 23:59 (24- hr clock)). 
For example, on study Day [ADDRESS_1055288] being death followed by [CONTACT_119927], mechanical ventilation, etc. The Day 2 measurement  is assessed as occurring anytime in that 24 -hour period (00:00 to 23:59). 
 
 National Early Warning Score (NEWS) 
NEWS has demonstrated an ability to discriminate subjects at risk of poor outcomes. (Smith, 2016). This score is based on 7 clinical parameters (see Table 2). The NEWS is being used as an 
efficacy measure. The NEW Score should be evaluated daily w hile hospi[INVESTIGATOR_119818] [ADDRESS_1055289] (EMR) using the last measurement prior to the time of assessment and a numeric score is given for each parameter (e.g., a RR of 9 is one point, oxygen saturation of 92 is two points). This is recorded for the day obtained (i.e., on Day 3, the vital signs and other parameters from Day 3 are used to obtain NEW Score for Day 3).  ECMO and mechanically ventilated subjects should be assigned a score of 3 
for RR (RR <8) regardless of the ventilator setting. Subjects on ECMO should get a score of  3 
for heart rate since they are on cardiopulmonary by[CONTACT_6476].  Table 2. National Early Warning Score (NEWS) 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 83 of 146  
  Level of consciousness = alert (A), and non- alert and arousable only to voice (V) or pain (P), and 
unresponsive (U).  
 
  Exploratory assessments 
 Viral Load and/or Shedding  
As outlined on the SOA, OP swabs and plasma and serum will be collected on Day 1; and Days 
3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and OP swabs and serum on Day 15 and 29 (if attends an in- person visit or sti ll hospi[INVESTIGATOR_057]). Samples are  stored as outlined in the MOP. These assays are 
not developed yet, and the ability to test samples at one central lab is not clear. Therefore, while viral load/shedding is thought to be an important endpoint, considering the l imitations above, it is 
listed as an exploratory endpoint.   OP swabs are preferred, but if these are not obtainable, nasopharyngeal (NP) swabs may be substituted. Due to limited lack of swabs and other supplies at some sites and limitations on personal protective equipment (PPE), the inability to obtain these samples are not considered protocol deviations and should be documented in the subject’s record.   If virology assays can be set up with enough numbers of specimens tested, these data will be submitted as part of the Clinical Study Report (CSR). This may be submitted separately, as a 
supplemental CSR.   Samples collected for viral assessment may be probed for the emergence of antiviral resistance at a future date. These data, if available, may be submitted as a supplement report.  
 
The schedule of assessments (SOA, Section 1.2) lists several research laboratory samples. It is 
preferred that these samples are collected and sent to the NIAID repository to be tested in one central laboratory. Current US Centers for Disease Control and Prevention (CDC) guidance is these samples can be processed in a Biosafety Laboratory (BSL) 2 environment. However, 

Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 84 of 146 institutions may impose restrictions on processing the samples (i.e., they may require BSL -3) or 
there may be restrictions on sending samples. In these circumstances, the following apply: 
 Blood for PCR SARS -CoV-2 
• If the samples can be processed but cannot be sent to the repository, the samples may be stored locally.  
• The sponsor may elect to have some or all of these samples run locally, pending confirmation of the assays to be used and the qualifications of the local laboratory. The sponsor will work with the site to determine when this could occur and how these data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.  
 Oropharyngeal swab 
• If the samples can be processed but cannot be sent to the repository, the samples may be stored loca lly.  
• The sponsor may elect to have some or all of these samples run locally, pending 
confirmation of the assays to be used and the qualifications of the local laboratory. The 
sponsor will work with the site to determine when this could occur and how these  data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.  
 Blood for serum (for secondary research)  
• If the samples can be processed and but not sent to the repository, the samples may be 
stored locally.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.  
 
8.2 Safety and Other Assessments  
Study procedures are specified in the SOA. A study physician licensed to make medical diagnoses and listed on the 1572 will be responsible for all trial- related medical decisions.  
 
Physical examination :  
A targeted physical examination will be performed at baseline prior to initial infusion on Day 1. The baseline physical examination can be one that is conducted from screening to Day 1. Post-baseline physical examinations will be done only when needed to e valuate possible adverse 
event(s) (i.e. any new signs or symptoms). No routine physical exam is needed for study visits after Day 1.  
 Study staff at some sites are not allowed into the subject’s rooms due to a limited supply of PPE and the need for strict respi[INVESTIGATOR_119837]-19 patients. Because of limited access to subjects, physical exams can be performed by [CONTACT_769135] 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055290] 
information from the hospi[INVESTIGATOR_119838].   
Clinical laboratory evaluations : 
• Fasting is not required before collection of laboratory samples. 
• Blood will be collected at the time points indicated in the SOA.  
• Clinical safety laboratory tests include WBC, dif ferential, Hgb, PLT, creatinine, 
glucose, total bilirubin, AST, ALT, and PT. Sites that do not have access to a test for PT will be allowed to report an international normalized ratio (INR).  
• Day 1 clinical laboratory evaluations are drawn prior to initial infusion as a 
baseline and results do not need to be reviewed to determine if initial infusion should be given. 
• Clinical laboratory testing will be performed at each clinical trial site in real time.  
  Table 3. Venipuncture Volumes
1 
 Screen  Baseline        
Day +/ - Window  −1 to 1  1 ± 1  3 ± 1  5 ±1 8 ± 1  11 ± 1  15 ± 2  29 ± 3  
Safety hematology, 
chemistry and liver 
tests  X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2  X3 
10mL2 X3 
10mL2 
Blood for Serum   X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  
Plasma  
(includes PCR)   X 
8mL  X 
8mL  X 
8mL  X 
8mL  X 
8mL    
Total volume  10mL  42ml 42mL  42ml 42ml 42ml 34mL  34mL  
Total all study days         268~[ADDRESS_1055291] Values or 
Abnormal Clinical Findings  
If a physiologic parameter (e.g., vital signs, or laboratory value) is outside of the protocol-
specified range, then the measurement may be repeated once if, in the judgment of the investigator, the abnormality is the result of an acute, short-term, rapi[INVESTIGATOR_119846]. A physiologic parameter may also be repeated if there is a technical problem with 
the measurement caused by [CONTACT_566276] (i. e., 
inappropriate- sized BP cuff).  
 
 Unscheduled Visits  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055292]’s well -being, it is permissible in this protocol. However, no 
research data is collected at this visit.  
8.3 Adverse Events and Serious Adverse Events  
 Definition of Adverse Event (AE)  
AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related. An A E can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.  If multiple  abnormalities are part 
of the same clinical syndrome, they can be reported together as one AE under a unifying clinical diagnosis.   Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre- existing (baseline) 
medical condition increases above baseline to severity grade [ADDRESS_1055293] many symptoms and abnormalities in vital signs and laboratory values. Only Grade 3 and 4 AEs will be captured in this trial. In addition, the following AEs will be reported: 
• Any Grade [ADDRESS_1055294] administration will be reported as an AE. 
 Intermittent abnormal laboratory values or vital sign measurements common in the severely ill populations (such as electrolyte abnormalities, low blood pressure, hyperglycemia, etc.) that are part of t he same clinical diagnosis (e.g., uncontrolled diabetic) can be recorded once with the 
worst grade for each adverse event (grade 3 and 4 only for this trial), with the start and stops dates of the intermittent syndrome.  If there is clear resolution of the event, and then recurrence, it 
should be treated as a separate adverse event. Resolution is defined as return to baseline (either normal if was normal at Day 1, or baseline (Day 1) grade if already an abnormality on the toxicity table at Day 1) for > 48 hours.   
 Definition of Serious Adverse Event (SAE)  
An AE or suspected adverse reaction is considered serious (i.e., is an SAE) if, in the view of either the investigator or the Sponsor, it results in any of the following outcomes: 
• Death;  
• A life -threatening A E; 
• Inpatient hospi[INVESTIGATOR_1081]; 
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or 
• A congenital anomaly/birth defect.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055295] and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  “Life -threatening” refers to an AE that at occurrence represents an immediate risk of death to a 
subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening. Similarly, a hospi[INVESTIGATOR_769112] a SAE. 
 All SAEs, as with any AE, will be assessed for severity and relationship to study intervention.  All SAEs will be recorded on the SAE CRF.  All SAEs will be followed through resolution or stabilization by a licensed stu dy physician (for 
IND studies, a physician listed on the Form FDA 1572 as the site PI [INVESTIGATOR_54720]-Investigator).  All SAEs will be reviewed and evaluated by [CONTACT_435661] (for periodic review), and the IRB/IEC. 
 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]R)  
A S[LOCATION_003]R is any SAE where a causal relationship with the study product is at least reasonably possible but is not listed in the IIB, Package Insert, and/or Summary of Product Characteristics. 
 Classification of an Adverse Event  
The d etermination of seriousness, severity, and causality will be made by [CONTACT_63689]- site investigator 
who is qualified (licensed) to diagnose AE information, provide a medical evaluation of AEs, and classify AEs based upon medical judgment. This includes but is not limited to physicians, physician assistants, and nurse practitioners. 
 Severity of Adverse Events  
All AEs and SAEs will be assessed for severity using the DAIDS Table for Grading the Severity 
of Adult and Pediatric Adverse Events, version 2.1 (July 2017).  
 
For AEs not included in the Table, the following guidelines will be used to describe severity. In addition, all deaths related to an AE are to be classified as grade 5 according to the DAIDS Table.  
  
• Moderate (Grade 2) : Events that are usually alleviated with additional specific 
therapeutic intervention. The event interferes with usual activities of daily living and causes discomfort but poses no significant or permanent risk of harm to the research 
subject.  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 88 of 146 • Severe (Grade 3) : Events that interrupt usual activities of daily living, or significantly 
affect clinical status, or may require intensive therapeutic intervention. Severe events are 
usually incapacitating.  
 
• Severe (Grade 4) : Events that are potentially life threatening.  
 
• Deaths (Grade 5):  All deaths related to an AE are to be classified as grade 5. (per DAIDS 
Table).  
 
 Relationship to Study Intervention 
For each reported adverse reaction, the PI [INVESTIGATOR_435632]:  
• Related  – There is a temporal relationship between the study intervention and event, and 
the AE is known to occur with the study intervention or there is a reasonable possibility that the study intervention caused the AE . Reasonable possibility means that there is 
evidence to suggest a causal relationship between the study intervention and the AE.  
 
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established. 
 Time Period and Frequency for Event Assessment and Follow -Up 
For this study, all Grade [ADDRESS_1055296] 
infusions will be reported as an AE.   
 Investigators Reporting of AEs 
Information on all AEs will be recorded on the appropriate CRF. All clearly related signs, 
symptoms, and results of diagnostic procedures performed because of an AE should be grouped together and recorded as a single diagnosis. If the AE is a laboratory abnormality that is part of 
a clinical condition or syndrome, it should be recorded as the syndrome or diagnosis rather than 
the individual laboratory abnormality. Each AE will also be described in terms of duration (start 
and stop date), severity, association with the study product, action(s) taken, and outcome. 
 Serious Adverse Event Reporting  
 Investigators Reporting of SAEs 
Any AE that meets a protocol -defined criterion as a SAE must be submitted within 24 hours of 
site awareness on an SAE form to the DMID Pharmacovigilance Group, at the following 
address:  
 
DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS)  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055297]. Suite 650 
Bethesda, MD [ZIP_CODE], [LOCATION_003] SAE Hot Line: [PHONE_2618] (US) or [PHONE_2619] (outside US) 
SAE FAX Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Address: [EMAIL_1393] 
 Other supporting documentation of the event may be requested by [CONTACT_295051]. The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct.  At any time after completion of the study, if the site PI [INVESTIGATOR_769113] -investigator becomes 
aware of an SAE that occurred during the subject’s participation in the study, the site PI [INVESTIGATOR_29353]-investigator will report the event to the DMID Pharmacovigilance Group. 
 Regulatory Reporting of SAEs 
Following not ification from the site PI [INVESTIGATOR_29353] -investigator, DMID, as the IND 
Sponsor, will report any S[LOCATION_003]R in an IND safety report to the FDA and will notify all participating site PIs as soon as possible. DMID will report to the FDA any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 
calendar days after the Sponsor’s initial receipt of the information. If the event is not fatal or life-threatening, the IND safety report will be submitted within [ADDRESS_1055298] additional local reporting requirements (to the IRB and/or national regulatory 
authority).  
 Reporting of Pregnancy 
Pregnancy is not an AE. However, any pregnancy that occurs during study participation should 
be reported to the Sponsor on the appropriate CRF. Pregnancy should be followed to outcome.  
8.4 Unanticipated Problems  
 Definition of Unanticipated Problems  
An Unanticipated Problem (UP) is any event, incident, experience, or outcome that meets the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied; 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 90 of 146  Related to participation in the research (meaning there is a reasonable possibility that the 
incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
 Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 Unanticipated Problem Reporting  
To satisfy the requirem ent for prompt reporting, all UPs will be reported using the following 
timeline:  
 UPs that are SAEs will be reported to the IRB and to the Statistical and Data Coordinating Center (SDCC)/study Sponsor within 24 hours of the investigator becoming aware of the event per the above describe SAE reporting process.  
 Any other UP will be reported to the IRB and to the SDCC/study Sponsor within 3 days of the investigator becoming aware of the problem. 
9. STATISTICAL  CONSIDERATIONS 
This study is intended to allow for two types of adaptations: 1) sample size re-estimation and 2) addition of new experimental arm(s). A brief summary is provided here. Details will be described in the statistical analysis plan (SAP).  
 
Sample size re- estimation: The target of 400 recoveries corresponds to a total sample size that 
depends on the proportion of subjects who recover by [CONTACT_2006] 29. This proportion will be evaluated on pooled (i.e., blinded) data to evaluate the total sample size required. A prelimi nary estimate 
based on a 70% recovery probability is 572 patients.  
 
Addition of new experimental therapi[INVESTIGATOR_014]: If additional data become available to add an 
experimental therapy, the sample size will be updated accordingly. Analyses of newly added arm(s) wil l be performed comparing concurrently enrolled control subjects. This approach was 
used in the recent PALM study in patients with Ebola virus disease (29).  
9.[ADDRESS_1055299] is the “common odds ratio,” which quantifies the shift in the severity distribution resulting from treatment. For an efficacious treatment, an odds ratio greater than 1 quantifies an improvement in disease severity; a value of 2 indicates a bigger improvement than a value of 1.25. The null hypothesis to be tested is that the odds of improvement on the ordinal scale is the same for the placebo and experimental treatment arms (i.e., the common odds ratio is 1). It is worth noting that, for large sample sizes, the test based on the proportional odds model is nearly the same as the Wilcoxon rank sum test.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 91 of 146 9.2 Sample Size Determination  
 
Primary endpoint: The log- rank test will be used to compare treatment arms with respect to time 
to recovery. For the log-rank test, the two key determinants of power are the total number of 
events (i.e., recoveries) E and the treatment -to-control ratio of the rate of recovery, R. The 
number of events required for power 1−𝛽𝛽 to detect a recovery rate ratio of θ using a two- tailed 
test at alpha=0.05 is approximately 
𝐸𝐸=4�1.96+𝑧𝑧𝛽𝛽�2
{ln(𝜃𝜃)}2, 
where 𝑧𝑧𝛽𝛽 is the 100 (1−𝛽𝛽)th percentile of the standard normal distribution. 
For 85% power, approximately [ADDRESS_1055300] a 40% increase in the rate of 
recovery ( 𝜃𝜃= 1. 40) from remdesivir. A recovery rate ratio of 1.40 is similar to, but slightly 
higher than the figure of 1.31 reported in Cao, Wang, Wen et al. (2020) for a lopi[INVESTIGATOR_054]/ritonavir 
trial that used time to improvement by 2 categories as primary endpoint. A total of 400 recoveries is needed for a recovery ratio of 1.35 with 85% power. Table 4 provides power for 
various recovery rate ratios.  
 Table 4 Number of recoveries needed for 85% power assuming a type I error rate of 5% 
for various recovery ratios.  
 
Recovery  ratio 
(θ) Number of recoveries 
needed for 85% 
power  
1.25 723 
1.30 523 
1.35 400 
1.40 318 
 
Key secondary: A sample size can be computed using an (assumed) ordinal scale distribution for the placebo and the odds ratio representing clinical improvement. The odds ratio represents the odds of improvement in the ordinal scale for treatment relative to placebo [Whitehead, 1993]. 
The sample size to detect a given odds ratio for 1:[ADDRESS_1055301] at level α 
is given by 
12�𝑧𝑧
α/2+𝑧𝑧β�2
λ2(1−∑𝑝𝑝𝑖𝑖3𝐾𝐾
𝑖𝑖=1), 
 
where λ is the log odds ratio, 𝑝𝑝 𝑖𝑖 is the overall probability (combined over both arms) of being in 
the ith category of the K ordinal outcomes, and 𝑧𝑧α/2 and  𝑧𝑧𝛽𝛽 are the 1−α/2 and 1−β quantiles 
of the standard normal distribution.  
 Table 5 displays five scenarios considered for outcome probabilities in the placebo arm for 
sample size determination. There is significant uncertainty with these assumptions given the 
limited data available. Table 5 shows a range of sample sizes for odds ratios ranging from 1.25 to 
2.5 for 85% power. For 90% power, increase the sample size by 17%. Table 6 displays the 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 92 of 146 probabilities of being in different categories of the ordinal scale under an odds ratio of 1.75. A 
total sample size of 396 gives approximately 85% power to detect an odds ratio of 1.[ADDRESS_1055302] at level α= 0. 05. The categories of the 8 -point ordinal scale are:  
 
• Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing medical care 
(COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical care; 
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitat ions on activities.  
 Note that the data elements contributing to this scale will be captured separately, in order to facilitate different orderings or groupi[INVESTIGATOR_14839], as might arise if external data provide information about the clinical course of disease.  
  Table 5. Possible scenarios for the distribution of ordinal outcomes for the control arm at 
Day 15. 
 Anticipated  Different scenarios for control arm  
  Scenario 1  Scenario 2  Scenario 3  Scenario 4  Scenario 5  
  more mild disease                       more severe disease  
Severity Outcome  outcome (%)  outcome (%)  outcome (%)  outcome (%)  outcome (%)  
Death  2 1 1 2 3 
Hospi[INVESTIGATOR_057], on mechanical 
ventilation or ECMO  1 1 1 1 3 
Hospi[INVESTIGATOR_057], on non -
invasive ventilation or high 
flow oxygen devices  2 1 1 2 4 
Hospi[INVESTIGATOR_057], requiring 
supplemental oxygen  7 2 5 5 9 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen - 
requiring ongoing medical 
care (COVID -19 related or 
otherwise)  8 5 7 17 23 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen - no 
longer requires ongoing 
medical care  10 9 10 20 25 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 93 of 146 Not hospi[INVESTIGATOR_057], limitation 
on activities and/or requiring 
home oxygen  30 36 35 25 18 
Not hospi[INVESTIGATOR_057], no 
limitations on activities  40 45 40 28 15 
 
 Table 6. Sample size calculations for scenarios in Table 5 for a two-arm study assuming 
85% power, a two-sided type I error rate of 5%, and various true odds ratios.  
True odds 
ratio  Total sample size 
 Scenario 1  Scenario 2  Scenario 3  Scenario 4  Scenario 5  
1.25 2420  2554  2459  2293  2252  
1.5  744 786 755 700 684 
1.75 396 419 401 370 360 
2.0 262 277 265 243 236 
2.25 194 206 196 179 173 
2.5 154 163 155 141 136 
 Table 7. Treatment ordinal outcome proportions under an odds ratio of 1.75 for five 
scenarios in Table 6 at Day 15. 
  Scenario  
1 Scenario 
2 Scenario 
3 Scenario 
4 Scenario 
5 
  Anticipated  more mild disease                more severe disease  
Severity Outcome  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Death  2 1.2 1 0.6 1 0.6 2 1.2 3 1.7 
Hospi[INVESTIGATOR_057], on mechanical 
ventilation or ECMO  1 0.6 1 0.6 1 0.6 1 0.6 3 1.8 
Hospi[INVESTIGATOR_057], on non -invasive 
ventilation or high flow 
oxygen devices  2 1.2 1 0.6 1 0.6 2 1.2 4 2.5 
Hospi[INVESTIGATOR_057], requiring 
supplemental oxygen  7 4.3 2 1.2 5 3.0 5 3.1 9 5.8 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen - requiring ongoing medical 
care (COVID -19 related or 
otherwise)  8 5.3 5 3.1 7 4.4 17 11.5 23 17.4 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen - no 10 7.2 9 5.9 10 6.8 20 16.2 25 24.4 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 94 of 146 longer requires ongoing 
medical care;  
Not hospi[INVESTIGATOR_057], limitation 
on activities and/or requiring 
home oxygen  30 26.5 36 29.3 35 30.2 25 25.9 18 22.7 
Not hospi[INVESTIGATOR_057], no 
limitations on activities  40 53.8 45 58.9 40 53.8 28 40.5 15 23.6 
Note that columns may not sum to exactly 100 due to rounding errors. 
  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055303] one infusion. The primary analysis will be based 
on those subjects enrolled in order to 400 recoveries. Subsequent analysis will be performed on all enrolled subjects.   
 
9.4 Statistical Analyses  
 General Approach  
This is a double-blind placebo controlled randomized trial testing a superiority hypothesis with a two-sided type I error rate of 5%. Secondary hypotheses have been ordered according to relative 
importance, with one key secondary hypothesis highlighted. These will be described according to the appropriate summary statistics (e.g., proportions for categorical data, means with 95% confidence intervals for continuous data, median for time- to-event data).  
 A statistical analysis plan will be developed  and filed with the study sponsor prior to unblinding 
of study and database lock.   Unblinding of the study will occur after all subjects enrolled for [ADDRESS_1055304], where stratification is according to 
baseline disease severity (i.e. protocol defined mild/moderate vs severe disease). Deaths will be considered censored at Day 29. 
 
 Analysis of the Secondary Endpoint(s)  
 
1) The ordinal scale will be used to estimate a proportional odds model by [CONTACT_119935]. The hypothesis test will perform a stratified test to evaluate whether the common odds ratio for treatment is equal to o ne. The distribution of severity results will be summarized 
by [CONTACT_119936]. Efforts to minimize loss -to-follow-up will be 
considerable. However, small amounts of missing data may occur. In such cases, subjects without final outcome data wi ll be excluded from the analysis. Sensitivity analyses will 
evaluate the impact of making different assumptions about missing observations. These analyses will be defined in the SAP.  
 
2) Differences in time -to-event endpoints (e.g., time to at least a one category improvement 
in ordinal scale) by [CONTACT_119937] -Meier curves and 95% 
confidence bounds. The same procedure will be used to compare time to at least a two- category improvement.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 96 of 146 3) Change in ordinal scale at specific time points will be summarized by [CONTACT_119938] (e.g., 
proportion who have a 1-, 2-, 3-, or 4-point improvement or 1-, 2-, 3-, 4-point worsening).  
4) Duration of event (e.g., duration of mechanical ventilation) will be summarized according to median days with quartiles.  
5) Binary data (e.g., incidence of new oxygen use) will be summarized as a percent with 95% confidence intervals. Comparisons between arms will be presented as differences in proportions with 95% confidence intervals. 
6) Categorical data (e.g., 28 -day mortality or ordinal scale by [CONTACT_4475]) may be summarized 
according to proportions by [CONTACT_119939]/or odds ratios with confidence intervals.  
 Procedures for handling missing data, including informative censoring (e.g., a missing duration of oxygen use endpoint due to a death), will be described in the SAP.  
 Safety Analyses 
Safety endpoints include death through Day 29, SAEs and Grade [ADDRESS_1055305] and graded by [CONTACT_435662]-19 or study intervention. AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities (MedDRA). AEs will be presented by [CONTACT_9313], duration (in days ), start - and stop- date. Adverse events leading 
to premature discontinuation from the study intervention and serious treatment- emergent AEs 
will be presented either in a table or a listing.  
 
 Baseline Descriptive Statistics  
Baseline characteristics will be  summarized by [CONTACT_2939]. For continuous measures the 
mean and standard deviation will be summarized. Categorical variables will be described by [CONTACT_119942] (with the corresponding sample size numbers).   
 Planned Interim and Early A nalyses  
Early analyses:  
A blinded sample size re-estimation will be conducted after approximately [ADDRESS_1055306] recovered by [CONTACT_2006] 29, which will provide important information about the number of patients needed to achieve 400 recoveries. Additionally, the number of deaths will be evaluated.  Additional early analyses include monitoring enrollment, baseline characteristics, and follow-up rates throughout the course of the study by [CONTACT_3476]. Analyses will be conducted blinded to treatment assignment.  
 
Interim analyses:  
A DSMB will monitor ongoing results to ensure subject well- being and safety as well as study 
integrity. The DSMB will be asked to recommend early termination or modification only when there is clear and substantial evidence of a treatment difference. More details about the interim 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 97 of 146 analyses are described in section [IP_ADDRESS] and [IP_ADDRESS] below as well as a separate guidance 
document for the DSMB.  
 
 Interim Safety Analyses  
Safety analyses will evaluate Grade 3 and 4 AE and SAEs by [CONTACT_2939].  Safety monitoring 
will be ongoing (see section 10.1.6) and evaluate safety results weekly. The unblinded statistical 
team will prepare these reports for review by [CONTACT_4318].  
 
 Interim Efficacy Review  
The Lan -DeMets spending function analog of the O’Brien-Fleming boundaries will be used to 
monitor the primary endpoint as a guide for the DSMB for an overall two-sided type- I error rate 
of 0.05. Interim efficacy analyses will be conducted after the blinded sample size re -estimation 
of the primary efficacy endpoint at approximately 33%, 67%, and 100% of total information.   Conditional power will be presented as an additional guide to the DSMB. Conditional power allows computation of the probability o f obtaining a statistically significant result by [CONTACT_769136], incorporating and assuming a hypothesized treatment effect (e.g., the treatment effect assumed for sample size determination) thereafter. If conditional power is less than 20% under the original trial assumptions, consideration should be given to stoppi[INVESTIGATOR_21356].   The unblinded statistical team will prepare these closed reports for DSMB review and recommendations. Analyses will be presented with blinded codes for treatment arms to protect against the possibility that the DSMB report may fall into the wrong hands. A DSMB charter will further describe procedures and membership. An additional document on statistical issues related to monitoring will b e provided to the DSMB prior to interim analyses.  
 
 Sub-Group Analyses 
Subgroup analyses for the primary outcomes will evaluate the treatment effect across the following subgroups: geographic region, duration of symptoms prior to enrollment, baseline disease severity (stratification of mild/moderate and severe, as well as ordinal scale of 4/5 vs 6/7) 
age, race, sex and comorbidities. A forest plot will display confidence intervals across subgroups. Interaction tests will be conducted to determine whether the effect of treatment varies by [CONTACT_6496].  
 Exploratory Analyses 
An e xploratory analysis will compare treatment efficacy estimates according to the various 
scales outlined in section 8.1.2. Specifically, the probability of falling into  category “i” or better 
will be compared between arms for each i.   
  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix A - ACTT -1: Remdesivir vs Placebo  
DMID/NIAID/NIH  CONFIDENTIAL  Page 98 of 146 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS 
All supporting documentation and operational considerations are applicable to the entire 
platform trial and are not unique to the individual stages. These are therefore covered in the main protocol document.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  21 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 99 of 146 
 APPENDIX B - ACTT -2: BARICITINIB /REMDESIVIR VS. REMDESIVIR 
TRIAL  
1. PROTOCOL  SUMMARY 
1.1 ACTT -2 – Synopsis  
Study overview 
The cause of ARDS is a hyperinflammatory state characterized by [CONTACT_769137]. Baricitinib, an orally administered, selective inhibitor of Janus kinase 1 (JAK1) and JAK2, could be a therapeutic option because of the potential to inhibi t signaling from multiple 
cytokines in COVID- 19 patients (30) . Baricitinib treatment resulted in a reduction from baseline 
in serum IL -6 at Week 12 in patients with active RA in a Phase 2, randomized, placebo-
controlled study of baricitinib (31). In addition, baricitinib has recently been hypothesized (32) and shown (nonclinical data on file) to be a potent inhibitor of numb- associated kinases (NAKs), 
which play a critical role in the host epi[INVESTIGATOR_1231]’s ability to facilitate propagation of viruses.  
As these are unique mechanism of actions, the effects of combination therapy may exceed either component.   A preliminary review of data from ACTT -1 occurring after 606 recoveries and 103 deaths 
(approximately 67% of the 1063 subjects enrolled) demonstrated that subjects that received 
remdesivir had a 31% faster time to recovery (11 vs 15 days, recovery rate ratio  1.312 (1.119, 
1.541), p<0.001) , and a decrease in mortality (  8.0% vs 11.6%, p = 0.059). The DSMB asked that 
the sponsor be unblinded early given public health implications and implications for ACTT -2. 
Given these findings, there will be no placebo arm in ACTT- 2. We will instead  investigate 
remdesivir and baricitinib in combination versus remdesivir alone.  
 
Enrollment Period:   
It is anticipated the enrollment may be completed in [ADDRESS_1055307] a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and OP swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic. In this case, these visits may be conducted by [CONTACT_648], and only clinical data will be 
obtained. The Day [ADDRESS_1055308] laboratory tests or collection of samples and is  
conducted by [CONTACT_648].   We anticipate that this trial will require  732 recoveries.  Assuming that 70% of subjec ts achieve 
recover y in 28 days, the total sample size is approximately 1032.  
 
Study Population  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 100 of 146 Hospi[INVESTIGATOR_119800] (≥18 years old) with COVID -19. 
 
Inclusion Criteria  
1. Admitted to a hospi[INVESTIGATOR_435629] -19. 
2. Subject (or legally authorized representative) provides informed consent prior to 
initiation of any study procedures. 
3. Subject (or legally authorized representative) understands and agrees to comply with 
planned study procedures. 
4. Male or non-pregnant female adults ≥ 18 years of age at time of enrollment.  
5. Has laboratory -confirmed SARS -CoV-2 infection as determined by [CONTACT_435653], as documented by [CONTACT_147664]:  
• PCR positive in sample collected < 72 hours prior to randomization; OR  
• PCR positive in sample collected ≥ 72 hours prior to randomization, documented 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc) AND progressive disease suggestive of ongoing SARS-CoV-[ADDRESS_1055309] one of the following: 
• Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, etc.), OR  
• SpO2 ≤ 94% on room air, OR 
• Requiring supplemental oxygen, OR  
• Requiring mechanical ventilation  or ECMO . 
7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.  
8. Agrees to not participate in another clinical trial for the treatment of COVID -[ADDRESS_1055310] > 5 times the upper limit of normal.  
2. Estimated glomerular filtration rate (eGFR) < 30 ml/min or patient is receiving 
hemodialysis or hemofiltration  at time of screening . 
3. Neutropenia (absolute neutrophil count <1000 cells/μL) (<1.0 x 103/μL or <1.0 GI/L).  
4. Lymphopenia (absolute lymphocyte count <200 cells/μL) (<0.20 x 103/μL or <0.20 GI/L)  
5. Pregnancy or breast feeding.  
6. Anticipated discharge from the hospi[INVESTIGATOR_119804] a study site within 72 hours. 
7. Allergy to any study medication.  
8. Received three or more doses of remdesivir including the loading dose, outside of the 
study under the EUA (or similar mechanism) for COVID -19.  
9. Received convalescent plasma or intravenous immunoglobulin [IVIg]) for COVID-19, the current illness for which they are being enrolled . 
10. Received small molecule tyrosine kinase inhibitors (e.g. baricitinib, imatibib, genfinitib), in the 1 week prior to screening.   
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 101 of 146 11. Received monoclonal antibodies targeting cytokines (e.g., TNF inhibitors, anti -
interleukin -1 [IL -1], anti- IL-6 [tocilizumab or sarilumab] ), or T-cells (e.g., abatacept) in 
the 4 weeks prior to screening. 
12. Received monoclonal antibodies targeting B- cell (e.g., rituximab , and including any 
targeting multiple cell lines including B -cells)  in the 3 months prior to screening. 
13. Received other immunosuppressants in the 4 weeks prior to screening and in the 
judgement of the investigator, the risk of immunosuppression with baricitinib is larger than the risk of COVID-19.  
14. Received ≥20 mg/day of prednisone or equivalent for ≥[ADDRESS_1055311] diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by [CONTACT_119907], no screening required). 
17. Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opi[INVESTIGATOR_119835] a risk when taking investigational product.  
18. Have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. Note: Use of non-live (inactivated) vaccinations is allowed for all subjects .  
19. Have a history of VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE]) within [ADDRESS_1055312] a history of recurrent (>1) VTE (DVT/PE).  
20. Immunocompromised patients, patients with a chronic medical condition, or those taking a medication  that cannot be discontinued at enrollment, who, in the judgment of PI , are at 
increased  risk for serious infections or other safety concerns given the study products. 
 
Study Intervention 
Subjects will be randomized into two  arms (1:1).  
 Baricitinib  Placebo  
Remdesivir  Arm 1  
Baricitinib tablets + 
remdesivir IV  Arm 2  
Placebo tablets + 
remdesivir IV  
  All subjects will receive remdesivir as a 200 mg intravenous (IV) loading dose on Day 1, 
followed by a [ADDRESS_1055313] or placebo as follows: 
• Baricitinib will be administered as a 4 mg* orally (po) (two 2mg tablets) or crushed for 
NG tube, daily for the duration of the hospi[INVESTIGATOR_83263] a 14- day total course.  
• A placebo will be given as two tablets* po or crushed for NG tube, daily for the duration of the hospi[INVESTIGATOR_83263] a 14-day total course * Patients with eGFR <60 mL/min will receive a dose of one tablet (2 -mg or placebo) 
once daily.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 102 of 146  
Duration of therapy: 
• IV remdesivir  – 10 days while hospi[INVESTIGATOR_057]. 
• Oral (baricitinib or placebo) component – 14 days while hospi[INVESTIGATOR_057]. 
• Both stop on discharge from hospi[INVESTIGATOR_307]. 
 
1.2 Schedule of Assessments  
Table 1. Schedule of Assessments (SOA)  
  Screen  Baseline  Study Intervention Period  Follow -up Visits  
Day +/ - Window  −1 or 1  1 Daily until hospi[INVESTIGATOR_7954]  157  
± 2 227 
± 3 297 
± 3 
ELIGIBILITY        
Informed consent  X      
Demographics & Medical History  X      
Review SARS -CoV -2 results  X      
       
STUDY INTERVENTION        
Randomization   X     
Administration of investigational 
agent   • Remdesivir  daily infusion until day 
10 or discharge.  
• Baricitinib or placebo: daily by 
[CONTACT_769138] 14 or discharge     
      
      
STUDY PROCEDURES        
Targeted physical exam   X     
Vital signs including SpO 2 1  X4 Daily until discharge8 X9  X9 
Clinical data collection  2   X4 Daily until discharge8 X9 X9 X9 
Adverse event evaluation   X4 Daily until discharge8 X9 X9 X9 
Concomitant medication review   X4 From Day -7 to Day 1 5    
       
SAFETY LABORATORY        
Safety hematology, chemistry and 
liver tests X3 X4,5,6,7 Day 3, 5, 8, 11 (all ± 1 day) 
if hospi[INVESTIGATOR_057]6,[ADDRESS_1055314] for PCR 
SARS -CoV -2  X4,6 Day 3, 5, 8, 11 (all ± 1 day) 
if hospi[INVESTIGATOR_435621] 10  X4,6 Day 3, 5, 8, 11 (all ± 1 day) 
if hospi[INVESTIGATOR_057]  X9  X9 
Blood for serum (secondary 
research)   X4,6 Day 3, 5, 8, 11 (all ± 1 day) 
if hospi[INVESTIGATOR_057]  X9  X9 
Notes:  
1Vital signs include temperature,  systolic blood pressure, heart rate, respi[INVESTIGATOR_697], O2 saturation and level of 
consciousness. Vital signs collected as part of standard care may be used.  
2 Refer to Section 8.1.2 of the protocol for details of clinical data to be collected including ordinal score, NEWS, oxygen 
requirement, mechanical ventilator requirement, etc.  
3 Screening laboratory tests include: CBC with differential ( including  absolute neutrophil count and absolute lymphocyte 
count ), ALT, AST, creatinine (and calculate an estimated glomerular filtration rate (eGFR) the formula used is determined 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 103 of 146 by [CONTACT_30107], but should be consistent throughout the study), and pregnancy test. Laboratory tests performed in the [ADDRESS_1055315] administration. Results of Day 1 
(baseline ) laboratory assessment do not need to be reviewed to determine if initial study product  should be given.  
[ADDRESS_1055316],  
INR, d-dimer, and C -reactive protein  (CRP) . Note: D-dimer and CRP values  may predict severity and support  assessment 
of outcomes and unlike other safety laboratory values, D -dimer and CRP should not be  graded.   
7 Any laboratory tests performed as part of routine clinical care within the specified visit window can be used for safety 
laboratory testing. Window during the 10 days of dosing is ±[ADDRESS_1055317]’s ability to return to the 
site for the visit. In this case, the visit may be performed b y phone.  If subject is still hospi[INVESTIGATOR_473687] -up 
period, they should get Day 15, 22 and 29 assessments along with the daily clinical data collection.  
• If still hospi[INVESTIGATOR_53481] 15 and 29 or returns to the site for an in- person visit: collect clinical data, vital signs, 
safety laboratory tests, and research laboratory samples (OP swab and serum only) as able.  
• If phone call only on Days 15 and 29 and all Day 22 visits: assess adverse events, clinical status (ordinal scale), 
readmission to a hospi[INVESTIGATOR_307], and mortality only.  
10 Oropharyngeal swabs are preferred, but if these are not obtainable, nasopharyngeal or nasal swabs may be substituted.  
  
1.3 Study Sche ma 
 
 
 
2. INTRODUCTION 
2.1 Background  
 ACTT -2 – Baricitinib/Remdesivir vs. Remdesivir Trial  
A preliminary review of data from ACTT -1 occurring after 606 recoveries and 103 deaths 
(approximately 67% of the 1063 subjects enrolled) demonstrated that subjects that received 
remdesivir had a 31% faster time to recovery (11 vs 15 days, recovery rate ratio  1.312 (1.119, 
1.541), p<0.001) , and a decrease in mortality (  8.0% vs 11.6%, p = 0.059). The DSMB asked that 
the sponsor be unblinded early given public health implications and implications for ACTT-2. While an antiviral appears to have some efficacy in the treatment of COVID -19, the mortality 
rate is still high.  Infection by [CONTACT_119909] (e.g. SARS and SARS-CoV–2) often 
results in excessive cytokine and chemokine action with the development of acute respi[INVESTIGATOR_1505] (ARDS) (33 -35). It is postulated that thi s dysregulated inflammatory immune 
response is contributing to the excessive mortality, and targeting this response will further improve outcomes.   Baricitinib, an orally administered, selective inhibitor of JAK1 and JAK2, could be a therapeutic option because of the potential to inhibit signaling from multiple cytokines in COVID-19 

Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 104 of 146 patients  (30). Baricitinib inhibits signaling of cytokines implicated in COVID -19, including IL-2, 
IL-6, IL -10, IFN -γ, and G-CSF, with lower IC50 values translating to a greater overall inhibition 
of STAT signaling during the dosing interval (33). Baricitinib treatment resulted in a reduction 
from baseline in serum IL-6 at Week 12 in patients with active RA in a Phase 2, randomized, placebo -contr olled study of baricitinib ( data on file). The potent anti- inflammatory effects of 
baricitinib have also been demonstrated by [CONTACT_41381]- γ, IP-10, GM-
CSF and MCP- 1 in pediatric patients with steroid -dependent chronic inflammation, resulting in 
control of disease activity and the ability to wean or taper steroids (36).   A recent comment by [CONTACT_769139] . published in the Lance t (32), suggested a potential role 
for baricitinib in the treatment of COVID -19. The authors hypothesize that baricitinib, a JAK1/2 
inhibitor, will directly mitigate the inflammatory response triggered by [CONTACT_7544] -CoV-2 infection. 
In addition, baricitinib has been identified as a numb-associated kinase (NAK) inhibitor with high-affinity for AP2 -associated protein kinase 1 (AAK1 -8.2 nM, BIKE-20 nM and GAK-120 
nM). AAK1 and GAK were previously described as a crucial regu lator of clathrin -mediated 
endocytosis and propagation of coronavirus and other viruses (37). In light of this, baricitinib may have an unappreciated antiviral effect by [CONTACT_769140] -cell propagation of the virus in 
infected COVID -[ADDRESS_1055318] recovered  (personal communications, Vince Marconi). An additional patient received 
only one day of baricitinib but was made DNR/DNI while on supplemental oxygen. T his patient 
died the following day. An additional four patients have received treatment but are pending recovery. Of the eleven with complete data by [CONTACT_769141], six out of  eleven patients met 
criteria for severe disease and required intensive care level management, with two of these 
requiring several days of mechanical ventilation. Initiation of therapy with baricitinib led to resolution of fever within 48 hours in 10/[ADDRESS_1055319] inflammation markers by [CONTACT_57627] , decreased oxygen requirements in 7/8 patients needing 
supplemental oxygen at the time of hospi[INVESTIGATOR_063]. Complete recovery was observed in 10/11 patients. Overall, the 10 patients who made a full recovery tolerated the short course of 
treatment with baricitinib and did not develop any secondary bacterial or viral infections during 
the follow-up period (6 to 15 days). 
 Baricitinib is already approved for treatment of  rheumato id arthritis . It is administered orally 
once a day , with good oral bioavailabi lity. It has a short half-life (approximately 12 hours in RA 
patients), so treatment can be interrupted or stopped if necessary. It has few drug- drug 
interactions (due to low CYP inhibitory activity) so it can be given concomitantly with background therapi [INVESTIGATOR_014]. Baricitinib has a well- established safety profile, based on clinical trial data 
and post-marketing data in patients with RA. This profile, together with the observation that baricitinib is a potent AAK1/BIKE/GAK inhibitor with known anti- cytokine effects, provide the 
rationale to study baricitinib in the context of a randomized, controlled clinical trial in patients with COVID -19. 
2.2 Risk/Benefit Assessment  
 Known Potential Risks  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 105 of 146 Potential risks of participating in this trial are those associated with having blood drawn, the IV 
cathete rization, possible reactions to the study interventions (as noted in Section 2.3.2), and 
breach of confidentiality.  
 
Drawing blood may cause transient discomfort and fainting. Fainting is usually transient and managed by [CONTACT_226295]/her legs. Bruising at the blood collection sites may occur but can be prevented or lessened by [CONTACT_119911] a few minutes after the blood is taken. IV catheterization may cause insertion site pain, phlebitis, 
hematoma formation, and infusate extravasation; less frequent but significant complications include bloodstream and local infections. The use of aseptic (sterile) technique will make infection at the site where blood will be drawn or at catheter site less likely.  
 Risks to Privacy Subjects will be asked to provide personal health information (PHI). All attempts will be made to keep this PHI confidential within the limits of the law. However, there is a chance that 
unauthorized persons will see the subject’s PHI. All study records will be kept in a locked file cabinet or maintained in a locked room at the participating clinical site. Electronic files will be password protected. Only people who are involved in the conduct, oversight, monitoring, or auditing of this trial will be allowed access to the PHI that is collected. Any publication from this trial will not use information that will identify subjects. Organizations that may inspect and/or copy research records maintained at the participating site for quality assurance and data analysis include groups such as the IRB, NIAID and applicable regulatory agencies (e.g., FDA). For more 
informatio n about confidentiality and privacy see Section 10.1.3. 
 For each new therapeutic agent under investigation, findings from the preclinical and clinical studies will be briefly described in this section and a summary of the findings described in the Investigator Brochure (IB) will be in an appendix.  
 
 Remdesivir  
 Potential Risks of Remdesivir  
Remdesivir is an investigational therapeutic agent.  [ADDRESS_1055320] been observed with single doses of remdesivir up to 225 mg and multiple once daily doses of remdesivir 150 mg for up to 14 days. M ild (Grade 1)  reversible PT prolongation 
was also noted in some subjects but without any clinically significant change in INR or other evidence of hepatic effects. The mechanism of these elevations is currently unknown. Based on these clini cal observations, patients with ALT or AST >5 times the upper limit of normal will not 
be eligible for study enrollment. Regular laboratory assessments will be performed in order to 
monitor hepatic function and PT. Any observed liver function- related labor atory abnormalities or 
possibly related A Es will be treated appropriately and followed to resolution.  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 106 of 146 In nonclinical animal studies, toxicity studies found dose-dependent and reversible kidney injury 
and dysfunction. In clinical studies, no evidence of nephrotoxicity has been observed with single doses of remdesivir up to 225 mg or multiple once daily doses of remdesivir 150 mg for up to 14 days. A 150-mg dose of the solution and lyophilized formulations of remdesivir contains 9 g and 
4.5 g, respectively, of sulfobutylether- beta- cyclodextrin  (SBECD ), for which the maximum daily 
recommended daily dose (based on a European Medicines Agency ( EMA ) safety review) is 
approximately 250 mg/kg. Because SBECD is renally cleared, subjects with moderate or severe renal impairment may have SBECD exposures greater than those with less severe renal impairment or normal renal function. Based on this information, patients with  an estimated 
glomerular filtration rate (eGFR) of less than  30 ml/min (including subjects requiring 
hemo dialysis  or hemofiltration ) will not be eligible for study enrollment. 
 Remdesivir is a substrate for CYP2C8, CYP2D6, and CYP3A4. Howev er, coadministration with 
inhibitors of these CYP isoforms is unlikely to markedly increase remdesivir levels, as its metabolism is likely to be predominantly mediated by [CONTACT_435656].  See IB for full 
discussion of clinical experience and risks.   There is the potential of the SARS-CoV-[ADDRESS_1055321] demonstrated that a cl inically relevant interaction with 
contraceptive steroids is considered to be of limited clinical significance.  Therefore,  the use of 
hormonal contraception with remdesivir is not recommended as the sole method for preventing pregnancy.  
 Potential Benefits  of Remdesivir  
A preliminary review of data from ACTT -1 occurring after 606 recoveries and 103 deaths 
(approximately 67% of the 1063 subjects enrolled) demonstrated that subjects that received remdesivir had a 31% faster time to recovery (11 vs 15 days, recovery rate ratio  1.312 (1.119, 
1.541), p<0.001) , and a decrease in mortality (  8.0% vs 11.6%, p = 0.059). The DSMB asked that 
the sponsor be unblinded early given public health implications and implications for ACTT -2. As 
a result, all subjects in ACTT-[ADDRESS_1055322] been self -limited and resolved after cessation of the 
medication. There is the potential for renal toxicities as observed in pre -clinical data. By [CONTACT_769142] 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 107 of 146 those with elevated liver transaminases and decreased kidney function (eGFR  < 30 ml/min or 
requires hemodialysis or hemofiltration), and appropriate monitoring during the study, we can 
minimize the risk to subjects. While remdesivir is currently the only therapeutic agent likely to 
effective for COVID -19, there may not be benefits for an individual subject  depending on timing 
of initial infusion relative to disease onset and presence of viral replication . However , we will try 
to mitigate this risk by  [CONTACT_769143] a 
timely manner. The potential risks therefore are thought to be acceptable given the potential 
benefits.   
 Baricitinib  
 Potential Risks of Baricitinib  
Baricitinib is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapi[INVESTIGATOR_014].   The US product labeling indicates a boxed warning for the risk of serious infections, malignancies and thrombosis, while warnings and precautions include serious infections, thrombosis, gastrointestinal perforations, abnormal laboratory assessments (potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipi[INVESTIGATOR_805]), and avoidance with the use of live vaccines.  
 The Summary of Product Characteristics ( SmPC ) indicates as special warning and precautions 
for infections, including TB, hematological abnormalities, viral reactivation, use of live vaccines, increase in blood lipid parameters, increase in hepatic transaminase, malignancy, venous thromboembolism, hypersensitivity, and use of baricitinib with potent immunosuppressive medications.   Baricitinib has an established safety profile with a positive benefit/risk profile in rheumatoid arthritis. An integrated analysis of patients with active RA exposed to baricitinib with 3770 patients and 10,127 patient years for a maximum exposure of 7 years (as of February 2018) was recently published (38). No significant differences were seen for baricitinib 4-mg vs placebo in 
adverse events leading to permanent drug discontinuation, death, malignancy, serious infection, 
or major adverse cardiovascular events. Incidence rates for deep vein thrombosis/pulmonary 
embolism were numerically higher in baricitinib 4 -mg vs placebo; Incidence rates were similar 
by [CONTACT_769144] 2- mg/4 -mg-extended dataset. Malignancy (excluding non -melanoma skin cancer) 
Incidence rates  were 0.8 (2-mg) and 1.0 (4 -mg; as -randomized analysis). Fewer than 1% of 
patients discontinued due to abnormal laboratory results. The frequency of Herpes zoster was higher for baricitinib 4-mg vs placebo (1.4 vs 0.4) baricitinib 4- mg vs 2 -mg (1.4 vs 1.0).  
 It is difficult to extrapolate the potential risks of baricitinib in rheumatoid arthritis  to a COVID -
19 population. T he duration of baricitinib treatment will be limited to up to 14 days in this study 
and the half-life is approximately 12 hours which will lead to a very short washout period once discontinued. JAK–STAT signal blocking by [CONTACT_769145]. Interferons are important for the innate control of viral replication. Thus baricitinib 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 108 of 146 could potentially increase viral replication (39) though this has not been described in the cases 
series of baricitinib in COVID -19.  
 
Adverse drug reactions of baricitinib include venous thromboembolism (deep vein thrombosis /pulmonary embolism). Mitigating the risk of venous thromboembolism will be managed through adding appropriate exclusion and discontinuation criteria to the protocol to limit participation of patients who are at an increased risk of VTE. There is evidence to suggest that COVID -19 patients are at increased risk of thromboembolic events from infection with SARS-
CoV-2. The etiology this may be tissue injury from the SARS -CoV-2 or may be due to 
inflammation via pro -inflammatory cytokine upregulation of tissue factor. It is unknown if 
baricitinib would increase or decrease this risk. I nvestigators are recommended to add VTE 
prophylaxis in all hospi[INVESTIGATOR_769114] . As thrombocytopenia can be seen 
in COVID -19, the risk/benefit of VTE prophylaxis should be made by [CONTACT_68071].  
 Baricitinib is not recommended in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (probenecid in the main clinically relevant medication). Patients who take probenecid 
and are unable to discontinue it at study entry will not be eligible for the study.   
 While baricitinib does inhibit OAT1, OAT2, OAT3, organic cation transporter (OCT) 1, OCT2, OATP1B3,  BCRP, MATE1 and MATE2 -K in vitro, clinically meaningful changes in the PK of 
drugs that are substrates for these transporters are unlikely. In vitro, baricitinib did not inhibit the transporters Pgp or organic anion transporting polypeptide (OATP) 1B1. Cl inical drug- drug 
interaction studies showed no clinically meaningful effects on the PK of digoxin (Pgp substrate) 
or methotrexate (substrate of several transporters) when co -administered with baricitinib.  
 Drug -drug interactions with concomitantly administered baricitinib and remdesivir are unlikely. 
In vitro, baricitinib is a substrate of cytochrome P450 (CYP) 3A and the following transporters: organic anion transporter (OAT) 3, P- glycoprotein (Pgp), breast cancer resistance protein 
(BCRP), and multidrug and toxic extrusion protein (MATE) 2- K. However, in vivo, baricitinib is 
primarily eliminated by [CONTACT_8212], with minimal hepatic clearance.  The only clinically relevant 
drug-drug interaction observed with baricitinib is with concomitant administration of strong 
inhibitors of OAT3, such as probenecid. Available data for remdesivir does not suggest that remdesivir is an OAT3 inhibitor.  Therefore, the potential for remdesivir to affect the 
pharmacokinetics (PK) of baricitinib is not likely.   
  Baricitinib is also unlikely to affect the PK of other drugs, including remdesivir. Available data for remdesivir suggests that it is a substrate for CYP2C8, CYP2D6, CYP3A4, OATP1B1, and Pgp (EMA 2020). In vitro, baricitinib did not significantly inhibit or induce the activity of CYPs 3A, 1A2, 2B6, 2C9, 2C19, and 2D6. Additionally, no clinically meaningful changes in the PK of several CYP3A substrates were observed when co -administered with baricitinib.  Since 
baricitinib does not inhibit these particular  CYPs, and transporters, a drug -drug interaction 
between baricitinib and remdesivir is unlikely.   
 More detailed information about the known risks and reasonably expected adverse events of baricitinib may be found in the Investigator’s Brochure (IB).  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055323], t here may 
be benefits to society  if another safe, efficacious therapeutic agent can be identified during this 
global COVID-19 pandemic.   
 Assessment of Potential Risks and Benefits  of Baricitinib  
In the context of the cumulative knowledge for baricitinib regarding the safety profile, the potential to mitigate the hyperinflammatory state and cytokine release syndrome (CRS)  associated with 
SARS -CoV- 2 and the lack of an established effective treatment  for the life -threatening 
complications of COVID -19 due to CRS, the benefit/risk balance for this study is assessed to be 
favorable.  
 
3. OBJECTIVES  AND  ENDPOINTS 
The overall objective of the study is to evaluate the clinical efficacy and safety of different 
investigational therapeutics relative to the control arm among  hospi[INVESTIGATOR_769115] -19. 
 
OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
Primary   
To evaluate the clinical efficacy, as assessed 
by [CONTACT_435652], of different investigational therapeutics as compared to the control arm. Day of recovery is defined as the first day on 
which the subject satisfies one of the following three categories from the ordinal scale:  
• Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen – no longer requires ongoing 
medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on activities.  
Recovery is evaluated up until Day 29.  
Key Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics relative to the control arm in adults hospi[INVESTIGATOR_21391] -19 according to clinical status (8 -
point ordinal scale) at Day 15 
 
 
 • Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation 
or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental 
oxygen; 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 110 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen – requiring ongoing medical care 
(COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen – no longer requires ongoing medical care;  
• Not hospi[INVESTIGATOR_057], limitation on activities 
and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on 
activities.  
Additional Secondary   
To evaluate the clinical efficacy of different 
investigational therapeutics as compared to 
the control arm as assessed by:  
• Clinical Severity  
o Ordinal scale:  
 Time to an improvement of one category and two categories from Day 1 (baseline) using an ordinal scale.  
 Subject clinical status using ordinal scale at Days 3, 5, 8, 11, 15, 22, and 29.  
 Mean change in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and 29. 
  
  
• Clinical outcome assessed using ordinal scale daily while hospi[INVESTIGATOR_119818] 15, 22, and 29. 
   
    
o National Early Warning Score 
(NEWS):  
 Time to discharge or to a NEWS of ≤ [ADDRESS_1055324].  
 Change from Day 1 to Days 3, 5, 8, 11, 15, and 29 in NEWS.  
  
 
• NEWS assessed daily while hospi[INVESTIGATOR_435619] 15 and 29. 
o Oxygenation:  
 Oxygenation use up to Day 29. 
 Incidence and duration of new oxygen use during the study. 
  
• Days of supplemental oxygen (if 
applicable) up to Day 29 
 
o Non-invasive ventilation/high flow 
oxygen: 
 Non-invasive ventilation/high flow 
oxygen use up to Day 29.  • Days of non -invasive ventilation/high 
flow oxygen (if applicable) up to Day 29 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 111 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
 Incidence and duration of new non -
invasive ventilation or high flow 
oxygen use during the study. 
 
o Invasive Mechanical Ventilation / 
extracorporeal membrane oxygenation (ECMO):  
 Ventilator / ECMO use up to Day 29. 
 Incidence and duration of new mechanical ventilation or ECMO u se 
during the study.  
  
• Days of invasive mechanical ventilation/ECMO(if applicable) up to Day 29. 
 
• Hospi[INVESTIGATOR_059]  
o Duration of hospi[INVESTIGATOR_059] (days).  
  
• Days of hospi[INVESTIGATOR_119819] 29 
• Mortality  
o 14-day mortality  
o 28-day mortality  
  
• Date and cause of death (if applicable)  
 
2. To evaluate the safety of different 
investigational therapeutics as compared to the control arm as assessed by:  
• Cumulative incidence of SAEs through Day 29. 
• Cumulative incidence of Grade 3 and 4 clinical and/or laborator y AEs through 
Day 29 . 
• Discontinuation or temporary suspension of study product administration s (for any reason)  
• Changes in white blood cell (WBC) 
count with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), prothrombin time (PT reported 
as INR ), d-dimer, and C- reactive protein 
(CRP)  over time (analysis of lab values 
in addition to A Es noted above).   
  
• SAEs  
• Grade 3 and 4 AE s  
• WBC  with differential, hemoglobin, 
platelets, creatinine, glucose, total bilirubin, ALT, AST, INR, d-dimer, CRP 
on Day 1; Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and Days 15 and 29 (if attends in -person visit or still 
hospi[INVESTIGATOR_057]). 
 
Exploratory   
To evaluate the virologic efficacy of different 
investigational therapeutics as compared to 
the control arm as assessed by:   
 
 
[CONTACT_1738] 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 112 of 146 OBJECTIVES  ENDPOINTS  
(OUTCOME MEASURES)  
• Percent of subjects with SARS -CoV -2 
detectable in OP sample at Days 3, 5, 
8, 11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in OP 
sample at Days 3, 5, 8, 11, 15, and 29. 
• Development of resistance of SARS-
CoV-2 in OP sample at Days 3, 5, 8, 
11, 15, and 29.  
• Quantitative SARS -CoV-2 virus in 
blood at Days 3, 5, 8, and 11. 
 • Qualitative and quantitative polymerase 
chain reaction (PCR) for SARS -CoV-2 in 
OP swab on Day 1; Days 3, 5, 8, and 11 
(while hospi[INVESTIGATOR_057]); and Days 15 and 29 
(if attends in -person visit or still 
hospi[INVESTIGATOR_057]). 
• Qualitative and quantitative PCR for 
SARS -CoV-2 in blood on Day 1; Days 3, 
5, 8, and 11 (while hospi[INVESTIGATOR_057]). 
  
4. STUDY  DESIGN 
4.[ADDRESS_1055325] a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and OP swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic.  In this case, these visits may be conducted by [CONTACT_648], and only clinical data will be 
obtained. The Day [ADDRESS_1055326] laboratory tests or collection of samples and is  
conducted by [CONTACT_648].   The primary outcome is time to recovery by [CONTACT_2006] 29 (see table below for definition based on the ordinal scale). A key secondary outcome evaluates treatment -related improvements in the [ADDRESS_1055327], collecting clinical and virologic data on enrolled 
subjects using a standardized timeline and collection instruments should provide valuable information about the clinical course of and morbidities associated with COVID -19 in a diverse 
group of hospi[INVESTIGATOR_119800]. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 113 of 146  
The ACTT-2 design will specifically evaluate the contributions of blocking inflammatory pathways (with the JAK inhibitor) while all subjects receive the antiviral remdesivir.   
 
4.3 Justification for Dose  
 Justification for Dose of Remdesivir 
The dose of remdesivir  used in this study will be the same dose that was used in the Ebola 
clinical trials  and the same dose that was used in the initial stage of this trial (ACTT -1).  
 
 Justification for Dose of Baricitinib 
The [ADDRESS_1055328] of baricitinib on inhibition of cytokine signaling. In patients with rheumatoid arthritis,  the 4 -mg dose of baricitinib (but not lower doses) was shown 
to significantly reduce IL -6 levels, assessed after 12 weeks of treatment. In a compassionate use 
program in pediatric patients with chronic atypi[INVESTIGATOR_769116] (CANDLE) syndrome, patients on a mean dose of baricitinib 6- mg QD 
showed a striking reduction in cytokine signaling. In healthy volunteers, exposures observed at the baricitinib 4 mg (or higher) doses are associated with reduction of IL -6 induced ex vivo 
pSTAT3 activation (40).   In a vaccine response study, individuals treated with 4 mg baricitinib can mount an appropriate immune r esponse to a pneumococcal vaccine, suggesting that transient exposure to baricitinib 
will not result in clinically meaningful changes to adaptive immunity  (41) . In addition, the choice 
of the 4-mg dose is supported by [CONTACT_31577], safety, and efficacy data for baricitinib in Phase 2 and Phase 3 RA studies. The 4-mg dose of baricitinib is approved in multiple regions globally for the treatment of RA. In summary, the potential benefit of the 4-mg dose in reducing the 
hyperinflammatory state caused by [CONTACT_4113] -19, and the short duration of treatment with this dose 
with a well-established safety profile, provides the rationale for the assessment of the benefit/risk profile of the 4-m g dose of baricitinib in the setting of a randomized, controlled clinical trial in a 
hospi[INVESTIGATOR_6885].  
5. STUDY  POPULATION  
Male and non-pregnant female adults ≥[ADDRESS_1055329] the community at large. The estimated time from screening (Day -1 or Day 1) to end of study for an individual subject is approximately [ADDRESS_1055330] is eligible for study enrollment. There is no exclusion for receipt of SARS-CoV-2 
vaccine (experimental or licensed).  
 
5.1 Inclusion Criteria  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055331] (or legally authorized representati ve) provides informed consent prior to 
initiation of any study procedures. 
3. Subject (or legally authorized representative) understands and agrees to comply with 
planned study procedures. 
4. Male or non-pregnant female adults ≥ 18 years of age at time of enroll ment.  
5. Has laboratory -confirmed SARS -CoV-2 infection as determined by [CONTACT_435653], as documented by [CONTACT_147664]:  
• PCR positive in sample collected < 72 hours prior to randomization; OR 
• PCR posit ive in sample collected ≥ 72 hours prior to randomization, documented 
inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking > 24 hours, etc.) AND progressive disease suggestive of ongoing SARS -CoV-[ADDRESS_1055332] one of the following: 
• Radiographic infiltrates by [CONTACT_9661] (chest x -ray, CT scan, etc.), OR  
• SpO2 ≤ 94% on room air, OR 
• Requiring supplemental oxygen, OR  
• Requiring mechanical ventilation or ECMO.  
7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.  
8. Agrees to not participate in another clinical trial for  the treatment of COVID -[ADDRESS_1055333] > 5 times the upper limit of normal.  
2. Estimated glomerular filtration rate (eGFR) < 30 ml/min or patient is receiving 
hemodialysis or hemofiltration  at time of screening . 
3. Neutropenia (absolute neutrophil count <1000 cells/μL) (<1.0 x 103/μL or <1.0 GI/L). 
4. Lymphopenia (absolute lymphocyte count <200 cells/μL) (<0.20 x 103/μL or <0.20 GI/L)  
5. Pregnancy or breast feeding.  
6. Anticipated discharge from the hospi[INVESTIGATOR_119804] a study site within 72 hours. 
7. Allergy to any study medication.  
8. Received three or more doses of remdesivir, including the loading dose, outside of the 
study under the EUA (or similar mechanism) for COVID -19.  
9. Received convalescent plasma or intravenous immunoglobulin [IVIg]) for COVID-19, 
the current illness for which they are being enrolled . 
10. Received small molecule tyrosine kinase inhibitors (e.g. baricitinib, imatibib, genfinitib), in the 1 week prior to screening  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 115 of 146 11. Received monoclonal antibodies targeting cytokines (e.g., TNF inhibitors, anti -
interleukin -1 [IL -1], anti- IL-6 [tocilizumab or sarilumab] ), or T-cells (e.g., abatacept) in 
the 4 weeks prior to screening. 
12. Received monoclonal antibodies targeting B-cell (e.g., rituxi mab, and including any 
targeting multiple cell lines including B -cells)  in the 3 months prior to screening. 
13. Received other immunosuppressants in the 4 weeks prior to screening and in the 
judgement of the investigator, the risk of immunosuppression with baricitinib is larger than the risk of COVID-19.  
14. Received ≥20 mg/day of prednisone or equivalent for ≥[ADDRESS_1055334] diagnosis of current active tuberculosis (TB) or, if known, latent TB treated for less than 4 weeks with appropriate anti-tuberculosis therapy per local guidelines (by [CONTACT_119907], no screening required). 
17. Suspected serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opi[INVESTIGATOR_119835] a risk when taking investigational product.  
18. Have received any live vaccine (that is, live attenuated) within 4 weeks before screening, or intend to receive a live vaccine (or live attenuated) during the study. Note: Use of non-live (inactivated) vaccinations is allowed for all subjects.  
19. Have a history of VTE (deep vein thrombosis [DVT] or pulmonary embolism [PE]) within [ADDRESS_1055335] a history of recurrent (>1) VTE (DVT/PE). 
20. Immunocompromised patients, patients with a chronic medical condition, or those taking a medication  that cannot be discontinued at enrollment, who, in the judgment of PI , are at 
increased  risk for serious infections or other safety concern s given the study products. 
  
 Exclusion of Spec ific Populations  
Children and adolescents will not be included in this trial. Remdesivir has only been used in a small number of pediatric patients. Baricitinib has been used extensively in pediatric patients.  
Initial information about the epi[INVESTIGATOR_40270] -19 indicates that the overwhelming burden 
of severe disease occurs  among older adults, especially those with comorbidities.  Given 
significant gaps in knowledge in this population, and a low incidence of severe morbidity/ 
mortality in children, and that neither drug has demonstrated efficacy in COVID -19, this 
research is not known to have the prospect of direct benefit to individual child participants, and the risk/benefits do not warrant inclusion of this population into this trial at this time.   
 In nonclinical reproductive toxicity studies, remdesivir demonstrated no adverse effect on embryo -fetal development when administered to pregnant animals. Embryonic toxicity was seen 
when remdesivir was initiated in female animals prior to mating and co nception, but only at a 
system ically toxic dose. Remdesivir has not been studied in pregnant women. While baricitinib 
is a licensed drug with a known safety profile, the limited human data on use of baricitinib in 
pregnant women are not sufficient to infor m a drug -associated risk for major birth defects or 
miscarriage. Because the effects on the fetus and the pregnant woman are not fully known, 
pregnant women will not be eligible for the trial.  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055336] is cognitively impaired, federal and institutional 
regulations permit researchers to obtain consent from a legally authorized  representative (LAR) . 
The study team will obtain con sent from these vulnerable subjects using an IRB-approved 
protocol- specific process for consent using a LAR.  For subjects for whom a LAR gave consent, during the course of the study, if the subject regains the capacity to consent, informed consent must be obtained from the subject and the subject offered the ability to leave the study if desired.  
 
5.4 Lifestyle Considerations  
During this study, subjects are asked to: 
• Refrain from drinking alcohol through Day 15.  
• Avoid getting pregnant during the study from Day 1 through Day 29. 
• Agreed not to participate in another clinical trial for the treatment of COVID -19 or 
SARS -CoV-2. This includes interventional trials that evaluate treatment of SARS -CoV-2 
infection as well as the disease pathogenesis (e.g., exper imental treatment trials for the 
COVID -19-related thrombo- occlusive disease respi[INVESTIGATOR_769117]). Co -enrollment for natural history studies of COVID-19, 
studies of SARS -CoV-2 diagnostics, or strategy trials comparing different standards of 
care for non- COVID treatment (i.e. comparing two VTE prophylaxis regimens) is 
permitted ; however, participation in both ACTT and these studies can only occur if the 
recommended blood collection volumes ar e not exceeded .  
5.[ADDRESS_1055337] been completed, the investigator or designee is to review the inclusion/exclusion criteria and determine the subject’s eligibility for the study. If there is any uncer tainty, the PI [INVESTIGATOR_119820] a potential 
subject is eligible for study enrollment.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 117 of 146  
Only basic demographic information and the reason (s) for ineligibility will be collected on 
screen failures . Subjects who are found to be ineligible will be told the reason (s) for ineligibility.  
 Individuals who do not meet the criteria for participation in this study (screen failure) because of an abnormal laboratory finding may be rescreened once. 
5.6 Strategies for Recruitment and Retention  
 Recruitment  
It is anticipated that patients with COVID -19 will present to participating hospi[INVESTIGATOR_600], and that no 
external recruitment efforts towards potential subjects are needed.  Recruitment efforts may also 
include dissemination of information about this trial to other medical professionals / hospi[INVESTIGATOR_600].   
 The IRB will approve the recruitment process and all materials provided prior to any recruitment 
to prospective subjects direct ly. 
 Screening will begin with a brief discussion with study staff. Some will be excluded based on 
demographic data and medical history ( i.e., pregnant, < 18 years of age, renal failure, etc.). 
Information about the study will be presented to potential subjects  (or legally authorized 
representative)  and questions will be asked to determine potential eligibility. Screening 
procedures can begin only after informed consent is obtained.  
 Retention  
Retention of subjects in this trial is very important for determining the primary endpoint. As 
such, after hospi[INVESTIGATOR_2345], participating subjects will be reminded of subsequent study visits  
and every effort will be made to accommodate the subject’s schedule to facilitate follow -up 
within the spe cified visit window . Additionally, there are many circumstances that influence the 
ability to obtain outcome information after discharge . Follow-up visits may be conducted by 
[CONTACT_119916]-person visits are not feasible.   
 Compensation Plan for Subjects  
Compensation, if any,  will be determined locally and i n accordance with local IRB requirements, 
and subject to local IRB approval.   
 Costs  
There is no cost to subjects for the research tests, procedures/evaluations and study product while taking part in this trial. Procedures and treatment for clinical care including costs associated with 
hospi[INVESTIGATOR_435630], subject’s insurance or third party.  
6. STUDY  PRODUCT 
6.[ADDRESS_1055338](s) and Administration  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 118 of 146 Subjects will be randomized into  one of two  arms (1:1).  
 Baricitinib  Placebo  
Remdesivir  Arm 1  
Baricitinib tablets + 
remdesivir IV  Arm 2  
Placebo tablets + 
remdesivir IV  
 
 
 Study Product Description  
Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, SBECD, and hydrochloric acid and/or sodium hydroxide.  Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name [1-(ethylsulfonyl) -3-(4-
(7Hpyrrolo (2,3- d)pyrimidin -4-yl)-1H-pyrazol -1-yl)azetidin -3-yl]acetonitrile and will be supplied 
in [ADDRESS_1055339], with some overage 
per bottle. Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide. 
 Placebo tablets also manufactured by [CONTACT_769146], and they contain lactose 
monohydrate, microcrystalline  cellulose, croscarmellose sodium, and magnesium stearate. The 
coating for the placebo tablet is identical to that of the corresponding active tablet listed above. However, there is no lactose monohydrate in baricitinib, the active oral product. 
 
Baricitinib and placebo tablets will be supplied in [ADDRESS_1055340], with some overage per bottle.   
 Dosing and Administration 
All subjects will receive remdesivir as a 200 mg intravenous (IV) loading dose on Day 1, 
followed by a 100 mg once-daily IV maintenance dose for the duration of the hospi[INVESTIGATOR_83263] a 10-day total course.   If subjects already received the loading dose as under the EUA or similar mechanism, then start at 100 mg/day.  Any doses of remdesivir under an EUA (or similar mechanism) prior to 
enrollment will be counted, so the total duration of remdesivir (i.e. EUA + on this trial) is 10 
days (i.e., a maximum of 10 total infusions). If one or two doses of remdesivir were administered 
(under EUA or similar mechanism)  prior to study enrollment, this should be documented in 
eClinical as a concomitant medication given prior to Day 1.  
 
For the baricitinib component, subjects will receive either active product or placebo as follows: 
• Baricitinib will be administered as a 4 mg  orally ( po) (two 2mg tablets) or crushed for 
NG tube, daily for the duration of the hospi[INVESTIGATOR_83263] a 14- day total course.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 119 of 146 • A placebo will be given as two tablets po or crushed for NG tube, daily for the duration 
of the hospi[INVESTIGATOR_83263] a 14-day total course.  
 See Section 6.1.4 for dosing modifications for renal failure. 
 Dosing of the two medications does not need to occur at the same.  Any dose that is delayed may be given later that calendar day. Any dose that is missed  during the 
study due to any reason (not given that calendar day) is not made up. The treatment course continues as described above even if the subject becomes PCR negative.   Duration of therapy: 
• IV remdesivir  – 10 day s while hospi[INVESTIGATOR_057]  (i.e., maximum of 10 total infusions pre-
enrollment and during study). 
• Oral (baricitinib or placebo) component – 14 days while hospi[INVESTIGATOR_057] (i.e., maximum of 
14 total doses). 
• Both stop on discharge from hospi[INVESTIGATOR_307]. If readmitted after discharge, see Section 7.4. 
 
 Dose Escalation 
Not Applicable  
 Dose Modifications 
The site should use all available laboratory values to evaluate for potential dose modifications.  
These laboratory values may be drawn as part of standard of care or protocol- required  safety 
laboratories done as per the SOA.  The protocol- required safety laboratories (per the SOA) are 
anticipated to be sufficient for evaluating for most dose modifications, but if other laboratory 
data obtained as part of standard care are available, these should be also be used  in the 
evaluation .  
  
Remdesivir component: 
If the eGFR decreases to an eGFR < 25 ml/min, the remdesivir infusion should not be given on 
that day. The infusion may be resumed on the next day if the eGFR returns to ≥ 30 ml/min. If the subject’s renal function worsens to the point that they require hemodialysis or hemofiltration, remdesivir  will be discontinued. 
 If the ALT and/or AST increases to > [ADDRESS_1055341] ≤ 5 times upper limits of normal.  
Baricitinib /Oral Placebo  component: 
Dose of oral study product will be decreased based on eGFR. Specifically, subjects with eGFR 
<60 mL/min will receive a dose of one tablet (2- mg or placebo) once daily.  
 Oral s tudy product should be temporarily interrupted if the subject  develops any of the following 
during the study but may resume when that criteria is no longer fulfilled: 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 120 of 146  
• Total white blood cells (WBC) <1000 cells/μL  
• Absolute neutrophil count (ANC) <500 cells/μL  
• Absolute lymphocyte count (ALC) <200 cells/μL  
• ALT or AS T >[ADDRESS_1055342]  
• Infection that, in the opi[INVESTIGATOR_871], merits study drug being withheld 
• eGFR < 30 mL/min, resume when eGFR returns to ≥ 30 mL/min.  
o If subject’s renal function worsens to the point that they require hemodialysis or 
hemofiltration, oral study product and remdesivir as discussed above will be 
discontinued . 
 
For laboratory values that meet permanent discontinuation thresholds, study product should be 
discontinued. However, if in the opi[INVESTIGATOR_871], the laboratory abnormality is due to intercurrent illness or another identified factor, laboratory tests may be repeated.  
 
 Overdosage 
There is no known antidote for baricitinib . Overdose is not anticipated in the context of a clinical 
trial.  However, if a site inadvertently gives a subject [ADDRESS_1055343] when they 
should be receiving 2 mg because of a eGFR <60 mg/mL, the site should contact [CONTACT_1034]. 
The subject should receive supportive therapy based on the subject´s signs and symptoms. 
 
6.2 Preparation/Handling/Storage/Accountability  
 Acquisition and Accountability  
Investigational products (IP) will be shipped to the site either directly from participating companies, from the Sponsor, or from other regional or local drug repositories. All other supplies 
should be provided by [CONTACT_779]. Multiple lots of each IP may be supplied.  Study products received at the sites will be open label and not kit specific , unless specified in the 
protocol- specific Manual of Procedures (MOP)  or pharmacy manual . Drug preparation will be 
performed by [CONTACT_16529]’s unblinded research pharmacist on the same day of 
administration to the subject. See the MOP  Appendices for detailed information on the 
preparation, labeling, storage, and administration of investigational products.   
Accountability: 
The site PI [INVESTIGATOR_119828]. The site PI [INVESTIGATOR_119829]’s research pharmacist responsibility for study product accountability. The participating site’s research pharmacist will be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, storage conditions, and final disposition of the study product(s). Time of study drug administration  to the subject will be recorded on the 
appropriate data collection form ( CRF ). All study product(s), whether administered or not, must 
be documented on the appropriate study product accountability record or dispensing log. The Sponsor ’s monitoring staff will verify the participating site’s study product accountability 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 121 of 146 records and dispensing logs per the site monitoring plan. Refer to the protocol- specific MOP for 
details on storing study medications.  
Destruction:  
After the study treatment period has ended or as appropriate over the course of the study after 
study product accountability has been p erformed, used active and placebo product can be 
destroyed on- site following applicable site procedures  with a second staff member  observing and 
verifying  the destruction .  
Unused product at the end of the study should be saved until instructed by [CONTACT_1034]. 
 
 Formulation, Appearance, Packaging, and Labeling 
Remdesivir component  
The lyophilized formulation of remdesivir  is a preservative- free, white to off-white or yellow, 
lyophilized solid containing 150 mg or 100 mg of remdesivir to be reconstituted with 29 mL or 19 mL (respectively) of sterile water for injection respectively and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL remdesivir 
concentrated solution with sufficient volume to allow withdrawal of 30 mL (150 mg of remdesivir) or 20 mL (100 mg of remdesivir).   It is supplied as a sterile product in a s ingle -use, Type 1 clear glass vial. In addition to the active 
ingredient, the lyophilized formulation of remdesivir contains the following inactive ingredients: water for injection, SBECD, hydrochloric acid, and/or sodium hydroxide. For more information, refer to the MOP.  
 Remdesivir will be labeled according to manufacturer specifications and include the statement 
“Caution: New Drug Limited by [CONTACT_4496]  ([LOCATION_003])  Law to Investigational Use.” 
 
Baricitinib component  
According to the package insert, baricitinib tablets are available for oral administration as film-coated, immediate -release tablets. The 2 mg tablet is light pi[INVESTIGATOR_769118]. Each tablet contains 
2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, 
polyvinyl alcohol, talc and titanium dioxide.  
 
Oral placebo component  
Placebo tablets match the active product in appearance. The placebo tablets contain lactose 
monohydrate, microcrystalline  cellulose, croscarmellose sodium, and magnesium stearate. The 
coating for the placebo tablet is identical to that of the corresponding active tablet listed above. Placebo is supplied as 2 mg film-coated, in 36 count bottles, open label.  
 
Study interventions (baricitinib and placebo) will be supplied by [CONTACT_769147] (cGMP).  
 
 Product Storage and Stability  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055344] 
classification systems.  The study products may be prepared in a clean room but do not need to be 
prepared or handled in a fume hood. Baricitinib is a “Hazardous Chemical" as defined by [CONTACT_769148], [ADDRESS_1055345] with the body should always be considered during handling, preparation, and disposal procedures as indicated in the IB . 
6.3 Measures to Minimize Bias: Randomization and Blinding  
 Randomization  
Randomization will be stratified  by: 
• Site 
• Severity of illness at enrollment (by [CONTACT_119920])  
o Severe disease:  
 Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO, or 
 Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices. 
o Moderate disease:  
 Hospi[INVESTIGATOR_057], requiring supplemental oxygen, or 
 Hospi[INVESTIGATOR_057], not requiring supplemental oxygen. 
 The randomization procedure will be described in the MOP.   
 
 Blinding and Masking Procedures  
As both arms are receiving remdesivir, the remdesivir product is not blinded and study infusions can be labeled accordingly.  
 The baricitinib/placebo component is blinded. Baricitinib and p lacebo tablets are identical in 
appearance.  
 Unblinding of the study will occur after all subjects enrolled have reached the end of study, and these visits are monitored and data is cleaned , or if the DSMB recommends unblinding.  
 If AEs occur and investigators are concerned about the treatment allocation, the treatment can be discontinued. If a Serious Adverse Event occurs, that is thought to be related to the study drug, and the treating clinician believes  that knowledge of the treatment arm may change the therapy 
provided to the patient, the individual subject can be unblinded. The procedure for unblinding will be further detailed in the Manual of Operations.  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055346]. Administration and date, and  time, will 
be entered into the case report form (CRF).  
 
6.5 Concomitant Therapy  
 Permitted Concomitant Therapy and Procedures  
Receipt of any exclusionary treatment s or medication s prior to screening will be assessed to 
determine eligibility  as described in the exclusion criteria. This includes use of strong inhibitors 
of organic anion transporter 3 (OAT3) such as probenecid which are prohibited during the study. 
 
For patients that are eligible for the study, other t herapy received prior to enrollment with any 
other experimental treatment or off -label use of marketed medications that are intended as 
specific treatment for COVID -19 or the SARS-CoV-2 infection (i.e., post-exposure prophylaxis 
[PEP]) are permitted  but must be discontinued on enrollment. The re is no waiting period 
between discontinuation of these treatments and administration  of study products. However, 
these prior treatments and their end date should be documented on the Concomitant Medication 
(CCM) form  in the Advantage eClinical system .  
 
There are two scenarios in which outpatient experimental treatment or off -label use of marketed 
medications that are intended as specific treatment for COVID -[ADDRESS_1055347], subjects who are taking another antiviral for a concurrent infection (e.g. 
oseltamivir for an influe nza virus, lopi[INVESTIGATOR_054]/ritonavir for HIV, etc.) or another existing medical 
condition (e.g. hydroxychloroquine for lupus, etc.) may  continue with the treatment.  Note that 
these treatments may be thought of as an off- label medication for COVID -19, however, because 
they were being used prior to study enrollment for another indication, they are allowable.  Second, if there is a written polic y or guideline for the lo cal standard of care and treatment of 
COVID -19 patients or SARS -CoV-2 infection (i.e., not just an individual clinician decision), 
continuation of these outpatient medications are permitted.  This could include lopi[INVESTIGATOR_054]/ritonavir 
(Kaletra) , hydroxychloroquine or other agents. There should be plans on how the concomitant 
drugs are stopped in case of  additive toxicities.  
 
VTE prophylaxis is recommended for all patients unless there is a major contraindication such as 
active bleeding events or history of hepar in-induced thrombosis. 
 
 Prohibited Concomitant Therapy  
A subject cannot participate in another clinical trial for the treatment of COVID -19 until after  Day 
29 (s ee exclusion criteria) .  
 
If the re are NO written policies or guidelines for  local standard of care and treatment of COVID -
19 patients or SARS -CoV-2 infection, concomitant use of any other experimental treatment or 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055348] immune response.  
 
Once enrolled , use of a ny biologic therapy outside of local written standards of care are 
prohibited. This includes monoclonal antibodies targeting cytokines (e.g., TNF inhibitor s; 
interleukin -1[IL-1], IL -6 [tocilizumab or sarilumab]), or T- cells (e.g., abatacept) ; monoclonal 
antibodies targeting  B-cells (e.g., rituximab, and including any targeting multiple cell lines 
including B- cells); JAK inhibitor(s) other than baric itinib  (e.g., imatibib, genfinitib ); and 
interferon , plasma, or immunoglobulin (IgG) therapi[INVESTIGATOR_769119] -19.  
 
Strong inhibitors of organic anion transporter 3 (OAT3) such as probenecid are prohibited during the study.  Corticosteroids for the treatment of COVID -[ADDRESS_1055349] started (the start date) and end date if ended before Day [ADDRESS_1055350] did not actually receive during study (e.g., prn medications that were never given).   Do not report vitamins, herbal supplements, or topi[INVESTIGATOR_5910]. Do not report over-the-counter cold medicines and antipyretics that the subject reportedly took at home prior to hospi[INVESTIGATOR_059]. See the MOP for more information about recording concomitant medications.  
 
 Rescue Medicine 
Not Applicable  
 Non-Research Standard of Care 
Not Applicable  
7. STUDY  INTERVENTION  DISCONTINUATION  AND  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055351]  DISCONTINUATION/WITHDRAWAL 
7.[ADDRESS_1055352] a suspected drug -related 
event of hypersensitivity (Grade 2 or higher) during or shortly after receiving the IP.  While there 
are no criteria for grading “hypersensitivity” in the Division of AIDS (DAIDS) Table for Grading the Severity of Adverse Events, sites should use acute allergic reaction from that toxicity table. Subjects who have the study product stopped for a safety related issues will not continue with dosing. In addition, subjects who have an allergic reaction that is  temporally associated with study 
product administration and the PI [INVESTIGATOR_769120]. 
In addition, a subject in this clinical study may discontinue study drug at their request for any 
reason . Every effort should be made to encourage subjects to remain in the study for the duration 
of their planned outcome assessments. Subjects should be educated on the continued scientific importance of their data, even if they discontinue study drug.  
Unless  the subject withdraws consent, those who discontinue study drug early will remain in the 
study. The reason for subject discontinuation of study drug should be documented in the case 
report form.  
 
 Remdesivir Halting  
See Section 6.1.4. for information about dosing modifications due to laboratory abnormalities. 
 
 Oral Study Product  Halting  
See Section 6.1.4. for information about dosing modifications due to laboratory abnormalities. 
 The subject  should not receive any additional oral study product if the y develop any of the 
following conditions during the study:  
• Active TB infection or evidence of latent TB (though testing is not required per 
protocol). 
• VTE (DVT/PE) . 
• Suspected drug-induced liver injury with the appearance of fatigue, nausea, vomiting, 
right upper- quadrant pain or tenderness, fever , rash, and/or eosinophilia (>5%). 
• New malignancy  (except for successfully treated basal or squamous cell skin carcinoma)  
• ALT or AST >[ADDRESS_1055353]   
 
 Study Halting  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055354] to follow-up after signing the informed consent form (ICF) and administration of the study product, will not be replaced.  The reason for 
subject withdrawal from the study will be recorded on the appropriate CRF . 
7.[ADDRESS_1055355]’s records.   
7.[ADDRESS_1055356] (i.e., infusion until Day [ADDRESS_1055357] until Day 14). If the subject did not withdrawal his/her consent to participate in the study, there is no need 
to reconsent upon readmission to the study hospi[INVESTIGATOR_307]. However, the site will need to inform them that since  he/she was readmitted, study product administration will resume and confirm that they 
still agree to receive study product.  If the subject is re -admitted with diminished mental capacity, 
the site should discuss continued study participation with a LAR.   The study team  will need to notify the study pharmac ist of the readmission. The subject will not 
get the doses that they missed after being  discharged. Upon readmission, t he subject will get 
maintenance doses of infusion only since they already received the loading dose of the study product infusion on Day 1. No study product infusions should be given past Day [ADDRESS_1055358] came back to the s tudy hospi[INVESTIGATOR_769121]. For all data collection 
procedures required for those readmitted, please see the MOP.   
8. STUDY  ASSESSMENTS  AND  PROCEDURES 
8.1 Screening and Efficacy Assessments  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 127 of 146 
 Screening Procedures  
Screening procedures may be done over one to two calendar days (from Day -1 to Day 1). 
However, in many cases all the screening assessments can be done in less than [ADDRESS_1055359] administration  can occur on the same calendar day as the screening 
procedures.   After the informed consent, the following ass essments are performed to determine eligibility : 
• Confirm the positive SARS-CoV- [ADDRESS_1055360] result (per inclusion criteria) .  
• Take a f ocused medical  history, including the following information:  
• Day of onset of COVID-19 signs and symptoms . 
 
• History of v accin ations within 4 weeks before screening and planned vaccinations.  
• Exclusionary vaccine history includes: 
o Has received any live vaccine (that is, live attenuated) within 4 weeks 
before screening, or intend to receive a live vaccine (or live attenuated)  
during the study. Note: Use of non- live (inactivated) vaccinations is 
allowed for all subjects.  
 
• History of chronic medical conditions, including chronic oxygen requirement, prior to onset of COVID-19. See conditions included in exclusion criteria (Section 5.2) and on the Medical History (CMX) data collection form.  
 
• History of m edication allergies . 
 
• Medications and  therapi[INVESTIGATOR_435631] s taken in the 7 days prior to Day 1, 
and history of any medication listed in the exclusion criteria.  
 
• Ask if they are participating in another clinical trial or plan to enroll in another clinical  trial in the next 28 days . 
 
• Women of childbearing potential should be counseled to either practice abstinence or use at 
least one primary form of contraception not including hormonal contraception from the time 
of screening through Day 29. Women should be confirmed to not be breastfeeding. 
• Note: If a wom an is either postmenopausal (i.e., has had ≥12 months of spontaneous 
amenorrhea) or s urgically sterile (i.e., has had a hysterectomy, bilateral ovariectomy 
(oophorectomy), or bilateral tubal ligation), she is not considered to be of 
childbearing potential.  
• Height and weight  (height can be self -reported) . 
• Results of recent radiographic imaging (x -ray or CT scan) . 
• SpO2 . 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 128 of 146 • Blood for screening laboratory evaluations if not done as part of routine clinical care in the 
preceding 48 hours: 
 CBC with differential  
• Evaluate if subject is neutropenic (absolute neutrophil count <1000 cells/μL) 
(<1.0 x 103/μL or <1.0 GI/L) and/or lymphopenic (absolute lymphocyte count 
<200 cells/μL) (<0.20 x 103/μL or <0.20 GI/L) 
 ALT and A ST 
• Assess if ALT or AST > 5 times the upper limit of normal. 
 Creatinine  (and calculate eGFR ).  
• Determine if eGFR < 30 ml/min  as these subjects are not eligible. Also,  subject 
receiving hemodialysis or hemofiltration  are not eligible . 
• Any automated calculation by [CONTACT_226300].  The site should select a formula to be used for all 
subjects enrolled at the site for the duration of the study. 
• Urine or s erum pregnancy test (in women of childbearing potential) . 
 
Clinical screening laboratory evaluations will be performed locally by [CONTACT_50821].  The 
volume of venous blood to be collected is presented in Table 3. 
 
The overall eligibility of the subject to participate in the study will be assessed once all screening values are available.  The screening process can be suspended prior to complete assessment at 
any time if exclusions are identified by [CONTACT_3476].  
 Study subjects who qualify will be randomized in the Advantage eClinical system, and all others will be registered as screen failures . The ordinal scale and the NEWS should be done at the time 
of randomization; the site will need this data to randomize the subject in eClinical . The study 
team has [ADDRESS_1055361] 
administration  including the collection of OP swab and blood and  completing or recording a 
baseline physical examination that was done. 
 Efficacy Assessments  
For all baseline assessments and follow-up visits, refer to the Schedule of Assessments (SOA) 
for procedure to be done, and details below for each assessm ent. 
 
 Measures of clinical support , limitations and infection control 
The subject’s clinical status will be captured on each study day while hospi[INVESTIGATOR_769122] [ADDRESS_1055362] 
returns for an in -person clinic visit  or by [CONTACT_119926]- person visit is not possible . Clinical status  
will also be captured on Day 22 during a phone visit. Clinical status is largely measured by [CONTACT_769149]. Unlike the NEWS, the ordinal scale can also be evaluated over the 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055363] administration, as time permits.  The following measures are recorded  for the ordinal 
scale: 
• Hospi[INVESTIGATOR_059] . 
• Oxygen requirement. 
• Non-invasive mechanical ventilation (via mask)  requirement. 
• High flow oxygen requirement . 
• Invasive mechanical ventilation  (via endotracheal tube or tracheostomy tube)  
requirement . 
• ECMO requirement . 
• Ongoing medical care preventing hospi[INVESTIGATOR_2345] (COVID -19 related or other medical 
conditions). 
• Limitations of physical activity (self -assessed).  
• Isolated for infection control purposes.  
 Ordinal Scale  
The ordinal scale is the primary measure of clinical outcome.  
 The scale used in this study is as follows  (from worst to best): 
• Death;  
• Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen – requiring ongoing medical care (COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen – no longer requires ongoing medical care;  
o This would include those kept in hospi[INVESTIGATOR_769123]/infection control, awaiting 
bed in rehabilitation facility or homecare, etc.  
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on activities  
 To determine a subject’s clinical status using the ordinal scale: On Day 1, report the ir clinical 
status at randomization.  As there should be <[ADDRESS_1055364] 
clinical assessment for the previous day (i.e., midnight to midnight; 00:00 – 23:59 (24- hr clock)).  
For those who are discharged prior to Day 15, collect ordinal scale on follow -up Days 15, [ADDRESS_1055365] clinical assessment for the previous day (i.e., midnight to midnight; 
00:00 – 23:59 (24-hr clock)). For example, on study Day 3  when completing the form,  the worse 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055366] being death followed by [CONTACT_119927], 
mechanical ventilation, etc. The Day 2 measurement is assessed as occurring anytime in that 24 -
hour period (00:00 to 23:59).   It is important to capture all deaths that occur during the study as this is one of the outcomes of 
the study. D eath is a category on the ordinal scale.  If a subject dies  during the study, the site will 
need to complete an ordinal scale assessment for the day after death. If a subject dies within the 
window of the final study visit (i.e., Day 29 ± 3 days), complete an ordinal scale assessment on 
the day after death .  
 For more information about the data collected for the  ordinal scale, see the MOP.  
 National Early Warning Score (NEWS) 
Vital signs  and other clinical assessments  are collected for the calculation of the NEWS, and 
include temperature, systolic blood pressure, heart rate, respi[INVESTIGATOR_697], O2 saturation and level of consciousness. Vital signs collected per standard of care can be used. NEWS  has 
demonstrated an ability to discriminate subject s at risk of poor outcomes. (Smith, 2016). This 
score is based on 7 clinical parameters  (see Table 2). The NEW S is being used as an efficacy 
measure. The NEW Score should be evaluated daily w hile hospi[INVESTIGATOR_119818] [ADDRESS_1055367] (EMR) using the last measurement 
prior to the time of assessment (including parameters collected prior to the time of consent) and a numeric score is given for each parameter (e.g., a RR of 9 is one point, oxygen saturation of 92 is 
two points). This is recorded for the day obtained ( i.e., on Day 3, the vital signs and other 
parameters  from Day 3 are used to obtain NEW Score for Day 3 ). ECMO and mechanically 
ventilated subjects should be assigned a score of 3 for RR (RR <8) regardless of the ventilator setting. Subjects on ECMO should get a score of 3 for heart rate sinc e they are on 
cardiopulmonary by[CONTACT_6476].  Table 2. National Early Warning Score (NEWS) 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 131 of 146  
 Level of consciousness = alert (A), and non-alert and arousable only to voice (V) or pain (P), and unresponsive 
(U).  
If the subject is on ECMO or invasive mechanical ventilation, they will be given score of 3 (≤8 RR) for 
respi[INVESTIGATOR_119844].  For subjects on ECMO, they will also receive a score of 3 
(≤40 HR) for heart rate.  
 
  Exploratory assessments 
 Viral Load an d/or Shedding  
As outlined on the SOA, OP samples (collected by [CONTACT_769150]) and plasma and serum will be collected 
on Day 1 ; and Days  3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and OP swabs and serum on Day 15 and 
29 (if attends an in- person visit or still hospi[INVESTIGATOR_057] ). Samples are stor ed as outlined in the MOP.  
These assays are not developed yet, and the ability to test samples at one central lab is not clear.  
Therefore,  while viral load/ shedding is thought to be an important endpoint, considering the 
limitations  above, it is listed as an exploratory endpoint.  
 
OP samples  are preferred, but if these are not obtainable, nasopharyngeal (NP) samples  
(collected by [CONTACT_769151]) or nasal swab may b e substituted. Due to limited lack of swabs and other 
supplies at some sites and limitation s on personal protective equipment ( PPE), the inability to 
obtain these samples are not considered protocol deviations and should be documented in the subject’s record .  
 If virology assays can be set up with enough numbers of specimens tested, these data will be 
submitted as part of the Clinical Study Report (CSR) . This may be submitted separately, as a 
supplemental C SR.  
 Samples collected for viral assessment may be probed for the emergence of antiviral resistance at a future date.  These data, if available, may be submitted as a supplement report.  

Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 132 of 146  
The schedule of assessments ( SOA, Section 1.2) lists several research laboratory samples.  It is 
preferred that these samples are collected and sent to the NIAID repository to be tested in one 
central laborato ry. Current US Centers for Disease Control and Prevention (CDC) guidance is 
these samples can be processed in a Biosafety Laboratory (BSL) 2 environment. However, institutions may impose restrictions on processing the samples (i.e., they may require BSL -3) or 
there may be restrictions on sending samples. In these circumstances, the following apply:  Blood for PCR SARS -CoV-2 
• If the samples can be processed but cannot be sent to the repository, the samples may be 
stored locally.  
• The sponsor may elect to have  some or all of these samples run locally, pending 
confirmation of the assays to be used and the qualifications of the local laboratory. The 
sponsor will work with the site to determine when  this could occur and how these data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitted.   
 Oropharyngeal or Nasopharyngeal/nasal specimen  
• If the samples can be processed but cannot be sent to the repository, the samples may be 
stored locally.  
• The sponsor may elect to have some or all of these samples run locally, pending confirmation of the assays to be used and the qualifications of the local laboratory. The 
sponsor will work with the site to determine when this could occur and how these data can 
be imported into the study database.  
• If a BSL -3 environment is needed for processing these samples, these samples may be 
omitte d.  
 Blood for serum (for secondary research)  
• If the samples can be processed and but not sent to the repository, the samples may be stored locally.  
• If a BSL -[ADDRESS_1055368] of baricitinib o n serum cytokine levels, blood samples will be assessed 
using a multiplex assay that is less sensitive to variability in sample integrity due to sample processing limitations during the pandemic.  Cytokines to be tested may include (but not be 
limited to) I L-2, IL -19, IL -4, IL -10, IL -8, G- CSF, GM -CSF, MCP -1, MIP1α, IL- 7, IL -13, IL -31, 
IL-15, IL -6, IFNα, IFNγ and TNFα. The list of cytokines tested is subject to change as new 
information about the pro- inflammatory state of COVID -19 is known. Given the challenges of 
obtaining samples and evolving knowledge about COVID-19, these will be considered exploratory endpoints. The description of the final methodology utilized, and the assay performance characteristics will be included in the final study report.   
8.2 Safety and Other Assessments  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 133 of 146 Study procedures are specified in the SOA. A study physician licensed to make medical 
diagnoses and listed on the 1572 will be responsible for all trial- related medical decisions.  
 
Physical examination :  
A targeted physical examination will be performed at baseline prior to initial study product 
administration  on Day 1. The baseline physical examination can be one that is conducted from 
screening to Day 1. No routine physical exam is needed for study visits  after Day [ADDRESS_1055369]’s rooms due to a limited supply of PPE and the need for strict respi[INVESTIGATOR_119837] -[ADDRESS_1055370] information  from the hospi[INVESTIGATOR_119838].  
 
Clinical laboratory evaluations : 
• Fasting is not required before collection of laboratory samples. 
• Blood will be collected at the time points indicated in the SOA.   
• Clinical safety laboratory tests  include WBC, differential, Hgb, PLT, creatinine, 
glucose, total bilirubin, AST, ALT , INR, d-dimer, and C- reactive protein .  
• Day [ADDRESS_1055371] administration should be given. 
• Clinical laboratory testing will be performed at each clinical trial site in real time.   
 Table 3. Venipuncture Volumes
1 
 Screen  Baseline        
Day +/ - Window  −1 to 1  1 ± 1 3 ± 1 5 ±1 8 ± 1  11 ± 1  15 ± 2  29 ± 3  
Safety hematology, 
chemistry and liver 
tests  X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2 X 
10mL2  X3 
10mL2 X3 
10mL2 
Blood for Serum   X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  X 
24mL  
Plasma  
(includes PCR)   X 
8mL  X 
8mL  X 
8mL  X 
8mL  X 
8mL    
Total volume  10mL  42ml 42mL 42ml 42ml 42ml 34mL  34mL  
Total all study days         268~[ADDRESS_1055372] Values or 
Abnormal Clinical Findings  
If a physiologic parameter (e.g., vital signs, or laboratory value) is outside of the protocol-
specified range, then the measurement may be repeated once if, in the judgment of the 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 134 of 146 investigator, the abnormality is the result of an acute, short-term, rapi[INVESTIGATOR_769124]. A physiologic parameter may also be repeated if there is a technical problem with the measurement caused by [CONTACT_769152] e measuring device (i.e., 
inappropriate- sized BP cuff).  
 
 Unscheduled Visits  
If clinical considerations require the subject to be contact[CONTACT_769153]’s well -being, it is permissible in this protocol.  However, no 
research data is collected at this visit.   
8.3 Adverse Events and Serious Adverse Events  
 Definition of Adverse Event (AE)  
AE means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered inte rvention related. An AE can therefore be any unfavorable 
and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.  If mu ltiple abnormalities are part 
of the same clinical syndrome, they can be reported together as one AE under a unifying clinical 
diagnosis.   Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre- existing (baseline) 
medical condition increases above baseline to severity grade [ADDRESS_1055373] many symptoms and abnormalities in vital signs and laboratory values. Only Grade 3 and 4 AEs will be captured in this trial. In addition, the following AEs will be reported: 
• Any Grade [ADDRESS_1055374] administration wi ll be reported as an AE.  
• Any venous thromboembolism at any time during the study.  
 
Unsolicited  laboratory values collected as part of standard of care, will need to be reported only 
if Grade 3 or above and only if clinically significant and/or part of a di agnosis or a clinical 
syndrome.  In this case, if laboratory and vital sign abnormalities are part of the clinical 
syndrome, they should be reported as one AE under one clinical diagnosis or 
syndrome.  Example: Low oxygen level/arterial blood gases could b e part of respi[INVESTIGATOR_769125]. 
 Intermittent abnormal laboratory values or vital sign measurements common in the severely ill populations (such as electrolyte abnormalities, low blood pressure, hyperglycemia, etc.) that are part of the same clini cal diagnosis (e.g., uncontrolled diabetic) can be recorded once with the 
worst grade for each adverse event (grade 3 and 4 only for this trial), with the start and stops dates of the intermittent syndrome.  If there is clear resolution of the event, and then recurrence, it 
should be treated as a separate adverse event. Resolution is defined as return to baseline (either 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 135 of 146 normal if was normal at Day 1, or baseline (Day 1) grade if already an abnormality on the 
toxicity table at Day 1) for > 48 hours.  D-dimer  and CRP should not be graded. There are collected on the same schedule as the safety 
laboratory tests (see SOA). However, they will be used in the assessment of study outcomes.    
 Definition of Serious Adverse Event (SAE)  
An AE or suspected adverse reaction is considered serious (i.e., is an SAE) if, in the view of either the investigator or the Sponsor , it results in any of the following outcomes: 
• Death ; 
• A life -threatening AE ; 
• Inpatient hospi[INVESTIGATOR_1081] ; 
• A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or 
• A congenital anomaly/birth defect.  
 Grade 4 AEs (potentially life -threatening events) are not always SAEs unless they are 
imminently life threatening.  
 
Important medical events that may not meet the above criteria may be considered serious when, 
based upon appropriate medical judgment, they may jeopardize the subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  “Life -threatening” refers to an AE that at occurrence represents an immediate risk of death to a 
subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening . Similarly, a hospi[INVESTIGATOR_178105] a SAE. 
 All SAEs, as with any AE, will be assessed for severity and relationship to study intervention.  All SAEs will be recorded on the AE CRF  and reported to DMID  (see Section  8.3.6). 
 All SAEs will be followed through resolution or stabilization by a licensed study physician (for IND studies, a physician listed on the Form FDA 1572 as the site PI [INVESTIGATOR_54720] -Investigator). 
 All SAEs will be reviewed and evaluated by [CONTACT_435661]  (for periodic 
review), and the IRB/IEC. 
 Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]R)  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055375] reasonably 
possible but is not listed in the Investigator Brochure ( IB), Package Insert, and/or Summary of 
Product Characteristics.  
 Classification of an Adverse Event  
The determination of seriousness, severity, and causality will be made by [CONTACT_63689]- site investigator 
who is qualified (licensed) to diagnose AE information, provide a medical evaluation of AEs , 
and classify AEs based upon medical judgment. This includes but is not limited to physicians, 
physician assistants, and nur se practitioners.  
 Severity of Adverse Events  
All AEs and SAEs will be assessed for severity using the DAIDS Table for Grading the Severity 
of Adult and Pediatric Adverse Events, version 2.1 (July 2017).  
 
For AEs not included in the Table, the following guidelines will be used to describe severity. In 
addition, all deaths related to an AE are to be classified as grade 5 according to the DAIDS Table.   
 
• Moderate (Grade 2) : Events that are usually alleviated with additional specific 
therapeutic int ervention. The event interferes with usual activities of daily living and 
causes discomfort but poses no significant or permanent risk of harm to the research subject.  
 
• Severe (Grade 3) : Events that interrupt usual activities of daily living, or significan tly 
affect clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.  
 
• Potentially life -threatening event  (Grade 4) : Events that are potentially life threatening.  
  
• Deaths (Grade 5):  All deaths related to an AE are classified as grade 5 (per DAIDS 
Table).  
  
 Relationship to Study Intervention 
For each reported adverse reaction, the PI [INVESTIGATOR_769126]: 
 
• Related  – There is a temporal relationship between the study intervention and event, and 
the AE is known to occur with the study intervention or there is a reasonable possibility 
that the study intervention caused the AE. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.  
 
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established. 
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 137 of 146 
 Time Period and Frequency for Event Assessment and Follow -Up 
For this study, all Grade 3  and 4 AEs, all SAEs occurring from the time the informed consent is 
signed through the Day 29 visit will be documented, recorded, and reported . 
 
 Investigator Reporting of AEs  
Information on AEs  will be recorded on the appropriate CRF . All clearly related signs, 
symptoms, and results of diagnostic procedures performed because of an AE should be grouped 
together and recorded as a single diagnosis. If the AE is a laboratory abnormality that is part of 
a clinical condition or syndrome, it should be recorded as the syndrome or diagnosis rather than 
the individual laboratory abnormality. Each AE will also be described in terms of duration (start and stop date), severity, association with the study product, action(s) taken, and outcome. 
Any new infection that occurs on study, regardless of infecting agent (i.e., viral or non- viral) 
will be captured if it is a Grade [ADDRESS_1055376] positive result(s) for the new infection (e.g., blood or urine culture, molecular diagnostic 
test result, etc.); there is no need to capture repeatedly  positive results unless there is a new 
pathogen identified from the same site (e.g., blood) during the infection event. The sponsor will identify infections considered to be opportunistic based on Winthrop et al. 2015. 
 Serious Adverse Event Reporting  
 Investigators Reporting of SAEs 
Any AE that meets a  protocol- defined criterion as an SAE that is judged to be related  to either 
study product must be submitted within 24 hours of site awareness on an SAE form to the DMID 
Pharmacovigilance Group, at the following address:  
 
DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS)  
[ADDRESS_1055377]. Suite 650 Bethesda, MD [ZIP_CODE], [LOCATION_003] SAE Hot Line: 1 -[PHONE_889] (US) or [PHONE_2619] (outside US) 
SAE FAX Number: 1 -[PHONE_1729] (US) or [PHONE_2621] (outside US) 
SAE Email Add ress: [EMAIL_1393] 
 Other supporting documentation of the event may be requested by [CONTACT_295051]. The DMID Medical Monitor will review and assess the SAE for regulatory reporting and potential impact on study subject safety and protocol conduct. At any time after completion of the study, if the site PI [INVESTIGATOR_29353]-investigator becomes aware of an SAE  that occurred during the subject’s participation in the study , the site PI 
[INVESTIGATOR_29353]-investigator will report the event to the DMID Pharmacovigilance Group. 
 
SAEs that that are judged to be not related  to study product are still captured on the AE case 
report form, but do not require separate reporting to the DMID Pharmacov igilance Group. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 138 of 146  
 Regulatory Reporting of SAEs 
Following notification from the site PI [INVESTIGATOR_29353]-investigator, DMID, as the IND 
Sponsor , will report any S[LOCATION_003]R in an IND safety report to the FDA and will notify all 
participating site P Is as soon as possible. DMID will report to the FDA any unexpected fatal or 
life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 
calendar days after the Sponsor ’s initial receipt of the information. If the event is not fatal or life -
threatening, the IND safety report will be submitted within [ADDRESS_1055378] additional local reporting requirements (to the IRB and/or national regulatory authority).  
 Reporting of Pregnancy  
Pregnancy is not an AE. However, any pregnancy that occurs during study participation should be reported to the Sponsor on the appropriate CRF . Pregnancy should be followed to outcome.  
8.4 Unanticipated Problems  
 Definition of Unanticipated Problems  
An Unanticipated Problem (UP) is any event, incident, experience, or outcome that meets the following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol-related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the subject population being studied; 
 Related to participation in the research (mean ing there is a reasonable possibility that the 
incident, experience, or outcome may have been caused by [CONTACT_32015]); and  
 Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recog nized. 
 Unanticipated Problem Reporting  
To satisfy the requirement for prompt reporting, all U ps will be reported using the following 
timeline:  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 139 of 146  UPs that are SAEs will be reported to the IRB and to the Statistical and Data 
Coordinating Center ( SDCC )/study Sponsor within 24 hours of the investigator becoming 
aware of the event per the above describe SAE reporting process.  
 Any other UP will be reported to the IRB and to the SDCC/study Sponsor within [ADDRESS_1055379] for ACTT -1 and ACTT -2 
R=remdesivir,  B=baricitinib and C=placebo  
 
ACTT -1 
Primary hypothesis  R vs C  
ACTT -2  
Primary hypothesis  R+B vs R  
   A key secondary hypothesis tests the null distribution of a similar distribution of [ADDRESS_1055380] is the “common odds ratio,” which quantifies 
the shift in the severity distribution resulting from trea tment. For an efficacious treatment, an 
odds ratio greater than 1 quantifies an improvement in disease severity; a value of 2 indicates a bigger improvement than a value of 1.25. The null hypothesis to be tested is that the odds of improvement on the ordinal scale is the same for the control and experimental treatment arms 
(i.e., the common odds ratio is 1). It is worth noting that, for large sample sizes, the test based on the proportional odds model is nearly the same as the Wilcoxon rank sum test.  
9.[ADDRESS_1055381] e Size Determination  
 
Primary endpoint: The log- rank test will be used to compare treatment arms with respect to time 
to recovery. For the log-rank test, the two key determinants of power are the total number of events (i.e., recoveries) E and the treatmen t-to-control ratio of the rate of recovery, R. The 
number of events required for power 1−𝛽𝛽 to detect a recovery rate ratio of θ using a two- tailed 
test at alpha=0.05 is approximately 
𝐸𝐸=4�1.96+𝑧𝑧
𝛽𝛽�2
{ln(𝜃𝜃)}2, 
where 𝑧𝑧𝛽𝛽 is the 100 (1−𝛽𝛽)th percentile of the standard normal distribution. 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 140 of 146 The force of recovery (sometimes loosely referred to as the “recovery ratio”) is the analogue of 
the hazard ratio and the term “ recovery rate ratio ” is the analogue of the hazard ratio in this 
setting. A recovery rate ratio of  1.31 was reported in Cao, Wang, Wen et al. (2020) for a 
lopi[INVESTIGATOR_054]/ritonavir trial that used time to improvement by [ADDRESS_1055382] size.  Therefore a recovery rat io of 
1.25 is assume d for this trial.  A total of 723 recoveries are needed for a recovery ratio of 1.25 
with 85% power. Table [ADDRESS_1055383] been achieved. The date of study closure will be 
estimated based on enrollment rate and recovery/enrollment percentages.  If approximately 70% 
of participants recover, the total sample size will be 1032. 
 Table 5. Number of recoveries needed for 8 5% power assuming a type I error rate of 5% 
for various recovery ratios.  
Recovery  rate 
ratio 
(θ) Number of recoveries 
needed for 85% 
power  
1.20 1080  
1.25 723 
1.30 523 
1.35 400 
1.40 318 
 
Key secondary: A sample size can be computed using an (assumed) ordinal scale distribution for 
the control arm and the odds ratio representing clinical improvement. The odds ratio represents 
the odds of improvement in the ordinal scale for combination treatment relative to the control 
arm [Whitehead, 1993]. The sample size to detect a given odds ratio for 1:[ADDRESS_1055384] at level α is given by 
12�𝑧𝑧α/2+𝑧𝑧β�2
λ2(1−∑𝑝𝑝𝑖𝑖3𝐾𝐾
𝑖𝑖=1), 
 
where λ is the log odds ratio, 𝑝𝑝 𝑖𝑖 is the overall probability (combined over both arms) of being in 
the ith category of the K ordinal outcomes, and 𝑧𝑧α/2 and  𝑧𝑧𝛽𝛽 are the 1−α/2 and 1−β quantiles 
of the standard normal distribution.  
 Table 6 displays five scenarios considered for outcome probabilities in the control arm for 
sample size determination. There is significant uncertainty with these assumptions given the 
limited data available. Table 6 shows a range of sample sizes for odds ratios ranging from 1.25 to 
2.5 for 85% power. For 90% power, increase the sample size by 17%. Table 8 displays t he 
probabilities of being in different categories of the ordinal scale under an odds ratio of 1.75. A total sample size of 396 gives approximately 85% power to detect an odds ratio of 1.[ADDRESS_1055385] at level α= 0. 05. The categories of the 8 -point ordinal scale are:  
 
• Death;  
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 141 of 146 • Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
• Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
• Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen – requiring ongoing medical care 
(COVID -19 related or otherwise);  
• Hospi[INVESTIGATOR_057], not requiring supplemental oxygen – no longer requires ongoing medical 
care; 
• Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
• Not hospi[INVESTIGATOR_057], no limitations on activities.  
 
Note that the data elements contributing to this scale will be captured separately, in order to facilitate different orderings or groupi[INVESTIGATOR_14839], as might arise if external data provide information about the clinical course of disease.  
 Table 6: Possible scenarios for the distribution of ordinal outcomes for the control arm at 
Day 15. 
 Anticipated  Different scenarios for control arm  
  Scenario 1  Scenario 2  Scenario 3  Scenario 4  Scenario 5  
  more mild disease                        more severe disease  
Severity Outcome  outcome (%)  outcome (%)  outcome (%)  outcome (%)  outcome (%)  
Death  2 1 1 2 3 
Hospi[INVESTIGATOR_057], on mechanical 
ventilation or ECMO  1 1 1 1 3 
Hospi[INVESTIGATOR_057], on non -
invasive ventilation or high 
flow oxygen devices  2 1 1 2 4 
Hospi[INVESTIGATOR_057], requiring 
supplemental oxygen  7 2 5 5 9 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen – 
requiring ongoing medical 
care (COVID -19 related or 
otherwise)  8 5 7 17 23 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen – no 
longer requires ongoing 
medical care  10 9 10 20 25 
Not hospi[INVESTIGATOR_057], limitation 
on activities and/or requiring 
home oxygen  30 36 35 25 18 
Not hospi[INVESTIGATOR_057], no 
limitations on activities  40 45 40 28 15 
 
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 142 of 146 Table 7: Sample size calculations for scenarios in Table 6 for a two-arm study assuming 
85% power, a two-sided type I error rate of 5%, and various true odds ratios.  
True odds 
ratio  Total sample size 
 Scenario 1  Scenario 2  Scenario 3  Scenario 4  Scenario 5  
1.25 2420  2554  2459  2293  2252  
1.5  744 786 755 700 684 
1.75 396 419 401 370 360 
2.0 262 277 265 243 236 
2.25 194 206 196 179 173 
2.5 154 163 155 141 136 
 
 Table 8. Treatment ordinal outcome proportions under an odds ratio of 1.75 for five 
scenarios in  Table 5 at Day 15. 
  Scenario  
1 Scenario 
2 Scenario 
3 Scenario 
4 Scenario 
5 
  Anticipated  more mild disease                more severe disease  
Severity Outcome  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Control % 
Treatment %  
Death  2 1.2 1 0.6 1 0.6 2 1.2 3 1.7 
Hospi[INVESTIGATOR_057], on mechanical 
ventilation or ECMO  1 0.6 1 0.6 1 0.6 1 0.6 3 1.8 
Hospi[INVESTIGATOR_057], on non -invasive 
ventilation or high flow 
oxygen devices  2 1.2 1 0.6 1 0.6 2 1.2 4 2.5 
Hospi[INVESTIGATOR_057], requiring 
supplemental oxygen  7 4.3 2 1.2 5 3.0 5 3.1 9 5.8 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen – requiring ongoing medical 
care (COVID -19 related or 
otherwise)  8 5.3 5 3.1 7 4.4 17 11.5 23 17.4 
Hospi[INVESTIGATOR_057], not requiring 
supplemental oxygen – no longer requires ongoing 
medical care ; 10 7.2 9 5.9 10 6.8 20 16.2 25 24.4 
Not hospi[INVESTIGATOR_057], limitation 
on activities and/or requiring 
home oxygen  30 26.5 36 29.3 35 30.2 25 25.9 18 22.7 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055386].  
 
9.4 Statistical Analyses  
 General Approach  
This is a double-blind placebo controlled randomized trial testing a superiority hypothesis with a two-sided type I error rate of 5%. Secondary hypotheses have been ordered according to relative 
importance, with one key secondary hypothesis highlighted. These will be described according to the appropriate summary statistics (e.g., proportions for categorical data, means with 95% confidence intervals for continuous data, median for time- to-event data).  
 A statistical analysis plan  will be developed and filed with the study sponsor prior to unblinding 
of study and database lock.   
 Analysis of the Primary Efficacy Endpoint 
The primary efficacy analysis  is a stratified log -rank test, where stratif ication is according to 
baseline disease severity  (i.e. protocol defined mild/moderate vs severe disease). Deaths will be 
considered as never recovering and censored at Day 29. In ACTT2, the analyses conducted will depend on the results from ACTT1 accordin g to Table 4. 
 
 Analysis of the Secondary Endpoint(s)  
 
7) The ordinal scale will be used to estimate a proportional odds model by [CONTACT_119935]. The hypothesis test will perform a stratified test to evaluate whether the common odds 
ratio for treatment is equal to one. The distribution of severity results will be summarized by [CONTACT_119936]. Efforts to minimize loss -to-follow-up wil l be 
considerable. However, small amounts of missing data may occur. In such cases, subjects without final outcome data will be excluded from the analysis. Sensitivity analyses will evaluate the impact of making different assumptions about missing observations. These analyses will be defined in the SAP.  
 
8) Differences in time -to-event endpoints (e.g., time to a t least  a one category improvement 
in ordinal scale) by [CONTACT_119937] -Meier curves and 95% 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055387] a two-
category  improvement.  
 
9) Change in ordinal scale at specific time points will be summarized by [CONTACT_119938] (e.g., 
proportion who have a 1-, 2-, 3-, or 4-point improvement or 1-, 2-, 3-, 4-point worsening).  
10) Duration of event (e.g., duration of mechanical ventilation) will be summarized according to median days with quartiles.  
11) Binary data (e.g., incidence of new oxygen use) will be summarized as a percent with 95% confidence intervals. Comparisons between arm s will be presented as differences in 
proportions with 95% confidence intervals. 
12) Categorical data (e.g., 28 -day mortality or ordinal scale by [CONTACT_4475]) may be summarized 
according to proportions by [CONTACT_119939]/or odds ratios with confidence intervals.  
 Procedures for handling missing data, including informative censoring (e.g., a missing duration of oxygen use endpoint due to a death), will be described in the SAP.  
 Safety Analyses 
Safety endpoints include death through Day 29, SAEs and Grade [ADDRESS_1055388] udy intervention. AEs  will be coded using the 
current version of the Medical Dictionary for Regulatory Activities (MedDRA). AEs  will be 
presented by [CONTACT_9313], duration (in days), start- and stop- date. Adverse events leading 
to premature discontinuation from the study intervention and serious AEs will be presented 
either in a table or a listing.  
 
 Baseline Descriptive Statistics  
Baseline characteristics will be summarized by [CONTACT_2939]. For continuous measures the mean and standard deviation wil l be summarized. Categorical variables will be described by [CONTACT_769154] (with the corresponding sample size numbers).  
 
 Planned Interim and Early Analyses  
A DSMB will monitor ongoing results to ensure subject  well -being and safety as w ell as study 
integrity. The DSMB will be asked to recommend early termination or modification only when 
there is clear and substantial evidence of a treatment difference. More details about the interim analyses are described in section [IP_ADDRESS] and [IP_ADDRESS] below as well as a separate guidance 
document for the DSMB.  
 
 Interim Safety Analyses  
Safety analyses will evaluate Grade 3 and 4 AE and SAEs by [CONTACT_2939].  Safety monitoring 
will be ongoing (see section 10.1.6). The unblinded statistical team will prepare these reports for 
review by [CONTACT_4318].  
 
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix B - ACTT -2: Baricitinib/Remdesivir vs Remdesivir  
DMID/NIAID/NIH  CONFIDENTIAL  Page 145 of 146 
 Interim Efficacy Review  
The Lan -DeMets spending function analog of the O’Brien- Fleming boundaries will be used to 
monitor the primary endpoint as a guide for the DSMB for an overall two-sided type- I error rate 
of 0.05. Interim efficacy analyses will be conducted at approximately 33 %, and 100% of total 
information.  
 Conditional power will be presented as an additional guide to the DSMB. Conditional power allows computation of the probability of obtaining a statistically significant result by [CONTACT_435663], incorporating and assuming a hypothesized treatment effect (e.g., the treatment effect assumed for sample size determination) thereafter. If conditional power is less than 20% under the original trial assumptions, consideration should be given to stoppi[INVESTIGATOR_21356].   The unblinded statistical team will prepare these closed reports for DSMB review and 
recommendations. Analyses will be presented with blinded codes for treatment arms to protect against the possibility that the DSMB report may fall into the wrong hands. A DSMB charter will further describe procedures and membership. An additional document on statistical issues related to monitoring will be provided to the DSMB prior to interim analyses.   
 Sub-Group Analyses 
Subgroup analyses for the primary outcomes will evaluate the treatment effect across the following subgroups: geographic region, duration of symptoms prior to enrollment, baseline disease severity (stratification variable of mild/moderate and severe, as well as ordinal scale of 4/5 vs 6/7) age, race, sex  and comorbidities. A forest plot will display conf idence intervals across 
subgroups. Interaction tests will be conducted to determine whether the effect of treatment varies by [CONTACT_6496]. 
 Exploratory Analyses 
An exploratory analysis will compare treatment efficacy estimates according to the various scales outlined in section 8.1.2. Specifically, the probability of falling into category “i” or better 
will be compared between arms for each i.   
 
10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  
CONSIDERATIONS  – ALL  STAGES  
All supporting documentation and operational considerations are applicable to the entire platform trial and are not unique to the individual stages. These are therefore covered in the main protocol document.   
Protocol 20-0006 Version 6.0 
Adaptive COVID -19 Treatment Trial (ACTT)  25 May 2020 
Appendix C – Country Specific Appendix 
DMID/NIAID/NIH  CONFIDENTIAL  Page [ADDRESS_1055389] (PREP Act) and the Declaration issued by [CONTACT_293368] U.S. Department of Health and Human Services under that Act. Under the 
PREP Act and the Declaration, covered persons (such as manufacturers, distributers, program planners, and other qualified persons who prescribe, administer or dispense study product) ar e 
immune from liability from the administration, or use of a covered countermeasure, such as remdesivir  and baricitinib . The PREP Act provides immunity for covered persons from liability, 
unless the injury was caused by [CONTACT_154389]. The Declaration invoking the PREP Act for COVID -[ADDRESS_1055390] also established the Countermeasures Injury Compensation Program (CICP) to 
provide compensation for serious injuries or death that occur as the direct result of the administration or use of certain countermeasures. Any requests for compensation must be filed within one year of the administration or use of the covered countermeasure. Requests for Benefits mu st be made to the Health Resources and Services Administration’s (HRSA) 
Countermeasures Injury Compensation Program (http://www.hrsa.gov/cicp/) by [CONTACT_154390] a Request for Benefits Form and all required medical records and supporting documentation. Additional information on filing a Request for Benefits is available on the CICP’s website at http://www.hrsa.gov/cicp/. Compensation may then be available for reasonable and necessary medical benefits, lost wages and/or death benefits to eligible individuals for cer tain injuries in 
accordance with regulations published by [CONTACT_154391] (found at 42 CFR part 110).  
If an individual suffers a serious physical injury or death from the administration or use of a 
covered countermeasure in this study, the individual, the individual’s legal or personal representative, the administrator/executor of a deceased individual’s estate, or certain survivors may request benefits from the CICP.  A serious physical injury means an injury that warranted 
hospi[INVESTIGATOR_059] (whether or not the person was actually hospi[INVESTIGATOR_057]) or that led to a significant loss of function or disability. The CICP is the payer of last resort. This means that it only covers expenses or provides benefits that other third-party payers (such as health insurance, the Department of Veterans Affairs, or Workers’ Compensation programs) do not have an obligation to pay. 
If the Secretary of HHS does not make a final determination on the individual’s request within 
[ADDRESS_1055391] is reduced by [CONTACT_92229]’s 
compensation available to the injured individual. Awards for non- economic damages, such as 
pain, suffering, physical impairment, mental anguish, and loss of consortium are also limited. If the individual accepts compensation, or if there is no willful misconduct, then the individual does not have a tort claim that can be filed in a US Federal or a State court.  